日本臨牀　70/増刊号5　最新臨床糖尿病学　下

出版社： 日本臨牀社
発行日： 2012-07-14
分野： 臨床医学：一般  >  雑誌
ISSN： 00471852
雑誌名：
特集： 最新臨床糖尿病学　下　―糖尿病学の最新動向―
電子書籍版： 2012-07-20 （初版第1刷）
書籍・雑誌
≪全国送料無料でお届け≫
品切れ

17,600 円(税込)

電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

17,600 円(税込)

購入する

目次

  • 日本臨牀　70/増刊号5　最新臨床糖尿病学　下

    ―目次―

    特集　最新臨床糖尿病学　下　―糖尿病学の最新動向―

    VIII． ライフステージ・タイプ別糖尿病の病態と治療 　 　
    　１． 小児糖尿病 　 　
    　２． 高齢者糖尿病 　 　
    　３． 妊娠糖尿病 　 　
    　４． 合併疾患を有する糖尿病の治療 　 　
    　５． 二次性糖尿病 　 　
    　６． インスリン自己免疫症候群 　
    　７． 脂肪萎縮性糖尿病　
    　８． 単一遺伝子異常による糖尿病 　 　
    　９． 糖尿病を伴う遺伝的症候群

    IX． 糖尿病合併症・糖尿病関連疾患 　 　
    　１． 我が国における糖尿病合併症の現状と今後の課題
    　２． 糖尿病合併症疾患感受性遺伝子研究の現状と今後の展望　
    　３． 糖尿病合併症発症・進展にかかわる主要因子とその機序 　
    　４． 糖尿病合併症予防戦略 　
    　５． 糖尿病合併症発症・進展阻止のための包括的管理 　　
    　６． 各種糖尿病合併症の概念・成因・診断・治療 　
    　７． 糖尿病に起因，関連する疾患 　 　
    　８． 糖尿病に起因する動脈硬化の治療法 　 　
    　９． 糖尿病と発がんとの関連

    X． 糖尿病診療における医療連携 　 　
    　１． クリニカルパスの活用の現状と今後の課題 　
    　２． 糖尿病非専門医との地域医療連携 　
    　３． 循環型医療連携の現状と今後の課題 　

    XI． 糖尿病患者の教育・看護 　 　
    　１． 米国糖尿病教育者協会の糖尿病自己管理教育
    　２． インスリン自己注射と患者教育
    　３． 教育入院における患者教育の意義
    　４． 糖尿病患者の心理指導

    XII． 特　論 　 　
    　１． 糖尿病と時計遺伝子
    　２． 高アディポネクチン血症と寿命
    　３． 糖尿病予防におけるスポートロジーの役割
    　４． 糖尿病専門医育成の現状と課題
    　５． 糖尿病治療における医療経済とその問題点
    　６． 新生児低血糖症の病態・診断・治療
    　７． 低血糖による認知機能障害

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

VIII ライフステージ・タイプ別糖尿病の病態と治療

P.14 掲載の参考文献
1) 雨宮伸:小児・思春期糖尿病における日本人の特性と今後の課題.日小児会誌 115:13-19,2011.
 
2) SEARCH for Diabetes in Youth Study Group:The burden of diabetes mellitus among US youth:prevalence estimates from the SEARCH for Diabetes in Youth study.Pediatrics 118:1510-1518,2006.
 
3) 浦上達彦:若年2型糖尿病の疫学動向.日本臨牀 66(増刊号4):21-25,2008.
 
4) Sugihara S,et al:HLA-class II and class I genotypes among Japanese children with Type 1A diabe-tes and their families.Pediatr Diabetes 13:33-44,2012.
 
5) Edghill EL,et al;Neonatal Diabetes International Collaborative Group:Insulin mutation screening in 1,044 patients with diabetes:mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood.Diabetes 57(4):1034-1042,2008.
PubMed
6) 日本小児内分泌学会(編):第10章 B.糖尿病 3.その他,特定の機序・疾患によるもの.小児内分泌学,p472-477,診断と治療社,2009.
 
7) Lee JM,et al:Diagnosis of diabetes using hemoglobin A1c:Should recommendations in adults be extrapolated to adolescents? J Pediatr 158:947-952,2011.
PubMed
8) Diabetes Research In Network(DirecNet)Study Group:Relationship of A1C to glucose concentra-tions in children with type 1 diabetes:assessments by high-frequency glucose determinations by sensors.Diabetes Care 31:381-385,2008.
 
9) White NH,et al;Diabetes Control and Complications Trial(DCCT)/Epidemiology of Diabetes Inter-ventions and Complications(EDIC)Research Group:Beneficial effects of intensive therapy of diabe-tes during adolescence:outcomes after the conclusions of the Diabetes Control and Complications Trial(DCCT).J Pediatr 139:804-812,2001.
 
10) Nayak AU,et al:Evidence for consistency of the glycation gap in diabetes.Diabetes Care 34:1712-1716,2011.
PubMed
11) Rewers M,et al:Assessment and monitoring of glycemic control in children and adolescents with diabetes.Pediatr Diabetes 10(Suppl 12):71-81,2009.
 
12) 日本糖尿病学会・日本小児内分泌学会(編):小児・思春期糖尿病管理の手びき,改訂第3版,コンセンサス・ガイドライン,南江堂,2011.
 
13) The International Expert Committee:International Expert Committee report on the role of AI C assay in the diagnosis of diabetes.Diabetes Care 32:1327-1334,2009.
 
14) 雨宮伸:小児糖尿病におけるHbA1c値の位置づけ-JDS値,NGSP値,IFCC値の相互の関係(日本国内での標準化堅持の重要性)を含めて.小児内科 44:617-622,2012.
 
P.20 掲載の参考文献
1) DIABETES ATLAS,5th ed.,International Diabetes Federation,2011.
 
2) Patterson CC,et al:Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20:a multicentre prospective registration study.Lancet 373:2027-2033,2009.
PubMed
3) Soltesz G,et al:Worldwide childhood type 1 diabetes incidence-what can we learn from epidemiol-ogy? Pediatr Diabetes 8(Suppl 6):6-14,2007.
 
4) 国立成育医療センター研究所,成育政策科学研究部:全国の小児慢性特定疾患治療研究事業の登録人数[http://www.nch.go.jp/policy/shoumann.htm].
 
5) 松浦信夫ほか:糖尿病疫学に関する研究-医療意見書の解析とその問題点-.厚生労働科学研究費補助金 難治性疾患克服研究事業 小児慢性特定疾患治療研究事業の登録・管理・評価に関する研究 平成15年度総括研究報告書(主任研究者 加藤忠明),p100-102,2004.
 
6) Kida K,et al:Incidence of Type 1 diabetes mellitus in children aged 0-14 in Japan,1986-1990,including an analysis for seasonality of onset and month of birth:JDS study.The Data Committee for Childhood Diabetes of the Japan Diabetes Society(JDS).Diabet Med 17:59-63,2000.
 
7) Matsuura N,et al:Descriptive epidemiology of IDDM in Hokkaido,Japan:the Childhood IDDM Hokkaido Registry.Diabetes Care 21:1632-1636,1998.
PubMed
8) Lack of regional variation in IDDM risk in Japan.Japan IDDM Epidemiology Study Group.Diabetes Care 16:796-800,1993.
 
9) Liese AD,et al:The burden of diabetes mellitus among US youth:prevalence estimates from the SEARCH for Diabetes in Youth Study.Pediatrics 118:1510-1518,2006.
PubMed
10) Fagot-Campagna A,et al:Type 2 diabetes among North American children and adolescents:an epi-demiologic review and a public health perspective.J Pediatr 136:664-672,2000.
 
11) Lipton R,et al:Incidence and onset features of diabetes in African-American and Latino children in Chicago,1985-1994.Diabetes Metab Res Rev 18:135-142,2002.
PubMed
12) Smith TL,et al:Incidence of childhood type 1 and non-type 1 diabetes mellitus in a diverse pop-ulation:the Chicago Childhood Diabetes Registry,1994 to 2003.J Pediatr Endocrinol Metab 20:1093-1107,2007.
 
13) 浦上達彦:若年2型糖尿病の疫学的動向.日本臨牀 66(増刊号4):21-25,2008.
Medical*Online
14) 浦上達彦:2型糖尿病.小児科 52(9):1237-1242,2011.
 
P.25 掲載の参考文献
1) 桑野聡ほか:入院時高血糖症例の検討.小児科診療 3:437-440,1999.
 
2) 清野裕ほか:糖尿病の分類と診断基準に関する委員会報告.糖尿病 53:450-467,2010.
 
3) 日本糖尿病学会・日本小児内分泌学会(編):診断基準.小児・思春期糖尿病管理の手引き,改訂第3版-コンセンサス・ガイドライン,p10-15,南江堂,2011.
 
4) 門脇孝ほか:糖尿病・糖代謝異常に関する診断基準検討委員会報告-空腹時血糖値の正常域に関する新区分.糖尿病 51:281-283,2010.
 
5) 日本糖尿病学会・日本小児内分泌学会(編):小児のメタボリックシンドローム.小児・思春期糖尿病管理の手引き,改訂第3版-コンセンサス・ガイドライン,p72-79,南江堂,2011.
 
6) 小川えりかほか:糖尿病診断における血糖値とHbA1cの関連:小児例での検討.糖尿病 54(Suppl 1):abstract I-8-17,S101,2011.
 
7) Wolfsdorf J,et al:Diabetic ketoacidosis in children and adolescents with diabetes.ISPAD Clinical Practice Consensus Guidelines 2009 Compendium.Pediatr Diabetes 10(Suppl 12):118-133,2009.
 
8) 浦上達彦ほか:小児インスリン依存型糖尿病の膵β細胞機能について-グルカゴン負荷試験と24時間尿中Cペプチド排泄における検討.日小児会誌 95:2167-2172,1991.
 
9) 横田一郎:小児糖尿病UPDATE-インスリン分泌能の評価.小児内科 34:1606-1610,2002.
 
10) Urakami T,et al:Autoimmune characteristics in Japanese children diagnosed with type 1 diabetes before 5 years of age.Pediatr Int 51:460-463,2009.
PubMed
11) Urakami T,et al:Urine glucose screening at schools in Japan to detect children with diabetes and its outcome-incidence and clinical characteristics of childhood type 2 diabetes in Japan.Pediatr Res 61:141-145,2007.
PubMed
12) 日本糖尿病学会・日本小児内分泌学会(編):疫学.小児・思春期糖尿病管理の手引き,改訂第3版-コンセンサス・ガイドライン,p34-40,南江堂,2011.
 
13) Rosenbloom AL,et al:Type 2 diabetes in children and adolescents.ISPAD Clinical Practice Consen-sus Guidelines 2009 Compendium.Pediatr Diabetes 10(Suppl 12):17-32,2009.
 
P.29 掲載の参考文献
1) Urakami T,et al:Incidence of children with slowly progressive form of type 1 diabetes detected by the urine glucose screening at schools in the Tokyo Metropolitan Area.Diabetes Res Clin Pract 80:473-476,2008.
PubMed
2) Kawasaki E,et al:Type 1 diabetes in Japan.Diabetologia 49:828-836,2006.
PubMed
3) Kawasaki E,et al:Differences in the humoral autoreactivity to zinc transporter 8 between childhood-and adult-onset type 1 diabetes in Japanese patients.Clin Immunol 138:146-153,2011.
PubMed
4) 山田研太郎ほか:ケトーシスを伴って急性発症する肥満NIDDM症例-清涼飲料水ケトーシス-.糖尿病 36:469-474,1993.
 
5) Rubio-Cabezas O,et al:Permanent neonatal diabetes mellitus-the importance of diabetes diiiferen-tial diagnosis in neonates and infants.Eur J Clin Invest 41:323-333,2011.
 
6) The Diabetes Control and Complications Trial Research Group.The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent dia-betes mellitus.N Engl J Med 329:977 -986,1993.
 
7) Churchill JN,et al:Use of continuous insulin infusion pumps in young children with type 1 diabe-tes:a systematic review.J Pediatr Health Care 23:173-179,2009.
 
8) Wolfsdorf J,et al;American Diabetes Association:Diabetic ketoacidosis in infants,children,and adolescents:A consensus statement from the American Diabetes Association.Diabetes Care 29:1150-1159,2006.
PubMed
9) Ly Tr,et al:Impaired awareness of hypoglycemia in a population-based sample of children and ado-lescents with type 1 diabetes.Diabetes Care 32:1802 -1806,2009.
 
10) Asvold BO,et al:Cognitive function in type 1 diabetic adults with early exposure to severe hypogly-cemia:A 16-year follow-up study.Diabetes Care 33:1945-1947,2010.
 
P.35 掲載の参考文献
1) Rosenbloom AL,et al:Type 2 diabetes in the child and adolescent.ISPAD Clinical Practice Consen-sus Guidelines 2009 Compendium.Pediatric Diabetes 10(Suppl 12):17-32,2009.
 
2) 小児・思春期糖尿病管理の手引き,コンセンサスガイドライン改訂第3版(日本糖尿病学会,日本小児内分泌学会編),南江堂,2011.
 
3) 杉原茂孝:'小児保健の現状と課題,提言'糖尿病からみて.小児保健研 70(Suppl):41-45,2011.
 
4) 杉原茂孝:糖尿病の登録・解析・情報提供に関する研究.平成23年度厚生労働科学研究費補助金(成育疾患克服等次世代育成基盤研究事業)小児慢性特定疾患の登録・管理・解析・情報提供に関する研究(研究代表者松井陽),平成23年度総括・分担研究報告書,2012.
 
5) Sugihara S,et al:Analysis of weight at birth and at diagnosis of childhood-onset type 2 diabetes mellitus in Japan.Pediatr Diabetes 9:285-290,2008.
PubMed
6) Sugihara S,et al:Survey of current medical treatments for childhood-onset type 2 diabetes mellitus in Japan.Clin Pediatr Endocrinol 14:65-75,2005.
PubMed
7) Law CM,et al:Thinness at birth and glucose tolerance in seven-year-old children.Diabet Med 12:24-29,1995.
PubMed
8) Yajnik CS,et al:Fetal growth and glucose and insulin metabolism in four-year-old Indian chil-dren.Diabet Med 12:330-336,1995.
 
9) McCane DR,et al:Birth weight and non-insulin dependent diabetes:thrifty genotype,thrifty phenotype,or surviving small baby genotype? BMJ 308:942-945,1994.
PubMed
10) Wei JN,et al:Low birth weight and high birth weight infants are both at an increased risk to have type 2 diabetes among schoolchildren in Taiwan.Diabetes Care 26:343-348,2003.
PubMed
11) Urakami T,et al:Urine glucose screening program at schools in Japan to detect children with diabe-tes and its outcome-Incidence and clinical characteristics of childhood type 2 diabetes in Japan.Pediatr Res 61:141-145,2007.
 
12) Urakami T,et al:Prevalence of components of the metabolic syndrome in schoolchildren with newly diagnosed type 2 diabetes mellitus.Pediatr Diabetes 10(8):508-512,2009.
PubMed
13) 岡田泰助ほか:学校検尿と治療中断が18歳未満発見2型糖尿病の合併症に与える影響.糖尿病 43:131-137,2000.
 
P.42 掲載の参考文献
1) Gloyn AL,et al:Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes.N Engl J Med 350:1838-1849,2004.
PubMed
2) Babenko AP,et al:Activating mutations in the ABCC8 gene in neonatal diabetes mellitus.N Engl J Med 355:456-466,2006.
PubMed
3) Stoy J,et al:Insulin gene mutations as a cause of permanent neonatal diabetes.Proc Natl Acad Sci USA 104:15040-15044,2007.
PubMed
4) Pearson ER,et al:Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.N Engl J Med 355:467-477,2006.
PubMed
5) Polak M,et al:Neonatal and very-early-onset diabetes mellitus.Semin Neonatal 9:59-65,2004.
PubMed
6) Aguilar-Bryan L,et al:Neonatal diabetes mellitus.Endocr Rev 29:265-291,2008.
PubMed
7) Suzuki S,et al:Molecular basis of neonatal diabetes in Japanese patients.J Clin Endocrinol Metab 92:3979-3985,2007.
PubMed
8) Edghill EL,et al:Insulin mutation screening in 1,044 patients with diabetes:mutations in the INS gene are a common cause of neonatal diabetes but a rare cause of diabetes diagnosed in childhood or adulthood.Diabetes 57:1034-1042,2008.
 
9) 清野裕ほか:糖尿病の分類と診断基準に関する委員会報告.糖尿病 53:450-467,2010.
 
10) Suzuki S,et al:Glycated albumin but not HbA1c reflects glycaemic control in patients with neonatal diabetes mellitus.Diabetologia 54:2247-2253,2011.
 
11) 厚生労働科学研究(難治性疾患克服研究事業)「日本人における新生児糖尿病発症原因遺伝子異常の実態把握および遺伝子変異部位による薬効変化に関する検討」班,2012.
 
12) Yorifuji T,et al:The C42R mutation in the Kir6.2(KCNJ11)gene as a cause of transient neonatal diabetes,childhood diabetes,or later-onset,apparently type 2 diabetes mellitus.J Clin Endocrinol Metab 90(6):3174-3178,2005.
PubMed
P.45 掲載の参考文献
1) Owen CG,et al:Does breastfeeding influence risk of type 2 diabetes in later life? A quantitative analysis of published evidence.Am J Clin Nutr 84:1043-1054,2006.
PubMed
2) Hales CN,Barker DJ:Type 2(non-insulin-dependent)diabetes mellitus:the thrifty phenotype hypothesis.Diabetologia 35:595-601,1992.
PubMed
3) Hanson MA,et al:Developmental origins of health and disease:new insights.Basic Clin Pharma-col Toxicol 102:90-93,2008.
 
4) Anazawa S,et al:Low birth weight and development of type 2 diabetes in a Japanese population.Diabetes Care 26:2210-2211,2003.
 
5) Sugihara S,et al:Analysis of weight at birth and at diagnosis of childhood-onset type 2 diabetes mellitus in Japan.Pediatr Diabetes 9:285-290,2008.
PubMed
6) Katz DL,et al:Strategies for the prevention and control of obesity in the school setting:systematic review and meta-analysis.Int J Obes 32:1780-1789,2008.
 
7) Freemark M,et al:The effects of metformin on body mass index and glucose tolerance in obese ado-lescents with fasting hyperinsulinemia and a family history of type 2 diabetes.Pediatrics 107:E55,2001.
 
8) The HEALTHY Study Group;Foster GD,et al:A school-based intervention for diabetes risk reduction.N Engl J Med 363:443-453,2010.
 
9) American Diabetes Association:Standards of medical care in diabetes-2009.Diabetes Care 32(Suppl 1):S13-S61,2009.
 
10) Rosenbloom AL,et al:ISPAD Clinical Practice Consensus Guidelines 2006-2007.Type 2 diabetes mellitus in the child and adolescent.Pediatr Diabetes 9:512-526,2008.
PubMed
11) August GP,et al:Prevention and treatment of pediatric obesity:an endocrine society clinical prac-tice guideline based on expert opinion.J Clin Endocrinol Metab 93:4576-4599,2009.
 
12) Sheila G,et al:Prevention and treatment of type 2 diabetes mellitus in children,with special empha-sis on American Indian and Alaska Native children.Pediatrics 112:e328-347,2003.
 
13) Libman IM,et al:Prevention and treatment of type 2 diabetes in youth.Horm Res 67:22-34,2007.
PubMed
14) Karam JG,et al:Prevention of type 2 DM:implications for adolescents and young adults.Pediatr Endocrinol Rev 5(Suppl 4) :980-988,2008.
 
15) Shiga K,et al:Children with type 2 diabetes meilitus are at greater risk of macrovascular complica-tions.Pediatr Int 51:563-567,2009.
 
P.50 掲載の参考文献
1) 柳澤克之:小児発症1型糖尿病のトランジション-内科の立場からの現状と問題点.日内分泌会誌 86:656,2010.
Medical*Online
2) 日本糖尿病学会/日本小児内分泌学会(編):小児科から内科への移行.小児・思秋期糖尿病管理の手びき,改訂第3版,p268-270,南江堂,2011.
 
3) Van Walleghem N,et al:Evaluation of a systems navigator model for transition from pediatric to adult care for young adults with type 1 diabetes.Diabetes Care 31:1529-1530,2008.
PubMed
4) Peters A,Laffel L;The American Diabetes Association Transitions Working Group:Diabetes care for emerging adults:recommendations for transition from pediatric to adult diabetes care systems.Diabetes Care 34:2477-2485,2011.
 
P.54 掲載の参考文献
1) Kesavadev JD,et al:Diabetes in old age:An emerging epidemic.J Assoc Physicians India 51:1083-1094,2003.
PubMed
2) Scheen AJ:Diabetes mellitus in the elderly:insulin resistance and/or impaired insulin secretion? Diabetes Metab 2:5S27-5S34,2005.
 
3) Basu R,et al:Mechanisms of age-associated deterioration in glucose tolerance:contribution of alterations in insulin secretion,action and clearance. Diabetes 52:1738-1748,2003.
PubMed
4) Roder ME,et al:Reduced pancreaticβ-cell compensation to the insulin resistance of aging:impact on proinsulin and insulin levels. J Clin Endocrinol Metab 85:2275-2280,2000.
 
5) Meneilly GS,et al:Increased disorderliness of basal insulin release,attenuated insulin secretory burst mass,and reduced ultradian rhythmicity of insulin secretion in older individuals. J Clin Endo-crinol Metab 82:4088-4093,1998.
 
6) Meneilly GS,et al:The effect of age and glycaemic level on the response of the β-cell to glucose-dependent insulinotropic polypeptide and peripheral tissue sensitivity to endogenously released insulin. J Clin Endocrinol Metab 83:2925-2932,1998.
 
7) Mobbs CV,et al:Secrets of the lac operon. Glucose hysteresis as a mechanism in dietary restric-tion,aging and disease. Interdiscip Top Gerontrol 35:39-68,2007.
 
8) Finkel T,Holbrook NJ:Oxidants,oxidative stress and the biology of ageing. Nature 408:239-247,2000.
PubMed
9) Kelley DE,et al:Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51:2944-2950,2002,
PubMed
10) Michikawa Y,et al:Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. Science 286:774-779,1999.
PubMed
11) Maechler P,Wolheim CB:Mitochondrial function in normal and diabetic beta-cells. Nature 414:807-812,2001.
 
12) Petersen KF,et al:Mitochondrial dysfunction in the elderly:possible role in insulin resistance. Sci-ence 300:1140-1142,2003.
 
13) Mariotti S,et al:The aging thyroid. Endocr Rev 16:686-715,1995.
PubMed
14) Russell-Aulet M,et al:In vivo semiquantification of hypothalamic growth hormone-releasing hor-mone(GHRH)output in humans:evidence for relative GHRH deficiency in aging. J Clin Endocrinol Metab 84:3490-3497,1999.
 
15) Tenover JL:Testosterone and the aging male. J Androl 18:103-106,1997.
PubMed
P.58 掲載の参考文献
1) 平成18年国民健康・栄養調査結果の概要,p29-30,厚生労働省健康局総務課生活習慣病対策室, 2008.
 
2) Basu R,et al:Mechanisms of the age-associated deterioration in glucose tolerance:contribution of alterations in insulin secretion, action, and clearance. Diabetes 52:1738-1748,2003.
PubMed
3) Petersen KF,et al:Mitochondrial dysfunction in the elderly:possible role in insulin resistance. Sci-ence 300:1140-1142,2003.
 
4) 藤平和弘,横野浩一:糖尿病の特徴.現代医療 34(2):129-133,2002.
 
5) Katakura M,et al:Prospective analysis of mortality, morbidity, and risk factors in elderly diabetic subjects:Nagano study. Diabetes Care 26:638-644,2003.
PubMed
6) 谷崎弓裕,清原裕:糖尿病とアルツハイマー病の関連-久山町研究から-.アンチ・エイジング医学 4:68-74,2008.
Medical*Online
7) Whitmer RA,et al:Hypoglycemic episodes and risk of dementia in older patients with type 2 diabe-tes mellitus. JAMA 301(15):1565-1572,2009.
 
8) Wahl PW,et al:Diabetes in older adults:comparison of 1997 American Diabetes Association classifi-cation of diabetes mellitus with 1985 WHO classification. Lancet 352:1012-1015,1998.
 
9) 井藤英喜:長寿科学総合研究班の作成した老年者の糖尿病治療ガイドラインの概要.Geriatr Med 34:899-902, 1996.
 
10) 井藤英喜:高齢者糖尿病の治療指針.PRACTICE 26(5):496-503,2009.
 
11) 日本糖尿病学会(編):高齢者の糖尿病.科学的根拠に基づく糖尿病診療ガイドライン2010,p219-230,南光堂,2010.
 
P.65 掲載の参考文献
1) 藤澤智巳ほか:高齢者糖尿病における臨床的多様性.日老医誌 39:390-392,2002.
 
2) 井藤英喜:長寿科学総合研究班の作成した'老年者の糖尿病治療ガイドライン'の概要.Geriatr Med 34:889-902,1996.
 
3) California Healthcare Foundation/American Geriatric Society Panel on Improving Care for Elders with Diabetes:Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 51:S265-S280,2003.
PubMed
4) 日本糖尿病学会(編):高齢者の糖尿病.糖尿病治療ガイド2010,p88,文光堂,2010.
 
5) Bremer JP,et al:Hypoglycemia unawareness in older compared with middle-aged patients with type 2 diabetes. Diabetes Care 32:1513-1517,2009.
PubMed
6) Budnitz DS,et al:Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 365:2002-2012,2011.
PubMed
7) Whitmer RA,et al:Hypoglycemic episodes and risk of dementia in older patients with type 2 diabe-tes mellitus. JAMA 301:1565-1572,2009.
 
8) Fujisawa T,et al:Present state of diabetes management in the elderly, Japan. Diabetes Res Clin Pract 77(Suppl 1):S82-S86,2007.
 
9) 池上博司ほか:高齢者糖尿病の臨床像ならびに合併症進行に関する検討.日眼紀要 52:118-121,2001.
 
10) Fujisawa T,et al:Association of plasma fibrinogen level and blood pressure with diabetic retinopa-thy, and renal complications associated with proliferative diabetic retinopathy, in Type 2 diabetes mellitus. Diabet Med 16:522-526,1999.
 
11) Desouza C,et al:Association of hypoglycemia and cardiac ischemia:a study based on continuous monitoring. Diabetes Care 26:1485-1489,2003.
PubMed
12) Nelson JM,et al:The relationship between glycemic control and falls in older adults. J Am Geriatr Soc 55:2041-2044,2007.
PubMed
13) Schwartz AV,et al;Health, Aging, and Body Composition Study:Diabetes-related complications,glycemic control, and falls in older adults. Diabetes Care 31:391-396,2008.
PubMed
14) 荒木厚,千葉優子:糖尿病患者における転倒.医学のあゆみ 239:457-461,2011.
Medical*Online
P.69 掲載の参考文献
1) Skyler JS,et al:Intensive Glycemic control and the prevention of cardiovascular events:implica-tions of the ACCORD,ADVANCE,and VA diabetes trials. Diabetes Care 32:187-192,2009.
 
2) Ben-Ami H,et al:Drug-induced hypoglycemic coma in 102 diabetic patients. Arch Intern Med 159:281-284,1999.
PubMed
3) Zoungas S,et al:Severe hypoglycemia and risks of vascular events and death. N Engl J Med 363:1410-1418,2010.
PubMed
4) Beckett NS,et al:Treatment of hypertension in patients 80 years of age or older. N Engl J Med 358:1887-1898,2008.
 
5) Shephers J,et al:Pravastatin in elderly individuals at risk of vascular disease(PROSPER):a random-ized controlled trial. Lancet 360:1623-1630,2002.
 
6) Holman RR,et al:10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589,2008.
PubMed
7) Laiteerapong N,et al:Correlates of quality of life in older adults with diabetes:the diabetes and aging study. Diabetes Care 34:1749-1753,2011.
PubMed
8) Matyka K,et al:Altered hierarchy of prospective responses against severe hypoglycemia in normal aging in healthy men. Diabetes Care 20:135-141,1997.
 
9) 日本糖尿病学会(編):高齢者の糖尿病.科学的根拠に基づく糖尿病治療ガイドライン,p211-219,南江堂,2007.
 
10) California Healthcare Foundation/American Geriatrics Society Panel on Improving Care for Elders with Diabetes:Guidelines for improving the care of the older person with diabetes mellitus. J Am Geriatr Soc 54:S265-S280,2003.
 
11) Lee SJ,et al:The risks and benefits of implementing glycemic control guidelines in frail older adults with diabetes mellitus. J Am Geriatr Soc 59:666-672,2011.
PubMed
12) Pogach LM,et al:Development of evidence-based clinical practice guidelines for diabetes. Diabe-tes Care 27(Suppl 2):B82-B89,2004.
 
13) Riddle M,et al:Contributions of basal and postprandial hyperglycemia over a wide range of A1C lev-els before and after treatment intensification in type 2 diabetes. Diabetes Care 34:2508-2514,2011.
 
14) Chapman RH,et al:Predictors of adherence with antihypertensive and lipid-lowering therapy. Arch Intern Med 165:1147-1152,2005.
PubMed
15) Monami M,et al:Dipeptidyl peptidase-4 inhibitors and bone fractures. Diabetes Care 34:2474-2476,2011.
PubMed
P.73 掲載の参考文献
1) Tessier D,et al:Effects of aerobic physical exercise in the elderly with type 2 diabetes mellitus.Arch Gerontol Geriatr 31:121-132,2000.
PubMed
2) Ligtenberg PC,et al:Effects of physical training on metabolic control in elderly type 2 diabetes melli-tus patients.Clin Sci(Lond) 93:127-135,1997.
 
3) Skarfors ET,et al:Physical training as treatment for type 2(non-insulin-dependent)diabetes in eld-erly men. A feasibility study over 2 years.Diabetologia 30:930-933,1987.
 
4) 佐藤祐造(編):高齢者と運動.高齢者運動処方ガイドライン,p1-6,南江堂,2002.
 
5) 三村寛一ほか:中高齢者の体力と生活・運動習慣に関する研究.大阪教育大学紀要 54:35-44,2006.
 
6) Sherman KJ,et al:Arandomized trial comparing yoga, stretching, and a self-care book for chronic low back pain. Arch Intern Med 171:2019-2026,2011.
 
7) Hedge SV,et al:Efffect of 3-month yoga on oxidative stress in type 2 diabetes with or without com-plications:a controlled clinical trial.Diabetes Care 34:2208-2210,2011.
 
8) 科学的根拠に基づく糖尿病診療ガイドライン2010策定に関する委員会:食事療法.科学的根拠に基づく糖尿病診療ガイドライン2010,p31-40,南江堂.2010.
 
9) 科学的根拠に基づく糖尿病診療ガイドライン2010策定に関する委員会:高齢者の糖尿病.科学的根拠に基づく糖尿病診療ガイドライン2010,p219-230,南江堂.2010.
 
10) 食品交換表編集委員会:食品交換表の使い方.糖尿病食事療法のための食品交換表,第6版,p12-23,日本糖尿病協会,文光堂,2002.
 
11) American Diabetes Association:Standards of Medical Care in Diabetes-2012.Diabetes Care 35:S11-S63,2012.
PubMed
12) 山下茂子:糖尿病の食事.さかえ 51(12):20-21,2011.
 
13) 泉妃咲ほか:健常者における低糖質ケーキが糖脂質指標に与える影響.糖尿病 55:2012.(in press)
 
14) Woo MH,et al:A comparative study of diet in good and poor glycemic control group in elderly patients with type 2 diabetes mellitus. Korean Diabetes J 34:303-311,2010.
PubMed
15) Seltzer HS:Drug-induced hypoglycemia. A review of 1,418 cases. Endocrinol Metab Clin North Am 18:163-183, 1989.
 
P.79 掲載の参考文献
1) Ellis G,et al:Comprehensive geriatric assessment for older adults admitted to hospital. Cochrane Database Syst Rev(7):CD006211,2011.
PubMed
2) 荒木厚:Master Lecture老年医学的総合評価.糖尿病診療マスター 1:400-409,2003.
 
3) Araki A,Ito H:Diabetes and geriatric syndromes. Geriatr Gerontol Int 9:105-114,2009.
PubMed
4) Araki A,et al:Low well-being, cognitive impairment and visual impairment were associated with functional disabilities in elderly Japanese patients with diabetes mellitus. Geriatr Gerontol Int 4:27-36,2004.
 
5) Gregg EW,et al:Diabetes and physical disability among older U.S. adults. Diabetes Care 23:1272-1277, 2000.
PubMed
6) Gregg EW,et al;The Study of Osteoporotic Fractures Research Group:Diabetes and incidence of functional disability in older women. Diabetes Care 25:61-67,2002.
 
7) Bainbridge KE,et al:Diabetes and hearing impairment in the United States:audiometric evidence from the National Health and Nutrition Examination Survey,1999 to 2004. Ann Intern Med 149:1-10,2008.
PubMed
8) Cukierman T,et al:Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia 48:2460-2469,2005.
PubMed
9) 荒木厚:糖尿病と認知症.PRACTICE(別冊), p61-68,医歯薬出版,2009.
 
10) Egede LE:Diabetes, major depression, and functional disabilities among the U.S. adults. Diabetes Care 27:421-428, 2004.
 
11) Black SA,et al:Depression predicted increased incidence of adverse health outcomes in older Mexi-can Americans with type 2 diabetes. Diabetes Care 26:2822-2828,2003.
 
12) Araki A,et al:Low well-being is an independent predictor for stroke in elderly patients with diabe-tes mellitus. J Am Geriatr Soc 52:205-210,2004.
 
13) Araki A,Ito H:Development of elderly diabetes burden scale for elderly patients with diabetes mellitus. Geriatr Gerontol Int 3:212-224,2003.
 
14) 高橋光子ほか:高齢糖尿病患者の身近な社会参加は生活満足度と関連する.日老医誌 47:140-147, 2010.
 
15) Park SW,et al:Decreased muscle strength and quality in older adults with type 2 diabetes:the health,aging,and body composition study. Diabetes 55:1813-1818,2006.
PubMed
16) Strotmeyer ES,et al:The relationship of reduced peripheral nerve function and diabetes with physi-cal performance in older white and black adults, The Health, Aging, and Body Composition(Health ABC)Study. Diabetes Care 31:1767-1772,2008.
 
17) Kristine E,et al:The Osteoporotic Fractures in Men(MrOS)Research Group:Acomparison of frailty indexes for the prediction of falls,disability,fractures and mortality in older men. J Am Geri-atr Soc 57:492-498,2009,
 
18) Feil DG,et al:Risk of hypoglycemia in older veterans with dementia and cognitive impairment:implications for practice and policy. J Am Geriatr Soc 59:2263-2272,2011.
 
P.83 掲載の参考文献
1) Kopf D,Frolich L:Risk of incident Alzheimer's disease in diabetic patients:Asystemic review of prospective trials. J Alzheimers Dis 16:677-685,2009.
 
2) Ott A,et al:Diabetes mellitus and the risk of dementia. Neurology 53:1937-1942,1999.
PubMed
3) Sakurai T, Yokono K:Comprehensive studies of cognitive impairment of the elderly with type 2 diabetes. Geriatr Gerontol Int 6:159-164,2006.
 
4) Araki A Ito H:Diabetes and geriatric syndrome. Geriatr Gerontol Int 9:105-114,2009.
PubMed
5) 井藤英喜:高齢者糖尿病の管理のすすめかた.Medical Practice 26:583-588,2009.
Medical*Online
6) Cukierman T,et al:Cognitive decline and dementia in diabetes. systematic overview of prospective observational studies. Diabetologia 48:2460-2469,2005.
PubMed
7) Araki A,et al:Low well-being is an independent predictor for stroke in elderly patients with diabe-tes mellitus. J Am Geriatr Soc 52:205-210,2004.
 
8) Gregg EW,et al;The Study of Osteoporotic Fractures Research Group:Diabetes and incidence of functional disability in older women. Diabetes Care 25:61-67,2002.
 
9) Black SA,et al:Depression predicted increased incidence of adverse health outcomes in older Mexi-can Americans with type 2 diabetes. Diabetes Care 26:2822-2828,2003.
 
10) Nelson JM,et al:The relationship between glycemic control and falls in older adults. J Am Geriatr Soc 55:2041-2044,2007.
PubMed
P.89 掲載の参考文献
1) Catalano PM,et al:Longitudinal changes in glucose metabolism during pregnancy in obese women with normal glucose tolerance and gestational diabetes mellitus. Am J Obstet Gynecol 180:903-916,1999.
PubMed
2) 杉山隆:妊娠時のインスリン抵抗性の機序と肥満・妊娠糖尿病との関連.日産婦会誌 58:1540-1547,2006.
 
3) Miyakoshi K,et al:Pancreatic beta-cell function in women with gestational diabetes mellitus defined by new consensus criteria. Diabetes Care 34:e8,2011.
PubMed
4) Catalano PM,et al:Longitudinal changes in insulin release and insulin resistance in non-obese pregnant women. Am J Obstet Gynecol 165:1667-1772,1991.
 
5) Catalano PM, Kirwan JP:Clinical utility and approaches for estimating insulin sensitivity in preg-nancy. Semin Perinatol 26:181-189,2002.
 
6) Buchanan TA:Pancreatic B-cell defects in gestational diabetes:implications for the pathogenesis and prevention of type 2 diabetes. J Clin Endocrinol Metab 86:989-993,2001.
PubMed
7) Kirwan JP,et al:TNF-alpha is a predictor of insulin resistance in human pregnancy. Diabetes 51:2207-2213, 2002.
PubMed
8) Shao J,et al:Phosphatidylinositol 3-kinase redistribution is associated with skeletal muscle insulin resistance in gestational diabetes mellitus. Diabetes 51:19-29,2002.
 
9) Kim H,et al:Serotonin regulates pancreatic beta-cell mass during pregnancy. Nat Med 16:804-808,2010.
PubMed
P.93 掲載の参考文献
1) 妊娠糖尿病診断基準検討委員会:妊娠糖尿病診断基準検討委員会報告.糖尿病と妊娠 10:21,2010.
 
2) 妊婦の糖尿病診断基準ならびに管理検討小委員会:栄養代謝問題委員会報告 糖代謝異常妊婦とくに妊娠糖尿病の診断に関する指針(案).日産婦誌 36:2055-2058,1984.
 
3) 大森安恵:我が国における糖尿病妊婦分娩例の実態.Diabetes Frontier 3:450-454,1992.
 
4) 佐中眞由実ほか:糖代謝異常妊娠全国調査の概要-1996-2002年.糖尿病と妊娠 5:37-41,2005.
 
5) 杉山隆ほか:妊娠糖尿病のスクリーニングに関する多施設共同研究報告.糖尿病と妊娠 6:7-12, 2006.
 
6) 森田益子ほか:当院における19.5年間の初産妊婦の耐糖能変化 広島市立安佐市民病院初産妊婦における妊娠後期75g経口糖負荷試験を中心として.糖尿病と妊娠 10:85-87,2010.
 
7) 三田尾賢ほか:当科における20年間の初産妊婦の耐糖能変化.日産婦誌 63:566,2011.
 
P.100 掲載の参考文献
1) The HAPO Study Cooperative Research Group:Hyperglycemia and Adverse Pregnancy Outcome(HAPO)Study. N Engl J Med 358:1991-2002,2008.
 
2) International Association of Diabetes and Pregnancy Study Groups Consensus Panel:International association of diabetes and pregnancy study groups recommendations on the diagnosis and classifica-tion of hyperglycemia in pregnancy. Diabetes Care 33(3):676-682,2010.
 
3) 日本産科婦人科学会:日本糖尿病・妊娠学会の妊娠糖尿病診断基準について.日本産科婦人科学会HP[http://www.jsog.jp/jsog_web/html/committee/specialty/pdf/gdm_100621_62_8.pdf](2010.7.4).
 
4) Hagbard L,Svanborg H:Prognosis of diabetes mellitus with onset during pregnancy. A clinical study of seventy-one cases. Diabetes 9:296-302,1960.
 
5) O'Sullivan JB:The interaction between pregnancy,diabetes,and long-term maternal outcome. In:Diabetes Mellitus in Pregnancy,2nd ed(ed by Reece EA,Coustan DR),p353-360,Churchill Livingstone,New York,1995.
 
6) O'Sullivan JB:Gestational diabetes:factors influencing rate of subsequent diabetes. In:Carbohy-drate Metabolism in Pregnancy and the Newborn(ed by Sutherland HW,Stowers JM),p429,Sprin-ger-Verlag,New York,1978.
 
7) O'Sullivan JB,Mahan CM:Criteria for oral glucose tolerance in pregnancy. Diabetes 13:278-285,1964.
PubMed
8) Carpenter MW, Coustan DR:Criteria for screening tests for gestational diabetes. Am J Obstet Gyn-ecol 144:768-773,1982.
 
9) 妊婦の糖尿病診断基準ならびに管理検討小委員会:栄養代謝問題委員会報告-糖代謝異常妊婦とくに妊娠糖尿病の診断に関する指針(案)-.日産婦会誌 36:2055-2058,1984.
 
10) Diabetes mellitus:report of a WHO study group. World Health Organ Tech Rep Ser 727:1-113,1985.
 
11) HAPO Study Cooperative Research Group:Hyperglycaemia and Adverse Pregnancy Outcome(HAPO)Study:associations with maternal body mass index. BJOG 117:575-584,2010.
 
12) Crowther CA,et al:Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 352(24):2477-2486,2005.
PubMed
13) Landon MB,et al:The National Institute of Child Health and Human Development Maternal-Fetal Medicine Unit Network randomized clinical trial in progress:Standard therapy versus no therapy for mild gestational diabetes. Diabetes Care 30(Suppl 2):S194-S199,2007.
 
14) 日下秀人ほか:JAGS trialによる新基準GDMスクリーニング法に関する検討.日本産科婦人科栄養・代謝研究会誌 17:24,2011.
 
15) O'Sullivan EP,et al:Atlantic Diabetes in Pregnancy(DIP):the prevalernce and outcomes of gestational diabetes mellitus using new diagnostic criteria. Diabetologia 54:1670-1675,2011.
PubMed
16) ACOG Committee Opinion No.504.Screening and diagnosis of gestational diabetes mellitus. Obstet Gynecol 118:751-753,2011.
PubMed
17) Ballamy L,et al:Type 2 diabetes mellitus after gestational diabetes:a systematic review and meta-analysis. Lancet 373:1773-1779,2009.
 
P.104 掲載の参考文献
1) HAPO Study Cooperative Research Group:Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 58:1991-2002,2008.
 
2) IADPSG Consensus Panel:International Association of Diabetes and Pregnancy Study Groups recom-mendations on the diagnosis and classification of hyperglycemia in pregnancy. Diabetes Care 33:676-682,2010.
 
3) 糖尿病診断基準に関する調査検討委員会:糖尿病の分類と診断基準に関する委員会報告.糖尿病 53:450-467,2010.
 
4) 妊娠糖尿病診断基準検討委員会:妊娠糖尿病診断基準変更に関する委員会報告.糖尿病と妊娠 10:21,2010.
 
5) 糖尿病診断基準検討委員会:糖尿病の分類と診断基準に関する委員会報告.糖尿病 42:385-404,1999.
 
6) 増本由美ほか:新しい妊娠糖尿病診断基準採用による妊娠糖尿病の頻度と周産期予後への影響.糖尿病と妊娠 10:88-91,2010.
 
7) Morikawa M,et al:Change in the number of patients after the adoption of IADPSG criteria for hyperglycemia during pregnancy in Japanese women. Diabetes Res Clin Pract 90:339-342,2010.
PubMed
8) 日本産科婦人科学会,日本産婦人科医会:CQ005妊婦の耐糖能の検査は? 産科診療ガイドライン-産科編2011,p16-20,日本産科婦人科学会,2011.
 
P.110 掲載の参考文献
1) 中林正雄ほか:妊娠糖尿病診断基準変更に関する委員会報告.糖尿病と妊娠 10:21,2010.
 
2) The HAPO Study Cooperative Research Group:Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358:1991-2002,2008.
 
3) 杉山隆ほか:妊娠糖尿病の新基準と最新エビデンス-新基準による妊娠糖尿病の周産期予後について.産婦人科の実際 60:821-830,2011.
 
4) Crowther CA,et al:Effect of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 352:2477-2486,2005.
PubMed
5) Landon MB,et al:A multicenter,randomized trial of treatment for gestational diabetes. N Engl J Med 361:1339-1348,2009.
PubMed
6) Sacks DA,et al:Toward universal criteria for gestational diabetes:the 75-gram glucose tolerance test in pregnancy. Am J Obstet Gynecol 172:607-614,1995.
PubMed
7) Yogev Y,et al:Diurnal glycemic profile in obese and normal weight nondiabetic pregnant women. Am J Obstet Gynecol 191:949-953,2004.
PubMed
8) Javanovic PL,et al:Maternal postprandial glucose levels and infant birth weight:The diabetes in early pregnancy study. Am J Obstet Gynecol 164:103-111,1991.
 
9) Combs CA,et al:Relationship of macrosomia to maternal postprandial glucose control during pregnancy. Diabetes Care 15:1251-1257,1992.
PubMed
10) Langer O,et al:Intensified versus conventional management of gestational diabetes. Am J Obstet Gynecol 170:1036-1045,1994.
PubMed
11) Langer O,et al:Glycemic control in gestational diabetes mellitus-How tight is tight enough:Small for gestational age versus large for gestational age? Am J Obstet Gynecol 161:646-653,1989.
PubMed
12) 日本糖尿病学会(編):妊婦の糖代謝異常.科学的根拠に基づく糖尿病診療ガイドライン2010,p193-205,南江堂,2010.
 
13) 鈴木貴博ほか:糖尿病合併妊娠におけるContinuous Glucose Monitoring System(CGMS)の使用経験とその有用性の検討.糖尿病と妊娠 8:89-94,2008.
 
14) Sameshima H,et al:Early glycemic control reduces large-for-gestational-age infants in 250 Japa-nese gestational diabetes pregnancies. Am J Perinatol 17:371-376,2000.
 
15) 清水一紀ほか:糖尿病合併妊婦および妊娠糖尿病におけるグリコアルブミンと母児合併症に関する調査.糖尿病と妊娠 10:27-31,2010.
 
16) 厚生労働省「日本人の食事摂取基準」策定検討会:エネルギー.日本人の食事摂取基準(2010年版),p43-61,第一出版社,2010.
 
17) De Boo HA, Harding JE:The developmental origins of adult disease(Barker)hypothesis. Aust NZ J Obstet Gynaecol 46:4-14,2006.
 
18) O'Sullivan JB:Diabetes mellitus after GDM. Diabetes 40(Suppl 2):131-135,1991.
 
19) Bellamy L,et al:Type 2 diabetes mellitus after gestational diabetes:a systematic review and meta-analysis. Lancet 373:1773-1779,2009.
PubMed
20) Retnakaran R,et al:β-cell function declines within the first year postpartum in women with recent glucose intolerance in pregnancy. Diabetes Care 33:1798-1804,2010.
 
21) 杉山 隆ほか:妊娠糖尿病のスクリーニングに関する多施設共同研究報告.糖尿病と妊娠 6:7-12,2006.
 
22) 増本由美ほか:新しい妊娠糖尿病診断基準採用による妊娠糖尿病の頻度と周産期予後への影響.糖尿病と妊娠 10:88-91,2010.
 
P.116 掲載の参考文献
1) 大森安恵:母子を糖尿病から守る予防キャンペーン-妊娠前における糖代謝異常検出への期待-.糖尿病と妊娠 11(1):2-5,2011.
 
2) Uchigata Y,et al:Time-course changes in clinical features of early-onset Japanese type 1 and type 2 diabetes:TWMU hospital-based study. Diabetes Res Clin Pract 82(1):80-86,2008.
PubMed
3) 大森安恵:日本糖尿病学会におけるGDMの定義と診断基準.糖尿病と妊娠の医学-糖尿病妊婦治療の歴史と展望,p84-87,文光堂,2008.
 
4) 中林正雄ほか:多施設における妊娠糖尿病の新しい診断基準を用いた臨床統計.糖尿病と妊娠 11(1):85-92,2011.
 
5) Pedersen J:Hyperglycemia-Hyperinsulinism Theory and Birth Weight. In:The Pregnant Diabetic and Her Newborn,2nd ed,p211-217, Munksgaard,Copenhagen,1977.
 
6) Weiss AMP:Diabetes in Pregnancy:Lesson from the Fetus. In:Diabetes and Pregnancy(ed by Dornhorst A, Hadden DR),p221-240,Wiley London,1996.
 
7) 和栗雅子ほか:妊娠中に発見された糖尿病症例にみる先天奇形の出現頻度.Diabetes Frontier 10(5):685-689,1999.
Medical*Online
8) Mills JL,et al:Malformations in infants of diabetic mother occur before the seventh gestational week:implication for treatment. Diabetes 28:292-293,1979.
PubMed
9) 赤澤昭一:糖尿病母体児における奇形の発生機序.Diabetes Frontier 10(5):672-678,1999.
Medical*Online
10) 荒木威ほか:献血者集団におけるグリコアルブミン値の解析.糖尿病 54(5):337-343,2011.
 
P.120 掲載の参考文献
1) 日本糖尿病・妊娠学会 妊娠糖尿病診断基準検討委員会:妊娠糖尿病診断基準変更に関する委員会報告.糖尿病と妊娠 10:21,2010.
 
2) O'Sullivan JB:The Boston gestational diabetes studies;review and perspectives. In:Carbohydrate metabolism in pregnancy and the newborn,4th ed(ed by Sutherland HW,et al),p287-294,Sprin-ger-Verlag,London,1989.
 
3) O'Sullivan JB:Diabetes mellitus after GDM. Diabetes 40:131-135,1991.
PubMed
4) Bellamy L,et al:Type 2 diabetes mellitus after gestational diabetes:asystematic review and meta-analysis. Lancet 373:1773-1779,2009.
 
5) 和栗雅子ほか:妊娠糖尿病および対照群の分娩後のフォローアップ-分娩後の糖尿病発症に関連する因子-.日未病システム会誌 12:148-151,2006.
 
6) 葛谷健ほか:糖尿病の分類と診断基準に関する委員会報告.糖尿病 42:385-404,1999.
 
7) 和栗雅子ほか:妊娠糖尿病の分娩後フォローアップに関する検討.糖尿病と妊娠 10:67-72,2010.
 
8) O'Sullivan JB:Body weight and subsequent diabetes mellitus. JAMA 248:949-952,1982.
PubMed
9) Coustan DR,et al:Gestational diabetes:Predictor of subsequent disordered glucose metabolism. Am J Obstet Gynecol 168:1139-1145,1993.
PubMed
10) Kios SL,et al:Predicting future diabetes in Latino women with gestational diabetes. Diabetes 44:586-591, 1995.
 
11) Damm P,et al:Predictive factors for the development of dia-betes in women previous gestational diabetes mellitus. Am J Obstet Gynecol 167:607-616,1992.
 
12) Pirkola J,et al:Prepregnancy overweight and gestational diabetes as determinants of subsequent diabetes and hypertension after 20-year follow-up. J Clin Endocrinol Metab 95:772-778,2010.
PubMed
13) Schaefer-Graf UM,et al:How do we reduce the number of cases of missed postpartum diabetes in women with recent gestational diabetes mellitus?Diabetes Care 32:1960-1964,2009.
PubMed
14) Golden SH,et al:Antepartum glucose tolerance test results as predictors of type 2 diabetes mellitus in women with a history of gestational diabetes mellitus:asystematic review. Gend Med 6(Suppl 1):109-122,2009.
 
15) ACOG:Committee Opinion Postpartum screening for abnormal glucose tolerance in women who had gestational diabetes mellitus. Obstet Gynecol 113:1419-1421,2009.
PubMed
P.125 掲載の参考文献
1) 佐中眞由実ほか:糖代謝異常妊娠全国調査の概要.糖尿病と妊娠 5:37-41,2005.
 
2) Fuhman K,et al:Prevention of congenital malformations in infant of insulin dependent diabetic mothers. Diabetes Care 6:219-223,1983.
 
3) Steel JM,et al:Can prepregnancy care of diabetic women reduce the risk of abnormal babies? BMJ 301:1070-1074,1990.
PubMed
4) 佐中眞由実ほか:妊娠.糖尿病の療養指導1998(日本糖尿病学会編),p147-152,診断と治療社,1998.
 
5) 末原節代ほか:当センターにおける糖代謝異常妊婦の頻度と先天異常に関する検討.糖尿病と妊娠 10:104-108,2010.
 
6) 穴澤園子:東京都済生会中央病院における糖尿病妊婦管理の経験から.糖尿病と妊娠 7:157-162,2007.
 
7) 佐中眞由実ほか:糖尿病腎症に関する妊娠の許容条件の検討.糖尿病と妊娠 6:127-135,2006.
 
8) The Diabetes Control and Complications Trial(DCCT)Research Group:Effect of pregnancy on micro-vascular complications in the diabetes control and complications trial. Diabetes Care 23:1084-1091,2000.
 
9) 妊婦の糖尿病代謝異常.科学的根拠に基づく糖尿病診療ガイドライン2010(日本糖尿病学会編),p193-205,南江堂,2010.
 
10) The HAPO study cooperative research group:Hyperglycemia and adverse pregnancy outcomes. N Engl J Med 358:1991-2002,2008.
 
11) Hernandez T,et al:Patterns of glycemia in normal pregnancy:should the current therapeutic tar-gets be challenged? Diabetes Care 34:1660-1668,2011.
 
12) Langer O,et al:Glycemic control in gestational diabetes mellitus-how tight is tight enough:Small for gestational age versus large for gestational age? Am J Obstet Gynecol 161:646-653,1989.
PubMed
13) 厚生労働省:日本人の食事摂取基準(2010年版)[http://www.mhlw.go.jp./shingi/2009/05/sO529-4.html].
 
14) 妊産婦のための食生活指針-「健やか親子21」推進検討会報告書[http://www.mhlw.go.jp/houdou/2006/02/hO201-3a.html].
 
15) Mukhopadhyay A,et al:Continuous subcutaneous insulin infusion vs intensive conventional insulin therapy in pregnant diabetic women:a systematic review and metaanalysis of randomized, con-trolled trials. Am. J Obstet Gynecol 197:447-456,2007.
 
P.130 掲載の参考文献
1) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009,p63-66,ライフサイエンス出版,2009.
 
2) Patel A,et al:Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus(the ADVANCE trial):a random-ized controlled trial. Lancet 370:829-840,2007.
 
3) Jamerson K,et al for the ACCOMPLISH trial investigators:Benazepril plus amlodipine or hydrochlo-rothiazide for hypertension in high-risk patients. N Engl J Med 359:2417-2428,2008.
 
4) Holman RP,et al:10-Year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589,2008.
 
5) Holman RP,et al:Long-term follow up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359:1565-1576,2008.
 
6) The ACCORD Study Group:Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575-1585,2010.
 
7) Cooper-DeHoff RM,et al:Tight blood pressure control and cardiovascular outcomes among hyper-tensive patients with diabetes and coronary artery disease. JAMA 304:61-68,2010.
 
P.136 掲載の参考文献
1) 日本動脈硬化学会(編):動脈硬化性疾患予防ガイドライン2007年版,2007.
 
2) Ginsberg HN,et al:Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 36:232-240,2005.
PubMed
3) Shimomura I,et al:Insulin selectively increases SREBP-lc mRNA in the livers of rats with strepto-zotocin-induced diabetes. Proc Natl Acad Sci USA 96:13656-13661,1999.
 
4) Turner RC,et al:Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus:United Kingdom Prospective Diabetes Study(UKPDS:23). BMJ 316(7134):823-828,1998.
PubMed
5) Sone H,et al:Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes:subanalysis of the Japan Diabetes Complications Study(JDCS). J Clin Endocrinol Metab 96(11)13448-3456,2011.
 
6) Haffner SM,et al:Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 339(4):229-234,1998.
PubMed
7) Colhoun HM,et al:Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS):multicentre randomised placebo-con-trolled trial. Lancet 364(9435):685-696,2004.
 
8) Kearney PM,et al:Cholesterol Treatment Trialists'(CTr)Collaborators:Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins:a meta-analysis.Lancet 371:117-125,2008.
 
9) Altmann SW,et al:Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 303(5661):1201-1204,2004.
PubMed
10) Kobayashi M,et al:Prevention and treatment of obesity,insulin resistance,and diabetes by bile acid-binding resin. Diabetes 56(1):239-247,2007.
PubMed
11) Jun M,et al:Effects of fibrates on cardiovascular outcomes:a systematic review and meta-analy-sis. Lancet 375(9729):1875-1884,2010.
 
12) ACCORD Study Group:Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362(17):1563-1574,2010.
 
13) Keech AC,et al:Effect of fenofibrate on the need for laser treatment for diabetic retinopathy(FIELD study):a randomised controlled trial. Lancet 370(9600):1687-1697,2007.
PubMed
14) Oikawa S,et al:Suppressive effect of EPA on the incidence of coronary events in hypercholestero-lemia with impaired glucose metabolism:Sub-analysis of the Japan EPA Lipid Intervention Study(JELIS). Atherosclerosis 206(2):535-539,2009.
 
15) Sakurai K,et al:Glucagon-like peptide-1 secretion by direct stimulation of L cells with luminal sugar versus non-nutritive sweetener. J Diabetes Investig 3(2):156-163,2012.
 
16) Dormandy JA,et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events):a random-ised controlled trial. Lancet 366(9493):1279-1289,2005.
 
P.140 掲載の参考文献
1) 佐々木陽:肥満の頻度と合併症有病率との関係.肥満研究 4(臨時増刊号):54-59,1998.
 
2) Nakagami T,et al:The DECODE-DECODA study group:Age,body mass index and type 2 diabe-tes-associations modified by ethnicity. Diabetologia 46:1063-1070,2003.
 
3) Balkau B,et al:International day for the evaluation of abdominal obesity(IDEA):a study of waist circumference,cardiovascular disease,and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation 116:1942-1951,2007.
PubMed
4) 森豊ほか:日本人高血圧におけるメタボリックシンドロームの意義とは. Life style Medicine 2:207-214,2008.
Medical*Online
5) Alexander CH,et al:NCEP-defined metabolic syndrome,diabetes,and prevalence of coronary heart disease among NHANE S III participants age 50 years and older. Diabetes 52:1210-1214,2003.
 
6) 日本糖尿病学会(編):科学的根拠に基づく糖尿病診療ガイドライン2010,南江堂,2010.
 
7) 村本あき子ほか:特定健診・保健指導における積極的支援の効果検証と減量目標の妥当性についての検討. 肥満研究 16:182-187,2010.
Medical*Online
8) Rubino F,et al:Metabolic surgery:the role of the gastrointestinal tract in diabetes mellitus. Nat Rev Endocrinol 6:102-109,2010.
PubMed
P.147 掲載の参考文献
1) 西川哲男:クッシング症候群とは? クッシング症候群について教えてください. 肥満と糖尿病 8(3):369,2009.
 
2) Omura M,et al:Prospective study on the prevalence of secondary hyperten-sion among hypertensive patients visiting a general outpatient clinic in Japan. Hypertens Res 27:193-202,2004.
 
3) van Raalte DH,et al:Novel insights into glucocorticoid-mediated diabetogenic effects:towards expansion of therapeutic options? Eur J Clin Invest 39:81-93,2009.
PubMed
4) Seino S,et al:Pancreaticβ-cell signaling:toward better understanding of diabetes and its treat-ment. Proc Jpn Acad Ser 86:563-577,2010.
 
5) Hansen KB,et al:Reduced glucose tolerance and insulin resistance induced by steroid treatment,relative physical inactivity,and high-calorie diet impairs the incretin effect in healthy subjects. J Clin Endocrinol Metab 95:3309-3317,2010.
PubMed
6) Pivonello R,et al:Pathophysiology of diabetes mellitus in Cushing's syndrome. Neuroendocrinol-ogy 92(Suppl 1):77-81,2010.
 
7) Rondinone CM:Adipocyte-derived hormones,cytokines,and mediators. Endocrine 29:81-90,2006.
PubMed
8) Castan-Laurell I,et al:Apelin,diabetes,and obesity. Endocrine 40:1-9,2011.
PubMed
9) Cassuto H,et al:Glucocorticoids regulate transcription of the gene for phosphoenolpyruvate car-boxykinase in the liver via an extended glucocorticoid regulatory unit. J Biol Chem 280:33873-33884,2005.
 
10) Patel R,et al:LXRβis required for glucocorticoid-induced hyperglycemia and hepatosteatosis in mice. J Clin Invest 121:431-441,2011.
 
11) Friedman TC,et al:Carbohydrate and lipid metabolism in endogenous hypercortisolism:shared fea-tures with metabolic syndrome X and NIDDM. Endocr J 43:645-655,1996.
 
12) Biering H,et al:Prevalence of diabetes in acromegaly and Cushing syndrome. Acta Med Austriaca 27:27-31,2000.
PubMed
13) Mancini T,et al:High cardiovascular risk in patients with Cushing's syndrome according to 1999 WHO/ISH guidelines. Clin Endocrinol 61:768-777,2004.
PubMed
14) Pecori Giraldi F,et al:Gender-related differences in the presentation and course of Cushing's dis-ease. J Clin Endocrinol Metab 88:1554-1558,2003.
 
15) Mullan K,et al:Is there value in routine screening for Cushing's syndrome in patients with dia-betes? J Clin Endocrinol Metab 95:2262-2265,2010.
 
16) Mazziotti G,et al:Diabetes in Cushing syndrome:basic and clinical aspects. Trends Endocrinol Metab 22:499-506,2011.
PubMed
17) van Raalte DH,et al:Glucagon-like peptide-1 receptor agonist treatment prevents glucocorticoid-induced glucose intolerance and islet-cell dysfunction in humans. Diabetes Care 34:412-417,2011.
PubMed
18) Pijl H,et al:Bromocriptine:a novel approach to the treatment of type 2 diabetes. Diabetes Care 23:1154-1161,2000.
 
19) Matsuzawa Y,et al:Salivary cortisol can reflect adiposity and insulin sensitivity in type 2 diabetes. In:Steroid-Clinical Aspect(ed by Hassan A), p141-149, InTech, Rijeka,2011.
 
20) 松澤陽子ほか:血液中および唾液中コルチゾール,コルチゾン測定の臨床的意義に関する検討-肥満を伴う2型糖尿病男性患者の分析から-.J Metabolic Syndrome 4:18-23,2007.
 
P.151 掲載の参考文献
1) Moller N,Jorgensen JO:Effects of growth hormone on glucose,lipid,and protein metabolism in human subjects. Endocr Rev 30:152-177,2009.
PubMed
2) Colao A,et al:Systemic complications of acromegaly:epidemiology,pathogenesis,and manage-ment. Endocr Rev 25:102-152,2004.
 
3) del Rincon JP,et al:Growth hormone regulation of p85alpha expression and phosphoinositide 3-kinase activity in adipose tissue:mechanism for growth hormone-mediated insulin resistance. Dia-betes 56:1638-1646,2007.
 
4) Nabarro JD:Acromegaly. Clin Endocrinol(Oxf)26:481-512,1987.
PubMed
5) Kreze A,et al:Risk factors for glucose intolerance in active acromegaly. Braz J Med Biol Res 34:1429-1433,2001.
PubMed
6) Tanimoto K,et al:The influence of age on the GH-IGF1 axis in patients with acromegaly. Eur J Endocrinol 159:375-379,2008.
PubMed
7) Matthews DR,et al:Homeostasis model assessment:insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419,1985.
PubMed
8) Kasayama S,et al:Impaired beta-cell function in the presence of reduced insulin sensitivity deter-mines glucose tolerance status in acromegalic patients. Clin Endocrinol(Oxf)52:549-555,2000.
 
9) Colao A,et al:Predictors of tumor shrinkage after primary therapy with somatostatin analogs in acromegaly:a prospective study in 99 patients. J Clin Endocrinol Metab 91:2112-2118,2006.
PubMed
10) Colao A,et al:Glucose tolerance and somatostatin analog treatment in acromegaly:a 12-month study. J Clin Endocrinol Metab 94:2907-2914,2009.
PubMed
11) Mazziotti G,et al:Effects of somatostatin analogs on glucose homeostasis:a metaanalysis of acromegaly studies. J Clin Endocrinol Metab 94:1500-1508,2009.
PubMed
12) van der Lely AJ,et al:Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 358:1754-1759,2001.
PubMed
13) Jorgensen JO,et al:Cotreatment of acromegaly with a somatostatin analog and a growth hormone receptor antagonist. J Clin Endocrinol Metab 90:5627-5631,2005.
 
14) Lindberg-Larsen R,et al:The impact of pegvisomant treatment on substrate metabolism and insu-lin sensitivity in patients with acromegaly. J Clin Endocrinol Metab 92:1724-1728,2007.
 
15) Colao A,et al:Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endo-crinol Metab 82:518-523,1997.
 
P.157 掲載の参考文献
1) Cryer PE:Adrenaline:aphysiological metabolic regulatory hormone in humans. Int J Obes Relat Metab Disord 17:S43-46,1993.
 
2) Rofougaran R,et al:Insulin-requiring diabetes mellitus,hyperlipidemia,and anginal chest pains as prominent features of pheochromocytoma. Am J Nephrol 17:474-476,1997.
PubMed
3) Winocour PH,et al:Lipid and lipoprotein metabolism in familial combined hyperlipidaemia during treatment of sporadic phaeochromocytoma:a case study. Postgrad Med J 68:371-375,1992.
PubMed
4) Wiesner TD,et al:Improvement of insulin sensitivity after adrenalectomy in patients with pheo-chromocytoma. J Clin Endocrinol Metab 88:3632-3636,2003.
 
5) Ishii C,et al:Diabetic ketoacidosis in a case of pheochromocytoma. Diabetes Res Clin Pract 54:137-142,2001.
 
P.160 掲載の参考文献
1) Chastain MA:The glucagonoma syndrome:a review of its features and discussion of new perspec-tives. Am J Med Sci 321:306-320,2001.
 
2) Soga J, Yakuwa Y:Glucagonomas/diabetico-dermatogenic syndrome(DDS):a statistical evalua-tion of 407 reported cases. J Hepatobiliary Pancreat Surg 5:312-319,1998.
 
3) Wermers RA,et al:The glucagonoma syndrome.Clinical and pathologic features in 21 patients. Medicine(Baltimore)75:53-63,1996.
PubMed
4) 柴田近ほか:グルカゴノーマの診断.肝胆膵 63:263-266,2011.
Medical*Online
5) 土井隆一郎ほか:グルカゴノーマの画像と病理.肝胆膵 49:687-692,2004.
Medical*Online
6) Frankton S,Bloom SR:Gastrointestinal endocrine tumours.Glucagonomas. Baillieres Clin Gastro-enterol 10:697-705,1996.
 
7) Oberg K:Pancreatic endocrine tumors. Semin Oncol 37:594-618,2010.
PubMed
8) 前島英樹,勝岡憲生:内臓悪性腫瘍の皮膚症状.綜合臨牀 53:2747-2749,2004.
Medical*Online
9) Boden G:Insulinoma and glucagonoma. Semin Oncol 14:253-262,1987.
PubMed
10) 瀬座勝志ほか:膵・胆道系の神経内分泌腫瘍の画像診断.胆と膵 28:193-199,2007.
Medical*Online
11) Pisegna JR,et al:Prospective comparative study of ability of MR imaging and other imaging modali-ties to localize tumors in patients with Zollinger-Ellison syndrome. Dig Dis Sci 38:1318-1328,1993.
 
P.164 掲載の参考文献
1) 日本糖尿病学会糖尿病診断基準検討委員会:糖尿病の分類と診断基準に関する委員会報告.糖尿病 42:385-404,1999.
 
2) 伊藤鉄英,五十嵐久人:膵性糖尿病の特徴と診断.スマートな糖尿病診断と治療の進め方(荒木栄一編),p88-93,中山書店,2011.
 
3) Ito T,et al:Epidemiological Study of Pancreatic Diabetes in Japan in 2005:A Nationwide Study. Pancreas 39:829-835,2010.
PubMed
4) 木原康之,原田大:膵性糖尿病の病態に基づいた最適治療-超速効型インスリン治療の有用性-.胆と膵 30:161-165,2009.
Medical*Online
5) 河邉顕ほか:膵性糖尿病の強化インスリン治療.胆と膵 32:493-497,2011.
Medical*Online
6) 中村光男ほか:膵内外分泌不全に対する膵消化酵素及びインスリン補充療法.膵臓 22:454-461,2007.
Medical*Online
7) Nishimori I,et al:Influence of steroid therapy on the course of diabetes mellitus in patients with autoimmune pancreatitis:findings from a nationwide survey in Japan. Pancreas 32:244-248,2006.
 
8) 中村光男,丹藤雄介:膵性糖尿病患者への対応-診断.慢性膵炎の断酒・生活指導指針.膵臓 25:658-659,2010.
 
9) 日本消化器病学会(編):慢性膵炎診療ガイドライン,南江堂,2009.
 
10) 伊藤鉄英ほか:慢性膵炎-治療.膵炎:診断と治療の進歩.日内会誌 99:55-61,2009.
 
11) 中村光男,丹藤雄介:膵性糖尿病患者への対応-食事指導慢性膵炎の断酒・生活指導指針.膵臓 25:660-661,2010.
 
12) 大野隆真:慢性膵炎における栄養療法-消化吸収障害・栄養障害の評価.慢性膵炎の断酒・生活指導指針.膵臓 25:635-636,2010.
 
13) Kawabe K,et al:The current managements of pancreatic diabetes in Japan. Clin J Gastroenterol 2:1-8,2009.
PubMed
14) 五十嵐久人:膵性糖尿病患者への対応-インスリン療法の留意点.慢性膵炎の断酒・生活指導指針.膵臓 25:662-664,2010.
 
P.169 掲載の参考文献
1) 堀田暁ほか:アンケート調査による日本人糖尿病の死因-1991～2000年の10年間,18,385名での検討-.糖尿病 50:47-61,2007.
 
2) Hansen KB,et al:2-Oleoyl glycerol is a GPR119 agonist and signals GLP-1 release in humans. J Clin Endocrinol Metab 96:E1409-1417,2011.
PubMed
3) Dixon JB,et al:Nonalcoholic fatty liver disease:predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 121:91-100,2001.
PubMed
4) Bowman P,et al:Heterozygous ABCC8 mutations are a cause of MODY. Diabetologia 55:123-127,2012.
PubMed
5) Smith BW,Adams LA:Nonalcoholic fatty liver disease and diabetes mellitus:pathogenesis and treat-ment. Nat Rev Endocrinol 7:456-465,2011.
 
P.173 掲載の参考文献
1) Yoon JC,et al:Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413:131-138,2001.
PubMed
2) Lambillotte C,et al:Direct glucocorticoid inhibition of insulin secretion.An in vitro study of dex-amethasone effects in mouse islets. J Clin Invest 99:414-423,1997.
 
3) Imano E,et al:Interferon induces insulin resistance in patients with chronic active hepatitis C. J Hepatol 28:189-193,1998.
 
4) Fabris P,et al:Type 1 diabetes mellitus in patients with chronic hepatitis C before and after inter-feron therapy. Aliment Pharmacol Ther 18:549-558,2003.
 
5) Fukui M,et al:Castration and diabetes. Diabetes Care 23:1032-1033,2000.
PubMed
6) Goldstein LE,et al:New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzap-ine treatment. Psychosomatics 40:438-443,1999.
 
7) Preiss D,et al:Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy:ameta-analysis. JAMA 305:2556-2564,2011.
 
8) Nagata M,et al:Effects of statins on the adipocyte maturation and expression of glucose transporter 4(SLC2A4):implication in glycaemic control. Diabetologia 49:1881-1892,2006.
 
9) Helderman JH,et al:Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 32:106-111,1983.
PubMed
10) Pickkers P,et al:Thiazide-induced hyperglycemia:a role for calcium-activated potassium chan-nels? Diabetologia 39:865-867,1996.
 
11) Gress TW,et al:Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. N Engl J Med 342:905-912,2000.
PubMed
12) Heisel O,et al:New onset diabetes mellitus in patients receiving calcineurin inhibitors:asystematic review and meta-analysis. Am J Transplant 4:583-595,2004.
 
13) Rubeaan K,et al:Phenytoin-induced insulin insensitivity. Diabet Med 8:968-970,1991.
PubMed
14) Park-Wyllie LY,et al:Outpatient gatifloxacin therapy and dysglycemia in older adults. N Engl J Med 354:1352-1361,2006.
PubMed
P.178 掲載の参考文献
1) Hirata Y,et al:Insulin autoimmunity in a case of spontaneous hypoglycemia. J Jpn Diabetes Soc 13:312-320,1970.
 
2) Uchigata Y,et al:Strong association of insulin autoimmune syndrome with HLA-DR4. Lancet 339:393-395,1992.
PubMed
3) Yao K,et al:Human insulin-spechic IgG antibody and hypoglycemic attacks after the injection of gold thioglucose. J Endocrinol Invest 15:43-47,1992.
PubMed
4) Eguchi Y,et al:Longitudinal changes of serum insulin concentration and insulin antibody features in persistent insulin autoimmune syndrome(Hirata Disease). Autoimmunity 19:279-284,1994.
 
5) Uchigata Y,et al:Differential immunogenetic determimants of polyclonal insulin autoimmune syn-drome(Hirata's disease)and monoclonal insulin autoimmune syndrome. Diabetes 44:1227-1232,1995.
 
6) Uchigata Y,et al:Worldwide differences in the incidence of insulin autoimmune syndrome(Hirata Disease)with respect to the evolution of HLA-DR4 alleles. Hum Immunol 61:154-157,2000.
 
7) Takayama-Hasumi S,et al:Insulin autoimmune syndrome is the third leading cause of spontaneous hypoglycemic attacks in Japan. Diabetes Res Clin Pract 10:211-214,1990.
PubMed
8) Uchigata Y,et al:Drug-induced insulin autoimmune syndrome. Diabetes Res Clin Pract 83:e19-20,2009.
PubMed
9) 山口実菜ほか:ブシラミンによって発症したと考えられるインスリン自己免疫症候群の一例.糖尿病 54:698-701,2011.
 
P.182 掲載の参考文献
1) Garg A:Lipodystrophies:Genetic and acquired body fat disorders. J Clin Endocrinol Metab 96:3313-3325,2011.
PubMed
2) Ebihara K,et al:Transgenic overexpression of leptin rescues insulin resistance and diabetes in a mouse model of lipoatrophic diabetes. Diabetes 50:1440-1448,2001.
 
3) Oral A,et al:Leptin-replacement therapy for lipodystrophy. N Engl J Med 346:570-578,2002.
 
4) Ebihara K,et al:Efficacy of long-term leptin-replacement therapy for lipoatrophic diabetes in Japan. N Engl J Med 351:615-616,2004.
 
5) Colombo C,et al:Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105:271-278,2000.
 
P.187 掲載の参考文献
1) Wang J,et al:A mutation in the insulin 2 gene induces diabetes with severe pancreatic β-cell dys-function in the Mody mouse. J Clin Invest 103:27-37,1999.
 
2) Oyadomari S,et al:Targeted disruption of the Chop gene delays endoplasmic reticulum stress-mediated diabetes. J Clin Invest 109:525-532,2002.
PubMed
3) Herbach N,et al:Dominant-negative effects of a novel mutated Ins2 allele causes early-onset diabe-tes and severe β-cell loss in Munich Ins2cC95S mutant mice. Diabetes 56:1268-1276,2007.
 
4) Aguilar-Bryan L,Bryan J:Neonatal diabtes. Endocr Rev 29:265-291,2008.
 
5) Greeley SAW,et al:Neonatal diabetes mellitus:Amodel for personalized medicine. Trends Endo-crinol Metab 21:464-472,2010.
 
6) Stoy J,et al:Insulin gene mutations as a cause of permanent neonatal diabetes. Proc Natl Acad Sci USA 104:15040-15044,2007.
PubMed
7) Glaser G:Insulin mutations in diabetes. The clinical spectrum. Diabetes 57:799-800,2008.
 
8) Stoy J,et al:Clinical and molecular genetics of neonatal diabetes due to mutations in the insulin gene. Rev Endocr Metab Disord 11:205-215,2010.
PubMed
9) Garin L,et al:Recessive mutations in the INS gene result in neonatal diabetes through reduced insu-lin biosynthesis. Proc Natl Acad Sci USA 107:3105-3110,2010.
 
10) Kang HS,et al:Transcription factor Glis3, a novel critical player in the regulation of pancreatic β-cell development and insulin gene expression. Mol Cell Biol 29:6366-6379,2009.
 
11) Senee V,et al:Mutations in GLIS3 are responsible for a rare syndrome with neonatal diabetes mel-litus and congenital hypothyroidism. Nat Genet 38:682-687,2006.
 
12) Bonnefond A,et al:Disruption of a novel Kruppel-like transcription factor p300-regulated pathway for insulin biosynthesis revealed by studies of the c.-331INS mutation found in neonatal diabetes mellitus. J Biol Chem 286:28414-28424,2011.
 
P.192 掲載の参考文献
1) Ullrich A,et al:Human insulin receptor and its relationship to the tyrosine kinase family of oncogenes. Nature 313:756-761,1985.
 
2) Ebina Y,et al:The human insulin receptor cDNA:the structural basis for hormone-activated trans-membrane signalling. Cell 40:747-758,1985.
 
3) Belfiore A,et al:Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 30:586-623,2009.
PubMed
4) Seino S,et al:Structure of the human insulin receptor gene and characterization of its promoter. Proc Natl Acad Sci USA 86:114-118,1989.
PubMed
5) Talukdar I,et al:hnRNP A1 and hnRNP F modulate the alternative splicing of exon 11 of the insulin receptor gene. PLoS One 6:e27869,2011.
PubMed
6) Kahn CR,et al:The syndromes of insulin resistance and acanthosis nigricans.Insulin-receptor dis-orders in man. N Engl J Med 294:739-745,1976.
 
7) 厚生省特定疾患ホルモン受容機構.異常調査研究班:平成7年度総括研究事業報告書,1995.
 
8) Taylor SI:Lilly Lecture:molecular mechanisms of insulin resistance.Lessons from patients with mutations in the insulin-receptor gene. Diabetes 41:1473-1490,1992.
PubMed
9) Musso C,et al:Clinical course of genetic diseases of the insulin receptor(type A and Rabson-Men-denhall syndromes):a 30-year prospective. Medicine(Baltimore)83:209-222,2004.
 
10) 平間記子ほか:ピオグリタゾンが奏効したインスリン受容体異常症姉妹例-血中アディポネクチン値の検討.Diabetes Jounal 36:56-59,2008.
 
11) 原田真耶ほか:インスリン受容体異常症A型に対する19年間のIGF-1治療.糖尿病 53:626-630,2010.
 
12) De Meyts P:The insulin receptor:a prototype for dimeric,allosteric membrane receptors?Trends Biochem Sci 33:376-384,2008.
PubMed
P.197 掲載の参考文献
1) van den Ouweland JM,et al:Mutation in mitochondrial tRNALEU(UUR)gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet 1:368-371,1992.
 
2) Kadowaki T,et al:A subtype of diabetes mellitus associated with a mutation of mitochondrial DNA. N Engl J Med 330:962-968,1994.
PubMed
3) Suzuki S,et al:Clinical features of diabetes mellitus with the mitochondrial DNA 3243(A-G) muta-tion in Japanese:Maternal inheritance and mitochondria-related complications. Diabetes Res Clin Pract 59(3):207-217,2003.
 
4) 日本糖尿病学会(編):糖尿病遺伝子診断ガイド,第2版,文光堂,2003.
 
5) Kirino Y,et al:Codon-specific translational defect caused by a wobble modification deficiency in mutant tRNA from a human mitochondrial disease. Proc Natl Acad Sci USA 101:15070-15075,2004.
PubMed
6) Suzuki S,et al:The effects of coenzyme Q10 treatment on maternal-inherited diabetes mellitus with deafness and mitochondrial DNA 3243(A to G)mutation. Diabetologia 41:584-588,1998.
 
7) Li R,Guan MX:Human mitochondrial leucyl-tRNA synthetase corrects mitochondrial dysfunction due to the tRNALeu(UUR)A3243G mutation, associated with mitochondrial encephalomyopathy,lactic acidosis,and stroke-like symptoms and diabetes. Mol Cell Biol 30:2147-2154,2010.
 
8) Karicheva OZ,et al:Correction of the consequences of mitochondrial 3243A>G mutation in the MT-TL1 gene causing the MELAS syndrome by tRNA import into mitochondria. Nucleic Acid Res 39:8173-8186,2011.
 
P.203 掲載の参考文献
1) Fajans SS,Bell GI:MODY:History,grenetics,pathophysiology,and clinical decision making. Dia-betes Care 34:1878-1884,2011.
 
2) 大谷敏嘉ほか:25歳未満発見インスリン非依存型糖尿病者の遺伝および臨床的特徴.糖尿病 30:739-746,1987.
 
3) Kropff J,et al:Prevalence of monogenic diabetes in young adults:acommunity-based,cross sec-tional study in Oxfordshire,UK. Diabetologia 54:1261-1263,2011.
 
4) Haldorsen IS,et al:The role of pancreatic imaging in monogenic diabetes mellitus. Nat Rev Endo-crinol 8:148-159,2011.
 
5) Bowman P,et al:Heterozygous ABCC8 mutations are a cause of MODY. Diabetologia 55:123-127,2012.
PubMed
6) 岩崎直子:その他のMODY遺伝子.検査値のみかた,改訂第3版(中井利昭編),p884-888,中外医学社,2006.
 
7) Iwasaki N,et al:Mutations in the hepatocyte nuclear factor 1-α/MODY 3 gene in Japanese sub-jects with early-and late-onset NIDDM in Japanese. Diabetes 46:1504-1508,1997.
 
8) Urakami T,et al:Annual incidence and clinical characteristics of type 2 diabetes in children as detected by urine glucose screening in the Tokyo metropolitan area. Diabetes Care 28:1876-1881,2005.
PubMed
9) Ellard S,et al:Best practice guidelines for the molecular genetic diagnosis of maturity-onset diabe-tes of the young MODY group. Diabetologia 51:546-553,2008.
 
10) 日本医学会医療における遺伝学的検査・診断に関するガイドライン,2011[www.jbcs.gr.jp/kensa_shindan/guideline.pdf].
 
11) 岩崎直子:糖尿病領域における遺伝カウンセリング-現状と今後の課題.医学のあゆみ 232:1217-1218,2010.
Medical*Online
12) Menzel R,et al:A low renal threshold for glucose in diabetic patients with a mutation in the hepato-cyte nuclear factor-1α(HNF-1α)gene. Diabet Med 15:816-820,1998.
 
13) Bellanne-Chantelot C,et al:Large genomic rearrangements in the hepatocyte nuclear factor-1β(TCF2)gene are the most frequent cause of maturity-onset diabetes of the young type 5. Diabetes 54:3126-3132,2005.
 
14) Hattersley AT,Pearson ER:Minireview:Pharmacogenetics and beyond:the interaction of therapeu-tic response,β-cell physiology,and genetics in diabetes. Endocrinology 147:2657-2663,2006.
 
15) Besser REJ,et al:Urinary C-peptide creatinine ratio is a practical outpatient tool for identifying hepatocyte nuclear factor 1-α/hepatocyte nuclear factor 4-αmaturity-onset diabetes of the young from long-duration type 1 diabetes. Diabetes Care 34:286-291,2011.
 
16) Iwasaki N,et al:Mutations in the hepatocyte nuclear factor 1α/MODY3 gene in Japanese subjects with early-and late-onset NIDDM. Diabetes 46:1504-1508,1997.
 
P.209 掲載の参考文献
1) Ebihara K,et al:Long-term leptin-replacement therapy for lipoatrophic diabetes. N Engl J Med 351:615-616,2004.
PubMed
2) Garg A:Lipodystrophies:genetic and acquired body fat disorders. J Clin Endocrinol Metab 96:3313-3325, 2011.
PubMed
3) Milunsky A,Neurath PW:Diabetes mellitus in Down's Syndrome. Arch Environ Health 17:372-376,1968.
PubMed
4) Gillespie KM,et al:Islet autoimmunity in children with Down's syndrome. Diabetes 55:3185-3188,2006.
PubMed
5) Zipf WB:Glucose homeostasis in Prader-Willi syndrome and potential implications of growth hor-mone therapy. Acta Paediatr(Suppl)88:115-117,1999.
 
6) Gravholt CH,et al:Morbidity in Turner syndrome. J Clin Epidemiol 51:147-158,1998.
PubMed
7) Ota K,et a1:Diabetes mellitus associated with Klinefelter's syndrome:a case report and review in Japan. Intern Med 41:842-847,2002.
 
8) Yu CE,et al:Positional cloning of the Werner's syndrome gene. Science 12:258-262,1996.
 
9) Yokote K,et al:Dysadipocytokinemia in Werner syndrome and its recovery by treatment with pioglitazone. Diabetes Care 27:2562-2563,2004.
PubMed
10) Inoue H,et al:A gene encoding a transmembrane protein is mutated in patients with diabetes melli-tus and optic atrophy(Wolfram syndrome). Nat Genet 20:143-148,1998.
 
11) Amr S,et al:A homozygous mutation in a novel zinc-finger protein,ERIS,is responsible for Wolf-ram syndrome 2. Am J Hum Genet 81:673-683,2007.
 
12) Ishihara H,et al:Disruption of the WFS1 gene in mice causes progressive beta-cell loss and impaired stimulus-secretion coupling in insulin secretion. Hum Mol Genet 13:1159-1170,2004.
PubMed
13) Savkur RS,et al:Aberrant regulation of insulin receptor alternative splicing is associated with insu-lin resistance in myotonic dystrophy. Nat Genet 29:40-47,2001.
 
14) Semple RK,et al:Elevated plasma adiponectin in humans with genetically defective insulin receptors. J Clin Endocrinol Metab 91:3219-3223,2006.
PubMed
15) Daimon M,et al:Hyperglycemia is a factor for an increase in serum ceruloplasmin in type 2 dia-betes. Diabetes Care 21:1525-1528,1998.
 

IX 糖尿病合併症・糖尿病関連疾患

P.218 掲載の参考文献
1) 日本透析医学会統計調査委員会:図説 わが国の慢性透析療法の現況,2010年12月31日現在.
 
2) 厚生労働省:わが国における視覚障害の現状,1991.
 
3) 厚生労働科学研究費補助金難治性疾患克服研究事業:網脈絡膜・視神経萎縮症に関する研究.平成17年度総括・分担研究報告書,2006.
 
4) 厚生労働省:平成21年度 人口動態統計.
 
P.224 掲載の参考文献
1) Krolewski AS,et al:Epidemiologic approach to the etiology of type 1 diabetes mellitus and its com-plications. N Engl J Med 317:1390-1398,1987.
 
2) Mooyaart AL,et al:Genetic associations in diabetic nephropathy:a meta-analysis. Diabetologia 54:544-553,2011.
PubMed
3) Tanaka N,et al:Association of solute carrier family 12(sodium/chloride)member 3 with diabetic nephropathy, identified by genome-wide analyses of single nucleotide polymorphisms. Diabetes 52:2848-2853,2003.
PubMed
4) Shimazaki A,et al:Genetic variations in the gene encoding engulfment and cell motility 1(ELMO1) are associated with susceptibility to diabetic nephropathy. Diabetes 54:1171-1178,2005.
PubMed
5) Kamiyama M,et al:Polymorphisms in the 3'UTR in the neurocalcin δ gene affect mRNA stabil-ity, and confer susceptibility to diabetic nephropathy. Hum Genet 122:397-407,2007.
 
6) Maeda S,et al:A single nucleotide polymorphism within the acetyl-coenzyme A carboxylase beta gene is associated with proteinuria in patients with type 2 diabetes. PLoS Genet 6:e1000842,2010.
 
7) Shimazaki A,et al:ELMO1 increases expression of extracellular matrix(ECM) proteins and inhibits cell adhesion to ECMs. Kidney Int 70:1769-1776,2006.
PubMed
8) Kobayashi M,et al:Overexpression of acetyl-coenzyme A carboxylase beta increases proinflamma-tory cytokines in cultured human renal proximal tubular epithelial cells. Clin Exp Nephrol 14:315-324, 2010.
 
9) Pezzolesi MG,et al:Genome-wide association scan for diabetic nephropathy susceptibility genes in type 1 diabetes mellitus. Diabetes 58:1403-1410,2009.
PubMed
10) Maeda S,et al:Replication study for the association between 4 loci identified by a genome-wide association study on European American subjects with type 1 diabetes and susceptibility to diabetic nephropathy in Japanese subjects with type 2 diabetes. Diabetes 59:2075-2079,2010.
PubMed
11) Freedman BI,et al:Differential effects of MYH9 and APOL1 risk variants on FRMD3 Association with Diabetic ESRD in African Americans. PLoS Genet 7:e1002150,2011.
PubMed
12) Okamoto K,et al:Common variation in GPC5 is associated with acquired nephrotic syndrome. Nat Genet 43:459-463,2011.
PubMed
13) Boger CA,et al:CUBN is a gene locus for albuminuria. J Am Soc Nephrol 22:555-570,2011.
PubMed
14) Abhary S,et al:A systematic meta-analysis of genetic association studies for diabetic retinopathy. Diabetes 58:2137-2147,2009.
PubMed
15) Grassi MA,et al:Genome-wide meta-analysis for severe diabetic retinopathy. Hum Mol Genet 20:2472-2481, 2011.
PubMed
P.230 掲載の参考文献
1) Brownlee M:Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820,2001.
PubMed
2) Marshall S,et al:Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transporting system. J Biol Chem 266:4706-4712,1991.
PubMed
3) Koya D,King GL:Protein kinase C activation and the development of diabetic complications. Diabe-tes 47:859-866,1998.
 
P.234 掲載の参考文献
1) Loh K,et al:Reactive oxygen species enhance insulin sensitivity. Cell Metab 10(4):260-272,2009.
PubMed
2) Wautier MP,et al:Activation of NADPH oxidase by AGE links oxidant stress to altered gene expres-sion via RAGE. Am J Physiol Endocrinol Metab 280:E685-694,2001.
 
3) Nishikawa T,et al:Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404(6779):787-790,2000.
PubMed
4) Inoguchi T,et al:Preferential elevation of protein kinase C isoform beta II and diacylglycerol levels in the aorta and heart of diabetic rats:differential reversibility to glycemic control by islet cell transplantation. Proc Natl Acad Sci USA 89(22):11059 -11063,1992.
 
5) Rask-Madsen C, King GL:Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance. Arterioscler Thromb Vasc Biol 25:487-496,2005.
PubMed
6) Inoguchi T,et al:High glucose level and free fatty acid stimulate reactive oxygen species produc-tion through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49(11):1939-1945,2000.
 
7) Inoguchi T,et al:Protein kinase C-dependent increase in reactive oxygen species(ROS) produc-tion in vascular tissues of diabetes:role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14:S227-232,2003.
 
8) Tsubouchi H,et al:Statin attenuates high glucose-induced and diabetes-induced oxidative stress in vitro and in vivo evaluated by electron spin resonance measurement. Free Radic Biol Med 39:444-452,2005.
PubMed
9) Maeda Y,et al:Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol 299(6):F1328-1338,2010.
PubMed
10) Kimura S,et al:Randomized comparison of pitavastatin and pravastatin treatment on the reduction of urinary albumin in patients with type 2 diabetic nephropathy. Diabetes Obes Metab,2012.[Epub ahead of print]
 
11) Stocker R,et al:Bilirubin is an antioxidant of possible physiological importance. Science 235(4792):1043-1046, 1987.
PubMed
12) Inoguchi T,et al:Relationship between Gilbert syndrome and prevalence of vascular complications in patients with diabetes. JAMA 298:1398-1400,2007.
PubMed
13) Fujii M,et al:Bilirubin and biliverdin protect rodents against diabetic nephropathy by downregulat-ing NAD(P)H oxidase. Kidney Int 78(9):905-919,2010.
 
14) Ikeda N,et al:Biliverdin protects against the deterioration of glucose tolerance in db/db mice. Dia-betologia 54(8):2183-2191,2011.
 
15) Ohnaka K,et al:Inverse associations of serum bilirubin with high sensitivity C-reactive protein,glycated hemoglobin, and prevalence of type 2 diabetes in middle-aged and elderly Japanese men and women. Diabetes Res Clin Pract 88(1):103-110,2010.
PubMed
P.242 掲載の参考文献
1) Verma S,Anderson TJ:Fundamentals of endothelial function for the clinical cardiologist. Circulation 105(5):546-549,2002.
PubMed
2) Xu J,Zou MH:Molecular insights and therapeutic targets for diabetic endothelial dysfunction. Cir-culation 120(13):1266-1286,2009.
 
3) Rask-Madsen C,King GL:Mechanisms of Disease:endothelial dysfunction in insulin resistance and diabetes. Nat Clin Pract Endocrinol Metab 3:46-56,2007.
PubMed
4) Cavalot F,et al:Postprandial blood glucose is a stronger predictor of cardiovascular events than fast-ing blood glucose in type 2 diabetes mellitus. J Clin Endocrinol Metab 91:813-819,2006.
 
5) Ceriello A,et al:Postprandial glucose regulation and diabetic complications. Arch Intern Med 164:2090-2095,2004.
PubMed
6) Nathan DM,et al;Diabetes Control and Complications Trial/Epidemiology of Diabetes Interven-tions and Complications(DCCT/EDIC)Study Research Group:Intensive diabetes treatment and car-diovascular disease in patients with type 1 diabetes. N Engl J Med 353(25):2643-2653,2005.
 
7) Chalmers J,Cooper ME:UKPDS and the legacy effect. N Engl J Med 359:1618-1620,2008.
PubMed
8) Nathanson D,Nystrom T:Hypoglycemic pharmacological treatment of type 2 diabetes:targeting the endothelium. Mol Cell Endocrinol 297(1-2):112-126,2009.
 
9) Guzik TI,et al:Mechanisms of increased vascular superoxide production in human diabetes melli-tus:role of NAD(P)H oxidase and endothelial nitric oxide synthase. Circulation 105:1656-1662,2002.
 
10) Cosentino F,et al:High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 96:25-28,1997.
PubMed
11) Carr ME:Diabetes Mellitus:A hypercoagulable state. J Diabetes Complications 15:44-54,2001.
PubMed
12) Vinik N,et al:Platelet dysfunction in type 2 diabetes. Diabetes Care 24(8):1476-1485,2001.
 
13) Ceriello A,et al:Hyperglycemia-induced thrombin formation in diabetes:the possible role of oxida-tive stress. Diabetes 44:924-928,1995.
 
14) Rao AK,et al:Activation of the tissue factor pathway of blood coagulation during prolonged hyper-glycemia in young healthy men. Diabetes 48(5):1156-1161,1999.
 
15) Meigs JB,et al:Hyperinsulinemia,hyperglycemia,and impaired hemostasis:the Framingham Off-spring Study. JAMA 283(2):221-228,2000.
 
16) Marx N,et al:Antidiabetic PPARγ-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23:283-288,2003.
 
17) Gonzalez MA,Selwyn AP:Endothelial function, inflammation,and prognosis in cardiovascular disease. Am J Med 115(8A):99S-106S,2003.
 
18) Varo N,et al:Elevated plasma levels of the atherogenic mediator soluble CD40 ligand in diabetic patients:a novel target of thiazolidinediones. Circulation 107(21):2664-2669,2003.
PubMed
19) Shanmugam N,et al:High glucose-induced expression of proinflammatory cytokine and che-mokine genes in monocytic cells. Diabetes 52:1256-1264,2003.
 
20) Tepper OM,et al:Human endothelial progenitor cells from type II diabetics exhibit impaired pro-liferation,adhesion,and incorporation into vascular structures. Circulation 106:2781-2786,2002.
 
21) El-Osta A,et al:Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J Exp Med 205:2409-2417,2008.
PubMed
22) Brasacchio D,et al:Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58:1229-1236,2009.
PubMed
23) Villeneuve LM,et al:Epigenetic histone H3 lysine 9 methylation in metabolic memory and inflamma-tory phenotype of vascular smooth muscle cells in diabetes. Proc Natl Acad Sci USA 105:9047-9052,2008.
 
24) Meerwaldt R,et al:The clinical relevance of assessing advanced glycation endproducts accumula-tion in diabetes. Cardiovasc Diabetol 7:29,2008.
 
P.246 掲載の参考文献
1) Nathan DM,et al:Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653,2005.
PubMed
2) Holman RR,et al:10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589,2008.
PubMed
3) Yamagishi S,Imaizumi T:Diabetic vascular complications:pathophysiology,biochemical basis and potential therapeutic strategy. Curr Pharm Des 11:2279-2299,2005.
PubMed
4) Yamagishi S,et al:Pigment epithelium-derived factor(PEDF):its potential therapeutic implication in diabetic vascular complications. Curr Drug Targets 9:1025-1029,2008.
PubMed
5) Yamagishi S,et al:Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 281:20213-20220,2006.
PubMed
6) Yamagishi S:Possible involvement of advanced glycation end products in carry-over benefits of ator-vastatin in ASCOT-BPLA. Eur Heart J 29:1922,2008.
 
7) Takenaka K,et al:Role of advanced glycation end products(AGEs)in thrombogenic abnormalities in diabetes. Curr Neurovasc Res 3:73-77,2006.
PubMed
8) Yamagishi S,et al:Atheroprotective properties of pigment epithelium-derived factor(PEDF) in car-diometabolic disorders. Curr Pharm Des 15:1027-1032,2009.
 
9) Yamagishi S,et al:Pigment-epithelium-derived factor(PEDF) prevents platelet activation and aggregation in diabetic rats by blocking deleterious effects of advanced glycation end products(AGEs). Diabetes Metab Res Rev 25:266-271,2009.
PubMed
10) Nakamura K,et al:Pigment epithelium-derived factor inhibits neointimal hyperplasia after vascular injury by blocking NADPH oxidase-mediated reactive oxygen species generation. Am J Pathol 170:2159-2170,2007.
PubMed
11) Ueda S,et al:Administration of pigment epithelium-derived factor inhibits left ventricular remodel-ing and improves cardiac function in rats with acute myocardial infarction. Am J Pathol 178:591-598,2011.
 
12) Yamagishi S,et al:Receptor for advanced glycation end products(RAGE):a novel therapeutic tar-get for diabetic vascular complication. Curr Pharm Des 14:487-495,2008.
 
13) Yamagishi S:Role of advanced glycation end products(AGEs) and receptor for AGEs(RAGE) in vas-cular damage in diabetes. Exp Gerontol 46:217-224,2011.
 
14) Yamagishi S, Matsui T:Soluble form of a receptor for advanced glycation end products as a bio-marker. Front Biosci(Elite Ed)2:1184-1195,2010.
 
15) Gaede P,et al:Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-591,2008.
PubMed
P.252 掲載の参考文献
1) Ross R:Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126,1999.
PubMed
2) Glass CK,Witztum JL:Atherosclerosis:the road ahead. Cell 104:503-516,2001.
PubMed
3) Manabe I,Nagai R:Regulation of smooth muscle phenotype. Curr Atheroscler Rep 5:214-222,2003.
PubMed
4) Fan J,Watanabe T:Inflammatory reactions in the pathogenesis of atherosclerosis. J Atheroscler Thromb 10:63-71,2003.
PubMed
5) Watanabe T,et al:T lymphocytes in atherosclerotic lesions. Ann N Y Acad Sci 748:40-55,1995.
 
6) Nishimura S,et al:Adipogenesis in obesity requires close interplay between differentiating adipo-cytes,stromal cells,and blood vessels. Diabetes 56:1517-1526,2007.
 
7) Nishimura S,et al:In vivo imaging revealed local cell dynamics in obese adipose tissue inflamma-tion. J Clin Invest 118:710-721,2008.
 
8) Nishimura S,et al:CD8+ effector T cells contribute to macrophage recruitment and adipose tissue inflammation in obesity. Nat Med 15:914-920,2009.
PubMed
9) Donath MY,et al:Islet inflammation in type 2 diabetes:from metabolic stress to therapy. Diabetes Care 31:S161-S164,2008.
PubMed
10) Harris RC,Neilson EG:Toward a unified theory of renal progression. Annu Rev Med 57:365-380,2006.
 
11) Brosius F:New insights into the mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev Endocr Metab Disord 9:245-254,2008.
PubMed
12) Fujiu K,et al:Renal collecting duct epithelial cells regulate inflammation in tubulointerstitial dam-age in mice. J Clin Invest 121:3425-3441,2011.
 
P.256 掲載の参考文献
1) Burnier M, Zanchi A:Blockade of the renin-angiotensin-aldosterone system:a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 24:11-25,2006.
PubMed
2) Lewis EJ,et al:The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy,The Collaborative Study Group. N Engl J Med 329:1456-1462,1993.
 
3) Brenner BM,et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861-869,2001.
PubMed
4) Baynes JW:Role of oxidative stress in development of complications in diabetes. Diabetes 40:405-412,1991.
PubMed
5) Kakimoto M,et al:Accumulation of 8-hydroxy-2'-deoxyguanosine and mitochondrial DNA dele-tion in kidney of diabetic rats. Diabetes 51:1588-1595,2002.
 
6) Inoguchi T,et al:High glucose level and free fatty acid stimulate reactive oxygen species produc-tion through protein kinase C-dependent activation of NAD(P)H oxidase in cultured vascular cells. Diabetes 49:1939-1945,2000.
 
7) Inoguchi T,et al:Protein kinase C-dependent increase in reactive oxygen species(ROS) production in vascular tissues of diabetes:role of vascular NAD(P)H oxidase. J Am Soc Nephrol 14:S227-232,2003.
PubMed
8) Mollnau H,et al:Effects of angiotensin II infusion on the expression and function of NAD(P)H oxidase and components of nitric oxide/cGMP signaling. Circ Res 90:E58-65,2002.
PubMed
9) Parving H,et al:Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433-2446,2008.
PubMed
10) Feldman D,et al:Effects of aliskiren on blood pressure, albuminuria, and (pro)renin receptor expression in diabetic TG(mRen-2)27 rats. Hypertension 52:130-136,2008.
PubMed
11) Maeda Y,et al:Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters. Am J Physiol Renal Physiol 299:F1328-1338,2010.
PubMed
12) Maeda Y,et al:Chymase inhibition prevents myocardial fibrosis via the attenuation of NOX4-associated oxidative stress in diabetic hamsters. J Diabetes Invest 2012.(in press)
 
13) Miyata K,et al:Aldosterone stimulates reactive oxygen species production through activation of NADPH oxidase in rat mesangial cells. J Am Soc Nephrol 16:2906-2912,2005.
PubMed
14) Ferrario CM,et al:Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1-7) in regulation of cardiovascular function. Am J Physiol Heart Circ Physiol 289:H2281-2290,2005.
PubMed
15) Ferrario CM,Varagic J:The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol 298:F1297-1305,2010.
PubMed
P.262 掲載の参考文献
1) Retnakaran R,et al:Risk factor for renal dysfunction in type 2 diabetes 1. UK Prospective Diabetes Study 74. Diabetes 55:1832-1839,2006.
PubMed
2) Molitch ME,et al:Higher levels of HDL cholesterol are associated with a decreased likelihood of albuminuria in patients with long-standing type 1 diabetes. Diabetes Care 29:78-82,2006.
PubMed
3) Eto M,et al:Apolipoprotein E genetic polymorphism,remnant lipoproteins,and nephropathy in type 2 diabetic patients. Am J Kidney Dis 40:243-251,2002.
PubMed
4) Klein R,et al:The Wisconsin Epidemiologic Study of Diabetic Retinopathy:XVII.The 14-year inci-dence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes. Ophthal-mology 105:1801-1815,1998.
 
5) Danser AH,et al:Angiotensin levels in the eye. Invest Ophthalmol Vis Sci 35:1008-1018,1994.
PubMed
6) Ferrari-Dileo G,et al:Angiotensin-converting enzyme in bovine,feline,and human ocular tis-sues. Invest Ophthalmol Vis Sci 29:876-881,1988.
 
7) Miljanovic B,et al:A prospective study of serum lipids and risk of diabetic macular edema in type 1 diabetes. Diabetes 53:2883-2892,2004.
PubMed
8) Keech AC,et al:Effect of fenofibrate on the need for laser treatment for diabetic retinopathy(FIELD study):a randomized controlled trial. Lancet 370:1687-1697,2007.
PubMed
9) Sands ML,et al:Incidence of distal symmetric(sensory) neuropathy in NIDDM.The San Luis Val-ley Diabetes Study. Diabetes Care 20:322-329,1997.
 
10) Cohen JA,et al:Risks for sensorimotor peripheral neuropathy and autonomic neuropathy in non-insulin-dependent diabetes mellitus(NIDDM). Muscle Nerve 21:72-80,1998.
PubMed
11) Tesfaye S,et al:Vascular risk factors and diabetic neuropathy. N Engl J Med 352:341-350,2005.
PubMed
12) Malik RA,et al:Effect of angiotensin-converting-enzyme(ACE) inhibitor trandolapril on human diabetic neuropathy:randomised double-blind controlled trial. Lancet 352:1978-1981,1998.
PubMed
13) Didangelos TP,et al:Effect of quinapril or losartan alone and in combination on left ventricular sys-tolic and diastolic functions in asymptomatic patients with diabetic autonomic neuropathy. J Diabe-tes Complications 20:1-7,2006.
 
14) Haffner SM,et al:Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234,1998.
PubMed
P.266 掲載の参考文献
1) Colagiuri S:Optimal management of type 2 diabetes:the evidence. Diabetes Obes Metab 14(Suppl 1):3-8,2012.
 
2) Wing RR;Look AHEAD Research Group:Long-term effects of a lifestyle intervention on weight and cardiovascular risk factors in individuals with type 2 diabetes mellitus:four-year results of the Look AHEAD trial. Arch Intern Med l70:1566-1575,2010.
 
3) Gaede P,et al:Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348(5):383-393,2003.
PubMed
4) Blonde L:Benefits and risks for intensive glycemic control in patients with diabetes mellitus. Am J Med Sci 343:17-20,2012.
PubMed
5) 日本糖尿病学会(編):糖尿病治療ガイド2010,文光堂,2010.
 
6) Ismail-Beigi F,et al:Individualizing glycemic targets in type 2 diabetes mellitus:Implications of recent clinical trials. Ann Intern Med 154:554-559,2011.
PubMed
7) UK Prospective Diabetes Study(UKPDS) Group:Intensive blood-glucose control with sulpho-nylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 352:837-853,1998.
PubMed
8) Gerstein HC,et al:Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 358:2545-2559,2008.
PubMed
9) Patel A,et al:Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572,2008.
PubMed
10) Duckworth W,et al:Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139,2009.
PubMed
11) Hemmingsen B,et al:Intensive glycaemic control for patients with type 2 diabetes:systematic review with meta-analysis and trail sequential analysis of randomized clinical trials. BMJ 343:d6898 doi:10.1136/bmj.d6898,2011.
 
12) Institute for Quality and Efficiency in Health Care:Benefit assessment of long-term blood glucose lowering to near-normal levels in patients with type 2 diabetes mellitus. Institute for Quality and Effi-ciency in Health Care Report,2011.
 
13) Montori VM, Fernandez-Balsells M:Glycemic control in type 2 diabetes:time for an evidence-based about-face?Ann Intern Med 150:803-808,2009.
PubMed
14) Ray KK,et al:Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes:a meta-analysis of randomized controlled trials. Lancet 373:1765-1772,2009.
PubMed
15) Skyler JS,et al:Intensive glycemic control and the prevention of cardiovascular events:implications of the ACCORD,ADVANCE and VA diabetes trials:a position statement of the American Diabetes Association and a scientific statement of the American College of Cardiology Foundation and the American Heart Association. Diabetes Care 32:187-192,2009. Erratum in:Diabetes Care 32:754,2009.
 
P.272 掲載の参考文献
1) 糖尿病治療ガイド編集委員会:治療,A治療目標とコントロール指標.糖尿病治療ガイド2010(日本糖尿学会編),p24-26,文光堂,2010.
 
2) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent dia-betes mellitus. N Engl J Med 329:977-986,1993.
 
3) The Diabetes Control and Complica-tions Trial/Epidemiology of Diabetes Interventions and Complications Research Group:Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med 342:381-389,2000.
 
4) Ohkubo Y,et al:Intensive insulin therapy prevents the progression of diabetic microvascular compli-cations in Japanese patients with non-insulin-dependent diabetes mellitus:a randomized prospec-tive 6-year study. Diabetes Res Clin Pract 28:103-117,1995.
 
5) UK Prospective Diabetes Study(UKPDS) Group:Effect of intensive blood-glucose control with met-formin on complications in overweight patients with type 2 diabetes(UKPDS 34). Lancet 352(9131):854-865,1998.
 
6) Kawasaki R,et al;Japan Diabetes Complications Study Group:Incidence and progression of dia-betic retinopathy in Japanese adults with type 2 diabetes:8 year follow-up study of the Japan Diabe-tes Complications Study(JDCS). Diabetologia 54:2288-2294,2011.
 
7) Katayama S,et al;Japan Diabetes Complications Study Group:Low transition rate from normo- and low microalbuminuria to proteinuria in Japanese type 2 diabetic individuals:the Japan Diabetes Complications Study(JDCS). Diabetologia 54:1025-1031,2011.
 
8) Adler AI,et al:Development and progression of nephropathy in type 2 diabetes:the United King-dom Prospective Diabetes Study(UKPDS 64), Kidney Int 63:225-232,2003.
 
9) Boussageon R,et al:Effect of intensive glucose lowering treatment on all cause mortality,cardiovas-cular death,and microvascular events in type 2 diabetes:meta-analysis of randomised controlled trials. BMJ 343:d4169,2011.
 
10) Nathan DM,et al;Diabetes Control and Complications Trial/Epidemiology of Diabetes Interven-tions and Complications(DCCT/EDIC) Study Research Group:Intensive diabetes treatment and car-diovascular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653,2005.
 
11) Holman RR,et al:10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359:1577-1589,2008.
PubMed
12) 佐々木敬:糖尿病血糖管理のエビデンス-UKPDS,UKPDS follow-up study.糖尿病ナビゲーター(門脇孝編),p276-277,メディカルレビュー社,2010.
 
13) The Action to Control Cardiovascular Risk in Diabetes Study Group:Effects of intensive glucose low-ering in type 2 diabetes. N Engl J Med 358:2545-2559,2008.
 
14) The ADVANCE Collaborative Group:Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 358:2560-2572,2008.
 
15) Duckworth W,et al:Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139,2009.
PubMed
16) Gaede P,et al:Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358(6):580-591,2008.
PubMed
17) Sone H,et al:Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes:a nationwide multicentre randomised controlled trial(the Japan Diabetes Com-plications Study). Diabetologia 53:419-428,2010.
 
18) 門脇孝:J-DOIT3.糖尿病ナビゲーター(門脇孝編),p310-311,メディカルレビュー社,2010.
 
19) 糖尿病治療ガイド編集委員会:糖尿病合併症とその対策.糖尿病治療ガイド2010(日本糖尿学会編),p72-84,文光堂,2010.
 
P.279 掲載の参考文献
1) Iimura O:Insulin resistance and hypertension in Japanese. Hypertens Res 19(Suppl 1):S1-8,1996.
 
2) American Diabetes Association:Role of cardiovascular risk factors in prevention and treatment of macrovascular disease in diabetes. Diabetes Care 12:573-579,1989.
PubMed
3) UK Prospective Diabetes Study Group:Efficacy of atenolol and captopril in reducing risk of macro-vascular complications in type 2 diabetes:UKPDS 39. BMJ 317:713-720,1998.
 
4) Hansson L,et al:HOT study group. Effect of intensive blood-pressure lowering and low-dose aspi-rin in patients with hypertension:principal results of the Hypertension Optimal Treatment(HOT) randomized trial. Lancet 351:1755-1762,1998.
 
5) 大西浩文ほか:端野・壮瞥町研究レビュー2007.Ther Res 28:513-525,2007.
Medical*Online
6) ACCORD Study Group,Cushman WC,et al:Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362(17):1575-1585,2010.
 
7) Heart Outcomes Prevention Evaluation(HOPE) Study Investigators:Effects of ramipril on cardiovas-cular and microvascular outcomes in people with diabetes mellitus:results of the HOPE study and MICRO-HOPE substudy. Lancet 359:253-259,2000.
 
8) Lindholm LH,et al:Cardiovascular morbidity and mortality in patients with diabetes in the losartan intervention for endpoint reduction in hypertension study(LIFE):a randomised trial against atenolol. Lancet 359:1004-1010,2002.
PubMed
9) Julius S,et al;VALUE trial group:Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine:the VALUE randomized trial. Lancet 363:2022-2031,2004.
 
10) J-MIND研究グループ,鹿住敏ほか:糖尿病性腎症の発症・進展に対するCa拮抗薬とACE阻害薬との長期効果の比較.糖尿病 42:5225,1999.
 
11) Uzu T,et al;Shiga Microalbminuria Reduction Trial(SMART) Group:Reduction of microalbuminuria in patients with type 2 diabetes:the Shiga Microalbuminuria Reduction Trial(SMART). Diabetes Care 30:1581-1583,2007.
 
12) Bakris GL,et al:GUARD(Gauging Albuminuria Reduction With Lotrel in Diabetic Patients With Hypertension) Study investigator:Effects of different ACE inhibitor combinations on albuminuria:results of the GUARD study. Kidney Int 73:1303-1309,2008.
PubMed
13) Holman RR,et al:Long-term follow-up after tight control of blood pressure in type 2 diabetes. N Engl J Med 359:1565-1576,2008.
PubMed
P.293 掲載の参考文献
1) Oikawa S,et al;J-LIT Study Group:Risk of coronary events in Japanese patients with both hyper-cholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy:implication from Japan Lipid Intervention Trial(J-LIT). Atherosclerosis 191(2):440-446,2007.
 
2) Collins R,et al;Heart Protection Study Collaborative Group:MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes:a randomised placebo-con-trolled trial. Lancet 361(9374):2005-2016,2003.
 
3) Colhoun HM,et al:Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS):multicentre randomised placebo-con-trolled trial. Lancet 364(9435):685-696,2004.
 
4) Knopp RH,et al:Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes:the Atorvastatin Study for Prevention of Coronary Heart Disease End-points in non-insulin-dependent diabetes mellitus(ASPEN). Diabetes Care 29(7):1478-1485,2006.
PubMed
5) Steinmetz A:Lipid-lowering therapy in patients with type 2 diabetes:the case for early intervention. Diabetes Metab Res Rev 24(4):286-293,2008.
PubMed
6) Kamari Y,et al:Should all diabetic patients be treated with a statin? Diabetes Care 32(Suppl 2):S378-383,2009.
 
7) Kearney PM,et al:Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 ran-domised trials of statins:a meta-analysis. Lancet 371(9607):117-125,2008.
 
8) Wanner C,et al:Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353(3):238-248,2005.
PubMed
9) Kjekshus J,et al;CORONA Group:Rosuvastatin in older patients with systolic heart failure. N Engl J Med 357:2248-2261,2007.
PubMed
10) Cheung BM:Statins for people with diabetes. Lancet 371(9607):94-95,2008.
PubMed
11) Moorhead JF,et al:Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. Lancet 2:1309-1311,1982.
PubMed
12) Fried LF,et al:Effect of lipid reduction on the progression of renal disease:A meta-analysis. Kid-ney Int 59:260-269,2001.
 
13) Sandhu S,et al:Statins for improving renal outcomes:a meta-analysis. J Am Soc Nephrol 17(7):2006-2016,2006.
PubMed
14) Keech A,et al:Effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus(the FIELD study):randomized controlled trial. Lancet 366:1849-1861,2005.
 
15) Ansquer JC,et al;DAIS Investigators:Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes:results from the Diabetes Atherosclerosis Intervention Study(DAIS). Am J Kidney Dis 45:485-493,2005.
 
16) Chew EY,et al:Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study(ETDRS) Report 22. Arch Ophthalmol 114:1079-1084,1996.
PubMed
17) Klein BE,et al:The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 98:1261-1265,1991.
PubMed
18) Keech AC,et al:Effect of fenofibrate on the need for laser treatment for diabetic retinopathy(FIELD study):a randomised controlled trial. Lancet 370:1687-1697,2007.
PubMed
19) Wiggin TD,et al:Elevated triglycerides correlate with progression of diabetic neuropathy. Diabetes 58:1634-1640,2009.
PubMed
20) Ginsberg HN,et al;ACCORD Study Group:Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362:1563-1574,2010.
 
P.304 掲載の参考文献
1) 川浪大治,宇都宮一典:糖尿病性昏睡.別冊医学のあゆみ 糖尿病・代謝症候群-state of arts 2004-2006,p267-269,医歯薬出版,2004.
 
2) Kitabchi AE,et al:Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32:1335-1343,2009.
PubMed
3) Imagawa A,et al:A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. Osaka IDDM Study Group. N Engl J Med 342:301-307,2000.
 
4) Lebovitz HE:Diabetic ketoacidosis. Lancet 345:767-772,1995.
PubMed
5) Krentz AJ,et al:The effect of glucose and insulin infusion on the fall of ketone bodies during treat-ment of diabetic ketoacidosis. Diabet Med 6:31-36,1989.
 
P.310 掲載の参考文献
1) Booth GL,et al:Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people:a population-based retrospective cohort study. Lancet 368:29-36,2006.
PubMed
2) Sarwar N,et al;Emerging Risk Factors Collaboration:Diabetes mellitus,fasting blood glucose concentration,and risk of vascular disease:a collaborative meta-analysis of 102 prospective studies. Lancet 375:2215-2222,2010.
PubMed
3) Doi Y,et al:Impact of glucose tolerance status on development of ischemic stroke and coronary heart disease in a general Japanese population:the Hisayama study. Stroke 41:203-209,2010.
 
4) Vijan S,Hayward RA:Treatment of hypertension in type 2 diabetes mellitus:blood pressure goals,choice of agents,and setting priorities in diabetes care. Ann Intern Med 138:593-602,2003.
PubMed
5) Hotta N,et al:Causes of death in Japanese diabetics:A questionnaire survey of 18,385 diabetics over a 10-year period. J Diabet Invest 1-2:66-76,2010.
 
6) Yokoyama H,et al;Japan Diabetes Clinical Data Management Study Group:Low incidence of car-diovascular events in Japanese patients with Type 2 diabetes in primary care settings:a prospective cohort study(JDDM 20), Diabet Med 28:1221-1228,2011.
 
7) Hashimoto K,et al:Glucose intolerance is common in Japanese patients with acute coronary syn-drome who were not previously diagnosed with diabetes. Diabetes Care 28:1182-1186,2005.
 
8) Urabe T,et al:Prevalence of abnormal glucose metabolism and insulin resistance among subtypes of ischemic stroke in Japanese patients. Stroke 40:1289-1295,2009.
PubMed
9) Hayashino Y,et al:Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan:factors influencing on inter-national application of evidence-based guidelines. Int J Cardiol 118:88-96,2007.
 
10) Selvin E,et al:Meta-analysis:glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141:421-431,2004.
PubMed
11) Eeg-Olofsson K,et al:New aspects of HbA1c as a risk factor for cardiovascular diseases in type 2 diabetes:an observational study from the Swedish National Diabetes Register(NDR). J Intern Med 268:471-482,2010.
PubMed
12) Sone H,et al;Japan Diabetes Complications Study Group:Serum level of triglycerides is a potent risk factor comparable to LDL cholesterol for coronary heart disease in Japanese patients with type 2 diabetes:subanalysis of the Japan Diabetes Complications Study(JDCS). J Clin Endocrinol Metab 96:3448-3456,2011.
 
13) Nishimura R,et al:Relationship between hemoglobin A1c and cardiovascular disease in mild-to-moderate hypercholesterolemic Japanese individuals:subanalysis of a large-scale randomized con-trolled trial. Cardiovasc Diabetol 10:58,2011.
 
14) Tominaga M,et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not im-paired fasting glucose.The Funagata Diabetes Study. Diabetes Care 22:920-924,1999.
 
15) Asia Pacific Cohort Studies Collaboration:Cholesterol,diabetes and major cardiovascular diseases in the Asia-Pacific region. Diabetologia 50:2289-2297,2007.
 
16) Kearney PM,et al;Cholesterol Treatment Trialists(CTT) Collaborators:Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins:a meta-analysis. Lancet 371:117-125,2008.
PubMed
17) Tajima N,et al;Primary Prevention Group of Adult Japanese(MEGA) Study:Pravastatin reduces the risk for cardiovascular disease in Japanese hypercholesterolemic patients with impaired fasting glucose or diabetes:diabetes subanalysis of the Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese(MEGA) Study. Atherosclerosis 199:455-462,2008.
PubMed
18) Sone H,et al;Japan Diabetes Complications Study Group:Comparison of Various Lipid Variables as Predictors of Coronary Heart Disease in Japanese Men and Women With Type 2 Diabetes:Subana-lysis of the Japan Diabetes Complications Study. Diabetes Care 35:1150-1157,2012.
 
19) Chan WB,et al:Triglyceride predicts cardiovascular mortality and its relationship with glycaemia and obesity in Chinese type 2 diabetic patients. Diabetes Metab Res Rev 21:183-188,2005.
PubMed
20) Hayashi T,et al;Japan CDM group:Low HDL-cholesterol is associated with the risk of stroke in elderly diabetic individuals:Changes in the risk for atherosclerotic diseases at various ages. Diabe-tes Care 32:1221-1223,2009.
 
21) Hu G,et al:The impact of history of hypertension and type 2 diabetes at baseline on the incidence of stroke and stroke mortality. Stroke 36:2538-2543,2005.
PubMed
22) 大村隆夫ほか:一般住民の22年間追跡調査における耐糖能異常と脳卒中発症の関連-久山町研究-. 糖尿病 36:17-24,1993.
 
23) 清原裕:地域住民中の糖尿病者における循環器疾患発症とその危険因子の関連-久山町研究-. 糖尿病合併症 14:80-84,2000.
 
24) Reboldi G,et al:Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes:a meta-analysis in 73,913 patients. J Hypertens 29:1253-1269,2011.
PubMed
25) Cushman WC,et al;ACCORD Study Group:Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575-1585,2010.
 
26) Bangalore S,et al:Blood pressure targets in subjects with type 2 diabetes mellitus/impaired fasting glucose:observations from traditional and bayesian random-effects meta-analyses of randomized trials. Circulation 123:2799-2810,2011.
PubMed
27) Yokoyama H,et al;Japan Diabetes Clinical Data Management Study Group:Reduced GFR and microalbuminuria are independently associated with prevalent cardiovascular disease in Type 2 diabe-tes:JDDM study 16. Diabet Med 25:1426-1432,2008.
 
28) Bouchi R,et al:Is a reduced estimated glomerular filtration rate a risk factor for stroke in patients with type 2 diabetes? Hypertens Res 32:381-386,2009.
PubMed
29) Yang X,et al:Hong Kong Diabetes Registry:Additive interaction of hyperglycemia and albuminuria on risk of ischemic stroke in type 2 diabetes:Hong Kong Diabetes Registry. Diabetes Care 31(12):2294-2300,2008.
 
30) Sone H,et al:Waist circumference as a cardiovascular and metabolic risk in Japanese patients with type 2 diabetes. Obesity 17:585-592,2009.
PubMed
31) Sone H,et al;Japan Diabetes Complications Study:Is the diagnosis of metabolic syndrome useful for predicting cardiovascular disease in asian diabetic patients?Analysis from the Japan Diabetes Complications Study. Diabetes Care 28:1463-1471,2005.
 
32) Sone H,et al;Japan Diabetes Complications Study(JDCS)Group:The new worldwide definition of metabolic syndrome is not a better diagnostic predictor of cardiovascular disease in Japanese diabe-tic patients than the existing definitions:additional analysis from the Japan Diabetes Complica-tions Study. Diabetes Care 29:145-147,2006.
 
33) Cull CA,et al:Impact of the metabolic syndrome on macrovascular and microvascular outcomes in type 2 diabetes mellitus:United Kingdom Prospective Diabetes Study 78. Circulation 116:2119-2126,2007.
PubMed
34) Doi Y,et al:Proposed criteria for metabolic syndrome in Japanese based on prospective evidence:the Hisayama study. Stroke 40:1187-1194,2009.
PubMed
35) Ogawa H,et al;Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes(JPAD) Trial Investigators:Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes:a randomized controlled trial. JAMA 300:2134-2141,2008.
PubMed
36) Pignone M,et al:Aspirin for primary prevention of cardiovascular events in people with diabetes:a position statement of the American Diabetes Association,a scientific statement of the American Heart Association,and an expert consensus document of the American College of Cardiology Foundation. Circulation 121:2694-2701,2010.
 
37) Katakami N,et al:The phosphodiesterase inhibitor cilostazol induces regression of carotid athero-sclerosis in subjects with type 2 diabetes mellitus:principal results of the Diabetic Atherosclerosis Prevention by Cilostazol(DAPC) study:a randomized trial. Circulation 121:2584-2591,2010.
 
38) Kohsaka S,et al:Impact of diabetes among revascularized patients in Japan and the u.s. Diabetes Care 35:654-659,2012.
 
P.316 掲載の参考文献
1) Fujishima M,et al:Smoking as cardiovascular risk factor in low cholesterol population:the Hisayama Study. Clin Exp Hypertens A 14(1-2):99-108,1992.
 
2) 大村隆夫ほか:一般住民の22年間追跡調査における耐糖能異常と脳卒中発症の関連:久山町研究. 糖尿病 36:17-24,1993.
 
3) Kannel WB,McGee DL:Diabetes and cardiovascular disease. The Framingham study. JAMA 241:2035-2038,1979.
PubMed
4) Abbott RD,et al:Diabetes and the risk of stroke.The Honolulu Heart Program. JAMA 257:949-952,1987.
PubMed
5) Shinohara Y,et al:Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients.Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 26:63-70,2008.
PubMed
6) Singer DE,et al:Association of HbA1c with prevalent cardiovascular disease in the original cohort of the Framingham Heart Study. Diabetes 41:202-208,1992.
PubMed
7) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34). UK Prospective Diabetes Study(UKPDS) Group. Lancet 352:854-865,1998.
PubMed
8) Gaede P,et al:Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 358:580-591,2008.
PubMed
9) 日本糖尿病学会:科学的根拠に基づく糖尿病診療ガイドライン,改訂第2版,南江堂,2007.
 
10) Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treat-ment and risk of complications in patients with type 2 diabetes(UKPDS 33). UK Prospective Diabe-tes Study(UKPDS) Group. Lancet 352:837-853,1998,
 
11) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 38. UK Prospective Diabetes Study Group. BMJ 317:703-713,1998.
Medical*Online
12) Hansson L,et al:Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension:principal results of the Hypertension Optimal Treatment(HOT)randomized trial.HOT Study Group. Lancet 351:1755-1762,1998.
 
13) 日本高血圧学会高血圧治療ガイドライン作成委員会:高血圧治療ガイドライン2009,日本高血圧学会,2009.
 
14) Colhoun HM,et al:Primary prevention of cardiovascular disease with atorvastatin in type 2 dia-betes in the Collaborative Atorvastatin Diabetes Study(CARDS):multicentre randomized placebo-con-trolled trial. Lancet 364:685-696,2004.
 
15) Collins R,et al:MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5,963 people with diabetes:a randomized placebo-controlled trial. Lancet 361:2005-2016,2003.
 
16) Kearney PM,et al:Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 ran-domised trials of statins:a meta-analysis. Lancet 371:117-125,2008.
 
17) 脳卒中合同ガイドライン委員会:脳卒中治療ガイドライン2009年版,杏林社,2009.
 
18) Dormandy JA,et al:Secondary prevention of macrovascular events in patients with type 2 diabetesin the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events):a random-ized controlled trial. Lancet 366:1279-1289,2005.
 
19) Wilcox R,et al:Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke:results from PROactive(PROspective pioglitAzone Clinical Trial In macroVascular Events 04). Stroke 38:865-873,2007.
 
P.321 掲載の参考文献
1) Mintz GS:Diabetic coronary artery disease:how little we know and how little intravascular ultrasound has taught us. J Am Coll Cardiol 52:263-265,2008.
 
2) Vancraeynest D,et al:Imaging the vulnerable plaque. J Am Coll Cardiol 57:1961-1979,2011.
PubMed
3) Nathan DM,et al;DCCT/EDIC Study Research Group:Intensive diabetes treatment and cardiovas-cular disease in patients with type 1 diabetes. N Engl J Med 353:2643-2653,2005.
 
4) Duckworth W,et al;VADT Investigators:Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 360:129-139,2009.
PubMed
5) Reaven PD,et al;Veterans Affairs Diabetes Trial:Intensive glucose-lowering therapy reduces car-diovascular disease events in veterans affairs diabetes trial participants with lower calcified atherosclerosis. Diabetes 58:2642-2651,2009.
 
6) Skyler JS,et al:Intensive glycemic control and the prevention of cardiovascular events:implications of the ACCORD, ADVANCE, and VA diabetes trials. Circulation 119:351-357,2009.
PubMed
7) Retnakaran R,Zinman B:Type 1 diabetes,hyperglycaemia,and the heart. Lancet 371:1790-1799,2008.
PubMed
P.331 掲載の参考文献
1) 日本脈管学会(編):下肢閉塞性動脈硬化症の診断・治療指針II(TASC II),メディカルトリビューン,2007.
 
2) Norgren L,et al:Inter-society consensus for the management of peripheral arterial disease(TASC II). J Vasc Surg 45(Suppl 1):S5-S67,2007.
 
3) 末梢閉塞性動脈疾患のガイドライン.Circ J 73(Suppl III):1507-1558,2009.
 
4) ESC Guidelines on the diagnosis and treatment of peripheral artery diseases. Eur Heart J 32:2851-2906,2011.
PubMed
5) Bhatt DL,et al:International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA 295:180-189,2006.
 
P.334 掲載の参考文献
1) Katsuki S,Hirota Y:Recent trends in incidence of cerebral hemorrhage and infarction in Japan.A report based on death rates,autopsy case and prospective study on cerebrovascular disease. Jpn Heart J 7:26-34,1966.
PubMed
2) Miyazaki M,et al:Comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population:the Hisayama Study. Diabetologia 47:1411-1415,2004.
 
3) Kawasaki R,et al:Impaired glucose tolerance,but not impaired fasting glucose,is associated with retinopathy in Japanese population:the Funagata study. Diabetes Obes Metab 10:646-651,2008.
 
P.339 掲載の参考文献
1) Klein R,et al:Relationship of hyperglycemia to the long-term incidence and progression of diabetic retinopathy. Arch Intern Med 154:2169-2178,1994.
 
2) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent dia-betes mellitus. N Engl J Med 329:977-986,1993.
 
3) The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complica-tions Research Group:Retinopathy and nephropathy in patients with type 1 diabetes four years after atrial of intensive therapy. N Engl J Med 342:381-389,2000.
 
4) White NH,et al;DCCT-EDIC Research Group:Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC:comparison of adults and adolescents. Diabetes 59(5):1244-1253,2010.
 
5) UK Prospective Diabetes Study(UKPDS) Group:Intensive blood-glucose control with sulphonyl-ureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 352:837-853,1998.
PubMed
6) Kohner EM,et al;UK Prospective Diabetes Study(UKPDS) Group:Relationship between the sever-ity of retinopathy and progression to photocoagulation in patients with Type 2 diabetes mellitus in the UKPDS(UKPDS 52). Diabet Med 18:178-184,2001.
 
7) Ohkubo Y,et al:Intensive insulin therapy prevents the progression of diabetic microvascular compli-cations in Japanese patients with non-insulin-dependent diabetes mellitus:a randomized prospec-tive 6-year study. Diabetes Res Clin Pract 28:103-117,1995.
 
8) Sone H,et al:Effects of lifestyle modifications on patients with type 2 diabetes:the Japan Diabetes Complications Study(JDCS) study design, baseline analysis and three year-interim report. Horm Metab Res 34:509-515,2002.
PubMed
9) Miyazaki M,et al:Comparison of diagnostic methods for diabetes mellitus based on prevalence of retinopathy in a Japanese population:the Hisayama Study. Diabetologia 47(8):1411-1415,2004.
 
10) Kawasaki R,et al:Impaired glucose tolerance,but not impaired fasting glucose,is associated with retinopathy in Japanese population:the Funagata study. Diabetes Obes Metab 10(6):514-515,2008.
 
11) Mauer M,et al:Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361(1):40-51,2009.
PubMed
12) Chaturvedi N,et al;DIRECT Programme Study Group:Effect of candesartan on prevention(DIRECT-Prevent 1) and progression(DIRECT-Protect 1) of retinopathy in type 1 diabetes:randomised,placebo-controlled trials. Lancet 372:1394-1402,2008.
 
13) Sjolie AK,et al;DIRECT Programme Study Group:Effect of candesartan on progression and regre-ssion of retinopathy in type 2 diabetes(DIRECT-Protect 2):a randomised placebo-controlled trial.Lancet 372:1385-1393,2008.
 
14) Colhoun HM,et al:Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS):multicentre randomised placebo-con-trolled trial. Lancet 364:685-696,2004.
 
15) Keech AC,et al:Effect of fenofibrate on the need for laser treatment for diabetic retinopathy(FIELD study):a randomised controlled trial. Lancet 370:1687-1697,2007.
PubMed
16) ACCORD Study Group,ACCORD Eye Study Group:Effects of medical therapies on retinopathy pro-gression in type 2 diabetes. N Engl J Med 363:233-244,2010.
 
17) Gaede P,et al:Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 348:383-393,2003.
PubMed
P.347 掲載の参考文献
1) Sultan MB,et al;Macugen 1013 Study Group:A phase 2/3,multicenter,randomized,double-masked,2-year trial of pegaptanib sodium for the treatment of diabetic macular edema. Ophthal-mology 118:11107-1118,2011.
 
2) Ishida S,et al:Coexpression of VEGF receptors VEGF-R2 and neuropilin-1 in proliferative diabetic retinopathy. Invest Ophthalmol Vis Sci 41:1649-1656,2000.
PubMed
3) Ishida S,et al:VEGF164 is proinflammatory in the diabetic retina. Invest Ophthalmol Vis Sci 44:2155-2162,2003.
PubMed
4) Mitchell P,et al;RESTORE study group:The RESTORE study:ranibizumab monotherapy or com-bined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 118:615-625,2011.
 
5) Miyamoto K,et al:Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. Proc Natl Acad Sci USA 96:10836-10841,1999.
PubMed
6) Ishida S,et al:VEGF164-mediated inflammation is required for pathological,but not physio-logical,ischemia-induced retinal neovascularization. J Exp Med 198:483-489,2003.
PubMed
7) Miyamoto K,et al:Vascular endothelial growth factor(VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1(ICAM-1). Am J Pathol 156:1733-1739,2000.
PubMed
8) Campochiaro PA,et al;FAME Study Group:Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for dia-betic macular edema. Ophthalmology 118:626-635,2011.
 
9) Diabetic Retinopathy Clinical Research Network(DRCR.net),Beck RW,et al:Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 127:245-251,2009.
PubMed
10) Nagai N,et al:Suppression of diabetes-induced retinal inflammation by blocking the angiotensin II type 1 receptor or its downstream nuclear factor-kappaB pathway. Invest Ophthalmol Vis Sci 48:4342-4350,2007.
PubMed
11) Satofuka S,et al:(Pro)renin receptor-mediated signal transduction and tissue renin-angiotensin system contribute to diabetes-induced retinal inflammation. Diabetes 58:1625-1633,2009.
PubMed
12) Chaturvedi N,et al:Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes.The EUCLID Study Group.EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351:28-31,1998.
 
13) Chaturvedi N,et al:Effect of candesartan on prevention(DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes:randomised, placebo-controlled trials. Lan-cet 372:1394-1402,2008.
 
14) Sjolie AK,et al:Effect of candesartan on progression and regression of retinopathy in type 2 diabetes(DIRECT-Protect 2):a randomised placebo-controlled trial. Lancet 372:1385-1393,2008.
PubMed
15) Mauer M,et al:Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361:40-51,2009.
PubMed
16) ACCORD Study Group;ACCORD Eye Study Group,Chew EY,et al:Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363:233-244,2010.
 
17) Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes:UKPDS 39.UK Prospective Diabetes Study Group. BMJ 317:713-720,1998.
Medical*Online
18) PKC-DRS2 Group,Aiello LP,et al:Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 113:2221-2230,2006.
PubMed
19) Bolton WK,et al;ACTION I Investigator Group:Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24:32-40,2004.
PubMed
20) Hotta N,et al:Long-term clinical effects of epalrestat, an aldose reductase inhibitor,on diabetic peripheral neuropathy:the 3-year,multicenter,comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 29:1538-1544,2006.
PubMed
P.354 掲載の参考文献
1) Davis MD:Vitreous contraction in proliferative diabetic retinopathy. Arch Ophthalmol 74:741-751,1965.
PubMed
2) 福田雅俊:糖尿病網膜症の病期分類.眼科MOOK 46 糖尿病と眼科診療,p117-125,金原出版,1991.
 
3) Early Treatment Diabetic Retinopathy Study Research Group:Fundus photographic risk factors for progression of diabetic retinopathy.ETDRS report number 12. Ophthalmology 98(5 Suppl):823-833,1991.
 
4) Aiello LM:Perspectives on diabetic retinopathy. Am J Ophthalmol 136:122-135,2003.
PubMed
5) Wilkinson CP,et al:Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 110:1677-1682,2003.
PubMed
6) Wessel MM,et al:Ultra-wide-field angiography improves the detection and classification of dia-betic retinopathy. Retina 10:1-7,2011.
 
P.359 掲載の参考文献
1) Brownlee M:Biochemistry and molecular cell biology of diabetic complications. Nature 414:813-820,2001.
PubMed
2) Davis S,et al:Isolation of angiopoietin-1,a ligand for the TIE2 receptor,by secretion-trap expres-sion cloning. Cell 87:1161-1169,1996.
 
3) Oh H,et al:Hypoxia and vascular endothelial growth factor selectively upregulate angiopoietin-2 in bovine microvascular endothelial cells. J Biol Chem 274:15732-15739,1999.
PubMed
4) Joussen AM,et al:Leukocyte-mediated endothelial cell injury and death in the diabetic retina. Am J Pathol 158: 147-152,2001.
PubMed
5) Noda Y,et al:Functional properties of hyalocytes under PDGF-rich conditions. Invest Ophthalmol Vis Sci 45: 2107-2114,2004.
PubMed
6) Hata Y,et al:Vascular endothelial growth factor expression by hyalocytes and its regulation by glucocorticoid. Br J Ophthalmol 92:1540-1544,2008.
PubMed
7) 石橋達朗:糖尿病網膜症に対する分子病理学的アプローチ.眼紀 52:88-96,2001.
 
8) Gao BB,et al:Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation. Nat Med 13:181-188,2007.
PubMed
9) Hata Y,et al:Retinal expression, regulation, and functional bioactivity of prostacyclin-stimulating factor. J Clin Invest 106:541-550,2000.
 
10) Kita T,et al:Role of TGF-βin mediating proliferative vitreoretinal diseases and ROCK as a poten-tial therapeutic target. Proc Natl Acad Sci USA 105:17504-17509,2008.
 
P.363 掲載の参考文献
1) The DCCT Research Group:Diabetes Control and Complications Trial(DCCT):results of feasibility study. Diabetes Care 10:1-19,1987.
 
2) White NH,et al:Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus:10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 126:1707-1715,2008.
 
3) Patel A,et al;ADVANCE Collaborative Group:Intensive blood glucose control and vascular out-comes in patients with type 2 diabetes. N Engl J Med 358:2560-2572,2008.
 
4) Klein R,et al:The Wisconsin Epidemiologic Study of Diabetic Retinopathy:XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes. Ophthalmology 115:1859-1868,2008.
PubMed
5) Chaturvedi N,et al:Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet 351(9095):28-31,1998.
 
6) Beulens JW,et al;AdRem project team;ADVANCE management committee:Effects of blood pres-sure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus:arandomised controlled trial. Diabetologia 52:2027-2036,2009.
 
7) Sjolie AK,et al;DIRECT Programme Study Group:Effect of candesartan on progression and regres-sion of retinopathy in type 2 diabetes(DIRECT-Protect 2):a randomised placebo-controlled trial. Lancet 372(9647):1385-1393,2008.
 
8) Harindhanavudhi T,et al;Renin Angiotensin System Study(RASS)group:Benefits of Renin-Angio-tensin blockade on retinopathy in type 1 diabetes vary with glycemic control. Diabetes Care 34:1838-1842,2011.
 
9) Lyons TJ,et al:Diabetic retinopathy and serum lipoprotein subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 45:910-918,2004.
PubMed
10) Keech AC,et al;FIELD study investigators:Effect of fenofibrate on the need for laser treatment for diabetic retinopathy(FIELD study):a randomised controlled trial. Lancet 370(9600):1687-1697,2007.
 
11) Chew EY,et al;ACCORD Study Group;ACCORD Eye Study Group:Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 363:233-244,2010.
 
12) Arimura N,et al:Vitreous mediators after intravitreal bevacizumab or triamcinolone acetonide in eyes with proliferative diabetic retinopathy. Ophthalmology 116:921-926,2009.
PubMed
13) Elman MJ,et al;Diabetic Retinopathy Clinical Research Network:Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 118:609-614,2011.
 
P.367 掲載の参考文献
1) Wong TY,et al:Global prevalence of diabetic retinopathy:pooled data from population studies from the United States,Australia,Europe and Asia. ARVO2011,2011.
 
2) Early vitorectomy for severe vitreous hemorrhage in diabetic retinopathy:Four-year results of a ran-domized trial:Diabetic Retinopathy Vitrectomy Study Report 5. Arch Ophthalmol 108:958-964,1990.
 
3) 池田恒彦:糖尿病網膜症における手術療法.Diabetes Frontier 22:390-395,2011.
Medical*Online
4) Lewis H,et al:Vitrectomy for diabetic macular traction and edema associated with posterior hyaloi-dal traction. Ophthalmology 99:753-759,1992.
 
5) Yamamoto T,et al:Vitrectomy for diabetic macular edema:The role of posterior vitreous detach-ment and epimacular membrane. Am J Ophthalmol 132:369-377,2001.
 
6) Diabetic Retinopathy Clinical Research Network Writing Committee:Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 117:1087-1093,2010.
PubMed
7) Enaida H,et al:Preclinical investigation of internal limiting membrane staining and peeling using intravitreal brilliant blue G. Retina 26:623-630,2006.
PubMed
8) Enaida H,et al:Brilliant blue G selectively stains the internal limiting membrane/brilliant blue G-assisted membrane peeling. Retina 26:631-636,2006.
PubMed
9) Yamamoto T,et al:Long-term follow-up results of pars plana vitrectomy for diabetic macular edema. Jpn J Ophthalmol 51:285-291,2007.
PubMed
10) 中野早紀子ほか:増殖糖尿病網膜症・手術後の良好な視力予後に関連する因子.臨床眼科 61:1747-1753,2007.
 
11) 西 勝弘ほか:増殖糖尿病網膜症に対する硝子体手術成績の検討.第65回日本臨床眼科学会,2011.
 
P.373 掲載の参考文献
1) Bril V,et al:Long-term effects of ranirestat(AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy. Diabetes Care 29:68-72,2006.
PubMed
2) The PKC-DRS Study Group:The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy:initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study(PKC-DRS) multicenter randomized clinical trial. Diabetes 54:2188-2197,2005.
 
3) Tuttle KR,et al:The effect of ruboxistaurin on nephropathy in type 2 diabetes. Diabetes Care 28:2686-2690, 2005.
PubMed
4) Forbes JM,et al:The breakdown of preexisting advanced glycation end products is associated with reduced renal fibrosis in experimental diabetes. FASEB J 17:1762-1764,2003.
PubMed
5) Wendt TM,et al:RAGE drives the development of glomerulosclerosis and implicates podocyte acti-vation in the pathogenesis of diabetic nephropathy. Am J Pathol 162:1123-1137,2003.
 
6) Bolton WK,et al:Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. Am J Nephrol 24:32-40,2004.
PubMed
7) Nishikawa T,et al:Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature 404:787-790,2000.
PubMed
8) Nishikawa T,et al:Evaluation of urinary 8-hydroxydeoxy-guanosine as a novel biomarker of mac-rovascular complications in type 2 diabetes. Diabetes Care 26:1507-1512,2003.
 
9) Goto H,et al:Endothelial MnSOD overexpression prevents retinal VEGF expression in diabetic mice. Biochem Biophys Res Commun 366:814-820,2008.
PubMed
10) Ziegler D,et al:Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid:a meta-analysis. Diabet Med 21:114-121,2004.
PubMed
11) Pergola PE,et al:Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365:327-336,2011.
PubMed
12) Green K,et al:Prevention of mitochondrial oxidative damage as a therapeutic strategy in diabetes. Diabetes 53(Suppl 1):S110-118,2004.
 
13) Gane EJ,et al:The mitochondria-targeted anti-oxidant mitoquinone decreases liver damage in a phase II study of hepatitis C patients. Liver Int 30:1019-1026,2010.
 
P.377 掲載の参考文献
1) 亀井和子ほか:糖尿病白内障水晶体における結合型polyolの研究.眼科臨床医報 92:1172-1174,1998.
 
2) 齋藤代志朗,東出朋巳:血管新生緑内障に対する最新の治療法.Diabetes Frontier 22:396-401,2011.
 
3) 出口雄三ほか:硝子体手術後の角膜上皮障害の発症についての検討.臨床眼科 65:445-449,2011.
 
4) 前田憲吾:糖尿病と脳神経麻痺.プラクティス 25:256-258,2008.
Medical*Online
P.382 掲載の参考文献
1) The Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent dia-betes mellitus. N Engl J Med 329:977-986,1993.
 
2) Ohkubo Y,et al:Intensive insulin therapy prevents the progression of diabetic microvascular compli-cations in Japanese patients with non-insulin-dependent diabetes mellitus:a randomized prospec-tive 6-year study. Diabetes Res Clin Pract 28:103-117,1995.
 
3) UK Prospective Diabetes Study(UKPDS) Group:Intensive blood-glucose control with sulphonyl-ureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes(UKPDS 33). Lancet 352:837-853,1998.
PubMed
4) The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complica-tions Research Group.Retinopathy and nephropathy in patients with type 1 diabetes four years after atrial of intensive therapy. N Engl J Med 342:381-389,2000.
 
5) Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group:Prolonged effect of intensive therapy on the risk of retinopathy complications in patients with type 1 diabetes mellitus:10 years after the Diabetes Control and Complications Trial. Arch Ophthalmol 126:1707-1715,2008.
 
6) UK Prospective Diabetes Study(UKPDS) Group:Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes(UKPDS 34). Lancet 352(9131):854-865,1998.
PubMed
7) Holman RR,et al:10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 359(15):1577-1589,2008.
PubMed
8) The Diabetes Control and Complications Trial Research Group:Early worsening of diabetic retinopa-thy in the diabetes control and complications trial. Arch Ophthalmol 116:874-886,1998.
 
9) Davis MD,et al:A note on the O'Hare classification of diabetic retinopathy.Symposium on the treatment of diabetic retinopathy. PHS Publ No.1890, U.S. Govt, pXXI-XXIV,Printing Office,Washington,DC,1968.
 
10) Early Treatment Diabetic Retinopathy Study Research Group:Early photocoagulation for diabetic retinopathy,ETDRS report number 9. Ophthalmology 98:766-785,1991.
 
11) The Diabetic Retinopathy Vitrectomy Study Research Group:Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy.Two-year results of a randomized trial.Diabetic Retinopathy Vitrectomy Study report 2. Arch Ophthalmol 103:1644-1652,1985.
 
12) Murata T,et al:The relationship between accumulation of advanced glycation end products and expression of vascular endothelial growth factor in diabetic retinas. Diabetologia 40:764-769,1997.
PubMed
13) Martidis A,et al:Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 109:920-927,2002.
PubMed
14) Nakano S,et al:Steroid eye drop treatment(difluprednate ophthalmic emulsion) is effective in reducing refractory diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 248:763-778,2010.
 
15) Tanito M,et al:Topical dexamethasone-cyclodextrin microparticle eye drops for diabetic macular edema. Invest Ophthalmol Vis Sci 52:7944-7948,2011.
PubMed
P.387 掲載の参考文献
1) Yokoyama H,et al;A nationwide survey from the Japan Diabetes Clinical Data Management Study Group(JDDM10):Microalbuminuria is common in Japanese type 2 diabetic patients. Diabetes Care 30:989-992,2007.
 
2) Wu AYT,et al:An alarmingly high prevalence of diabetic nephropathy in Asian type 2 diabetic patients:the Microalbuminuria Prevalence(MAP) Study. Diabetologia 48:17-26,2005.
 
3) Parving HH,et al:Prevalence and risk factors for microalbuminuria in a referred cohort of type II diabetic patients:a global perspective. Kidney Int 69:2057-2063,2006.
 
4) Yokoyama H,et al:Higher incidence of diabetic nephropathy in type 2 than in type 1 diabetes in early-onset diabetes in Japan. Kidney Int 58:302-311,2000.
PubMed
5) Hasslacher C,et al:Similar risks of nephropathy in patients with type I or type II diabetes mellitus. Nephrol Dial Transplant 4:859-863,1989.
 
6) Yokoyama H,et al:Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes:the Japan Diabetes Clinical Data Management study(JDDM15). Nephrol Dial Transplant 4:1212-1219,2009.
PubMed
7) Adler AI,et al:Development and progression of nephropathy in type 2 diabetes:the United King-dom Prospective Diabetes Study(UKPDS 64). Kidney Int 63:225-232,2003.
 
8) Sone H,et al:Long-term lifestyle intervention lowers the incidence of stroke in Japanese patients with type 2 diabetes:a nationwide multicentre randomized controlled trial(the Japan Diabetes Com-plications Study). Diabetologia 53:419-428,2010.
 
9) Araki S,et al:Factors associated with frequent remission of microalbuminuria in patients with type 2 diabetes. Diabetes 54:2983-2987,2005.
PubMed
10) 日本透析医学会統計調査委員会:2010年末の慢性透析患者に関する基礎集計,図説わが国の慢性透析療法の現況,2011.
 
P.392 掲載の参考文献
1) Hotta N,et al:Long-term clinical effects of epalrestat,an aldose reductase inhibitor,on diabetic peripheral neuropathy:the 3-year,multicenter,comparative Aldose Reductase Inhibitor-Diabetes Complications Trial. Diabetes Care 29:1538-1544,2006.
PubMed
2) Weigert C,et al:Glutamine:fructose-6-phosphate aminotransferase enzyme activity is necessary for the induction of TGF-beta1 and fibronectin expression in mesangial cells. Diabetologia 46:852-855,2003.
PubMed
3) Ishii H,et al:Amelioration of vascular dysfunctions in diabetic rats by an oral PKC beta inhibitor. Science 272:728-731,1996.
PubMed
4) Brownlee M:The pathobiology of diabetic complications:a unifying mechanism. Diabetes 54:1615-1625,2005.
PubMed
5) Brenner BM,et al:Dietary protein intake and the progressive nature of kidney disease:the role of hemodynamically mediated glomerular injury in the pathogenesis of progressive glomerular sclerosis in aging,renal ablation,and intrinsic renal disease. N Engl J Med 307:652-659,1982.
PubMed
6) Price DA,et al:The paradox of the low-renin state in diabetic nephropathy. J Am Soc Nephrol 10:2382-2391,1999.
 
7) Sugimoto H,et al:Increased expression of endothelial cell nitric oxide synthase(ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia 41:1426-1434,1998.
PubMed
8) Furuta T,et al:The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 21:480-485,1993.
PubMed
9) Hirata K,et al:Increased expression of selectins in kidneys of patients with diabetic nephropathy. Diabetologia 41:185-192,1998.
PubMed
10) Okada S,et al:Intercellular adhesion molecule-1-deficient mice are resistant against renal injury after induction of diabetes. Diabetes 52:2586-2593,2003.
PubMed
11) Chow FY,et al:Intercellular adhesion molecule-1 deficiency is protective against nephropathy in type 2 diabetic db/db mice. J Am Soc Nephrol 16:1711-1722,2005.
PubMed
12) Pergola PE,et al:Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365(4):327-336,2011.
PubMed
13) Sayyed SG,et al:An orally active chemokine receptor CCR2 antagonist prevents glomerulosclerosis and renal failure in type 2 diabetes. Kidney Int 80:68-78,2011.
PubMed
14) Sharma K,et al:Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22:1144-1151,2011.
PubMed
P.397 掲載の参考文献
1) 平成3年度厚生労働省 糖尿病に関する調査研究,1991.
 
2) 黒川清ほか:糖尿病性腎症病期分類 糖尿病性腎症に関する合同委員会報告.日腎会誌 44(1):i,2002.
 
3) National Kidney Foundation:K/DOQI clinical practice guidelines for chronic kidney disease:evaluation,classification and stratification. Am J Kidney Dis 39(Suppl 1):S1-S266,2002.
 
4) Imai E,et al:Prevalence of chronic kidney disease in the Japanese general population. Clin Exp Nephrol 13(6):621-630,2009.
PubMed
5) Imai E,et al:Slower decline of glomerular filtration rate in the Japanese general population:a longi-tudinal 10-year follow-up study. Hypertens Res 31:433-441,2008.
 
6) Levey AS,et al:The definition,classification,and prognosis of chronic kidney disease:a KDIGO Controversies Conference report. Kidney Int 80:17-28,2011.
PubMed
7) 和田隆志:平成23年度厚生労働省腎疾患対策事業糖尿病性腎症の病態解明と新規治療法の確立のための評価法の開発に関する研究,2012.
 
P.401 掲載の参考文献
1) 北村博司:糖尿病性腎症.腎生検病理アトラス(日本腎臓学会・腎病理診断標準化委員会,日本腎病理協会編),p149-154,東京医学社,2010.
 
2) 小寺亮,四方賢一:糖尿病性腎症.炎症と免疫 17:88-92,2009.
 
3) Li W,Verani RR:Idiopathic nodular glomerulosclerosis:a clinicopathologic study of 15 cases. Hum Pathol 39:1771-1776,2008.
PubMed
4) Inoue W,et al:Detection of immunoglobulins and other serum proteins in the dermal and glomeru-lar capillary walls from patients with diabetic nephropathy. Acta Pathol Jpn 36:1181-1189,1986.
 
P.405 掲載の参考文献
1) Bright R:Cases and observations illustrative of renal disease accompanied with the secretion of albu-minous urine. Guy's Hospital Report 10:338-340,1836.
 
2) Kimmelstiel P,Wilson C:Intercapillary Lesions in the Glomeruli of the Kidney. Am J Pathol 12:83-98,1936.
PubMed
3) Chavers BM,et al:Glomerular lesions and urinary albumin excretion in type I diabetes without overt proteinuria. N Engl J Med 320:966-997,1989.
PubMed
4) Brocco E,et al:Renal structure and function in non-insulin dependent diabetic patients with microalbuminuria. Kidney Int 63:S40-44,1997.
PubMed
5) MacIsaac RJ,et al:Nonalbuminuric renal insufficiency in type 2 diabetes. Diabetes Care 27:195-200,2004.
PubMed
6) Middleton RJ,et al:The unrecognized prevalence of chronic kidney disease in diabetes. Nephrol Dial Transplant 21:88-92,2006.
PubMed
7) Moriya T,et al:Glomerular structural changes and structural-functional relationships at early stage of diabetic nephropathy in Japanese type 2 diabetic patients. Med Electron Microsc 33:115-122,2000.
PubMed
8) Vlassara H,et al:Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats. Proc Natl Acad Sci USA 91:11704-11708,1994.
PubMed
9) Iehara N,et al:Advanced glycation end products modulate transcriptional regulation in mesangial cells. Kidney Int 50:1166-1172,1996.
PubMed
10) Abe H,et al:Type IV collagen is transcriptionally regulated by Smad1 under advanced glycation end product(AGE)stimulation. J Biol Chem 279:14201-14206,2004.
PubMed
11) 安部秀斉ほか:BMP4・Smad1シグナルと糖尿病性腎症.日腎会誌 53:1000-1005,2011.
 
12) 安部秀斉,土井俊夫:医学と医療の最前線-糖尿病性腎症の発症・進展の分子病態-.日内会誌 97:820-826,2008.
 
13) Mima A,et al:Angiotensin II-dependent Src and Smad1 signaling pathway is crucial for the develop-ment of diabetic nephropathy. Lab Invest 86:927-939,2006.
 
14) Matsubara T,et al:Expression of Smad1 is directly associated with mesangial matrix expansion in rat diabetic nephropathy. Lab Invest 86:357-368,2006.
PubMed
15) Mima A,et al:Urinary Smad1 is a novel marker to predict later onset of mesangial matrix expansion in diabetic nephropathy. Diabetes 57:1712-1722,2008.
PubMed
P.410 掲載の参考文献
1) Izzedine H,et al:Gastric bypass and resolution of proteinuria in an obese diabetic patient. Diabet Med 22:1761-1762,2005.
 
2) Hunley TE,et al:Scope and mechanisms of obesity-related renal disease. Curr Opin Nephrol Hypertens 19:227-234,2010.
 
3) Friden V,et al:The glomerular endothelial cell coat is essential for glomerular filtration. Kidney Int 79:1322-1330,2011.
PubMed
4) Shibata S,et al:Modification of mineralocorticoid receptor function by Rac1 GTPase:implication in proteinuric kidney disease. Nat Med 14:1370-1376,2008.
PubMed
5) Fujii M,et al:Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulat-ing NOX4 in db/db mice. Kidney Int 72:473-480,2007.
 
6) Bussolati B,et al:Statins prevent oxidized LDL-induced injury of glomerular podocytes by activat-ing the phosphatidylinositol 3-kinase/AKT-signaling pathway. J Am Soc Nephrol 16:1936-1947,2005.
 
7) Schwedhelm E,Boger RH:The role of asymmetric and symmetric dimethylarginines in renal dis-ease. Nat Rev Nephrol 7:275-285,2011.
 
8) Barnes JL,Glass II WF:Renal interstitial fibrosis:acritical evaluation of the origin of myofibro-blasts. Contrib Nephrol 169:73-93,2011.
 
9) Ohtomo S,et al:Thiazolidinediones provide better renoprotection than insulin in an obese,hyper-tensive type II diabetic rat model. Kidney Int 72:1512-1519,2007.
 
10) Sharma K,et al:Pirfenidone for diabetic nephropathy. J Am Soc Nephrol 22:1144-1151,2011.
PubMed
11) Pergola PE,et al:Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med 365:327-336,2011.
PubMed
12) Kumada Y,et al:Long-term outcome of percutaneous transluminal angioplasty in chronic haemo-dialysis patients with peripheral arterial disease. Nephrol Dial Transplant 23:3996-4001,2008.
 
13) Sharma K,et al:Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest 118:1645-1656, 2008.
PubMed
14) Othman M,et al:Influence of obesity on progression of non-diabetic chronic kidney disease:a ret-rospective cohort study. Nephron Clin Pract 113:c16-c23,2009.
 
15) Abboud H,Henrich WL:Clinical practice.Stage IV chronic kidney disease. N Engl J Med 362:56-65,2010.
PubMed
16) Saiki A,et al:Effect of weight loss using formula diet on renal function in obese patients with dia-betic nephropathy. Int J Obes(Lond) 29:1115-1120,2005.
 
P.417 掲載の参考文献
1) Taguma Y,et al:Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313:1617-1620,1985.
PubMed
2) Lewis EJ,et al:The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 29:1456-1462,1993.
 
3) Parving HH,et al:The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870-878,2001.
PubMed
4) Viberti G,Wheeldon NM:Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus:a blood pressure-independent effect. Circulation 106:672-678,2002.
PubMed
5) Brenner BM,et al:Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabe-tes and nephropathy. N Engl J Med 345:861-869,2001.
 
6) Lewis EJ,et al:Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345:851-860,2001.
PubMed
7) Makino H,et al:Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 30:1577-1578,2007.
PubMed
8) The Shiga Microalbuminuria Reduction Trial(SMART) Group:Reduction of microalbuminuria in patients with type 2 diabetes. Diabetes Care 30:1581-1583,2007.
 
9) Barnett AH,et al:Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 dia-betes and nephropathy. N Engl J Med 351:1952-1961,2004.
 
10) Bakris G,et al:Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. Kidney Int 74:364-369,2008.
PubMed
11) Ohno K,et al:Unique"delta lock"structure of telmisartan is involved in its strongest binding affin-ity to angiotensin II type 1 receptor. Biochem Biophys Res Commun 404:434-437,2011.
 
12) Bichu P,et al:Angiotensin receptor blockers for the reduction of proteinuria in diabetic patients with overt nephropathy:results from the AMADEO study. Vasc Health Risk Manag 5:129-140,2009.
PubMed
13) Schwedhelm E,et al:Antiproteinuric effects of angiotensin receptor blockers:telmisartan versus val-sartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. Nephrol Dial Transplant 23:3174-3183,2008.
 
14) Imai E,et al:Effects of olmesartan on renal and cardiovascular outcomes in type 2 diabetes with overt nephropathy:a multicentre, randomised, placebo-controlled study. Diabetologia 54:2978-2986,2011.
PubMed
15) Mann JF,et al:Renal outcomes with telmisartan, ramipril,or both,in people at high vascular risk(the ONTARGET study):a multicentre,randomised,double-blind, controlled trial. Lancet 372:547-553,2008.
 
16) Ravid M,et al:Use of enalapril to attenuate decline in renal function in normotensive, normoalbu-minuric patients with type 2 diabetes mellitus. A randomized,controlled trial. Ann Intern Med 128:982-988,1998.
 
17) Ruggenenti P,et al:Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941-1951,2004.
PubMed
18) Bilous R,et al:Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes:three randomized trials. Ann Intern Med 151:11-20,2009.
PubMed
19) Chaturvedi N,et al:Effect of candesartan on prevention(DIRECT-Prevent 1) and progression(DIRECT-Protect 1) of retinopathy in type 1 diabetes:randomised,placebo-controlled trials. Lan-cet 372:1394-1402,2008.
 
20) Mauer M,et al:Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361:40-51,2009.
PubMed
21) Haller H,et al:Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 364:907-917,2011.
 
22) Staessen J,et al:Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 91:457-465,1981.
PubMed
23) Sato A,et al:Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hyperten-sion 41:64-68,2003.
 
24) Naruse M,et al:Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 40:28-33,2002.
PubMed
25) Kosugi T,et al:eNOS knockout mice with advanced diabetic nephropathy have less benefit from renin-angiotensin blockade than from aldosterone receptor antagonists. Am J Pathol 176:619-629,2010,
PubMed
26) Nakagawa T:Diabetic nephropathy:Aldosterone breakthrough in patients on an ACEI. Nat Rev Nephrol 6:194-196,2010.
 
27) Schjoedt KJ,et al:Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int 68:2829-2836,2005.
PubMed
28) Epstein M,et al:Selective aldosterone blockade with eplerenone reduces albuminuria in patients with type 2 diabetes. Clin J Am Soc Nephrol 1:940-951,2006.
PubMed
29) Mehdi UF,et al:Addition of angiotensin receptor blockade or mineraloconicoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy. J Am Soc Nephrol 20:2641-2650,2009.
PubMed
30) Toyonaga J,et al:Spironolactone inhibits hyperglycemia-induced podocyte injury by attenuating ROS production. Nephrol Dial Transplant 26:2475-2484,2011.
PubMed
31) Parving HH,et al:Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358:2433-2446,2008.
PubMed
32) Persson F,et al:Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy:an AVOID substudy. J Renin Angiotensin Aldosterone Syst,2011.[Epub ahead of print]
 
33) Parving HH,et al:Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints(ALTITUDE):rationale and study design. Nephrol Dial Transplant 24:1663-1671,2009.
PubMed
34) [http://product.novartis.co.jp/ras/te/te_ras1112.pdf]
 
P.422 掲載の参考文献
1) Evans MJ, Kaufman MH:Establishment in culture of pluripotential cells from mouse embryos. Nature 292:154-156,1981.
PubMed
2) Thomson JA,et al:Embryonic stem cell lines derived from human blastocysts. Science 282:1145-1147, 1998.
PubMed
3) Takahashi K, Yamanaka S:Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126:663-676,2006.
PubMed
4) Takahashi K,et al:Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131:861-872,2007.
PubMed
5) Yu J,et al:Induced pluripotent stem cell lines derived from human somatic cells. Science 318:1917-1920,2007.
PubMed
6) Lau F,et al:Induced pluripotent stem(iPS) cells:an up-to-the-minute review. F1000 Biol Rep 1:84,2009.
 
7) Dressler GR:Advances in early kidney specification, development and patterning. Development 136:3863-3874,2009.
PubMed
8) Osafune K,et al:Identification of multipotent progenitors in the embryonic mouse kidney by a novel colony-forming assay. Development 133:151-161,2006.
PubMed
9) Osafune K:iPS cell technology-based research for the treatment of diabetic nephropathy. Semin Nephrol.(in press)
 
10) Chen S,et al:A small molecule that directs differentiation of human ESCs into the pancreatic lineage. Nat Chem Biol 5:258-265,2009.
 
11) Kim K,et al:Epigenetic memory in induced pluripotent stem cells. Nature 467:285-290,2010.
PubMed
12) Song B,et al:Generation of induced pluripotent stem cells from human kidney.mesangial cells. J Am Soc Nephro 122:1213-1220,2011.
 
13) Zhou T,et al:Generation of induced pluripotent stem cells from urine. J Am Soc Nephro122:1221-1228,2011.
PubMed
14) Ezquer FE,et al:Systemic administration of multipotent mesenchymal stromal cells reverts hyper-glycemia and prevents nephropathy in type 1 diabetic mice. Biol Blood Marrow Transplant 14:631-640,2008.
 
15) Lee RH,et al:Multipotent stromal cells from human marrow home to and promote repair of pancre-atic islets and renal glomeruli in diabetic NOD/scid mice. Proc Natl Acad Sci USA 103:17438-17443, 2006.
 
P.427 掲載の参考文献
1) Sugiyama H,et al:Japan Renal Biopsy Registry:the first nationwide, web-based, and prospective registry system of renal biopsies in Japan. Clin Exp Nephrol 15:493-503,2011.
PubMed
2) 横山仁:厚生労働科学研究費補助金(腎疾患対策研究事業)糖尿病性腎症の病態解明と新規治療法確立のための評価法の開発(研究代表者:和田隆志),平成22年度研究報告書,2010.
 
3) 横山仁ほか:腎臓病総合レジストリーの構築と応用-登録解析による臨床病理学的研究-.日透析医会誌 25:467-472,2010.
 
4) 横山仁:腎病理・腎臓病総合レジストリーの構築と応用.腎と透析 67(増刊号):207-212,2009.
 
5) 山崎勝也,小林正:大規模試験から得られた発症・進展制御のエビデンス JDCP研究.日本臨牀 68(増刊号9):91-96,2010.
 
P.431 掲載の参考文献
1) Tesfaye S,et al:Diabetic neuropathies:update on definitions,diagnostic criteria,estimation of severity,and treatments. Diabetes Care 33:2285-2293,2010.
PubMed
2) Sosenko JM:The prevalence of diabetic neuropathy according to ethnicity. Curr Diab Rep 9:435-439,2009.
PubMed
3) Tesfaye S,et al:Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors:the EURODIAB IDDM Complications Study. Diabetologia 39:1377-1384,1996.
PubMed
4) Veves A,et al:Painful diabetic neuropathy:epidemiology,natural history,early diagnosis,and treatment options. Pain Med 9:660-674,2008.
PubMed
5) Ziegler D,et al:The epidemiology of diabetic neuropathy.Diabetic Cardiovascular Autonomic Neu-ropathy Multicenter Study Group. J Diabetes Complications 6:49-57,1992.
 
6) Karvestedt L,et al:Peripheral sensory neuropathy associates with micro- or macroangiopathy:results from a population-based study of type 2 diabetic patients in Sweden. Diabetes Care 32:317-322,2009.
PubMed
7) Low PA,et al:Autonomic symptoms and diabetic neuropathy:apopulation-based study. Diabetes Care 27:2942-2947,2004.
 
8) Vinik AI, Ziegler D:Diabetic cardiovascular autonomic neuropathy. Circulation 115:387-397,2007.
PubMed
9) Tesfaye S,et al:Vascular risk factors and diabetic neuropathy. N Engl J Med 352:341 -350,2005.
 
10) Partanen J,et al:Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus. N Engl J Med 333:89-94,1995.
PubMed
11) 後藤由夫:糖尿病性神経障害に関する調査研究.日臨内科医会誌 17:125-138,2002.
Medical*Online
12) 八木橋操六:糖尿病性神経障害の簡易診断基準と病期分類の試み.末梢神経 16:79-85,2005.
 
13) 佐藤譲ほか:糖尿病神経障害の発症頻度と臨床診断におけるアキレス腱反射の意義,東北地方15,000人の実態調査.糖尿病 50:799-806,2007.
 
14) Yasuda H,et al:Rationale and usefulness of newly devised abbreviated diagnostic criteria and stag-ing for diabetic polyneuropathy. Diabetes Res Clin Pract 77(Suppl 1):178-183,2007.
 
P.436 掲載の参考文献
1) Yagihashi S,et al:Neuropathy in diabetic mice overexpressing human aldose reductase and effects of aldose reductase inhibitor. Brain 124:2448-2458,2001.
PubMed
2) Ho EC,et al:Aldose reductase-deficient mice are protected from delayed motor nerve conduction velocity,increased c-Jun NH2-terminal kinase activation,depletion of reduced glutathione,increased superoxide accumulation,and DNA damage. Diabetes 55:1946-1953,2006.
PubMed
3) Obrosova IG,et al:High-fat diet induced neuropathy of pre-diabetes and obesity:effects of "healthy" diet and aldose reductase inhibition. Diabetes 56:2598-2608,2007.
PubMed
4) Leinninger GM,et al:Mechanisms of disease:mitochondria as new therapeutic targets in diabetic neuropathy. Nat Clin Pract Neurol 2:620-628,2006.
PubMed
5) Brownlee M:The pathgenesis of diabetic complications.A unifying mechanism. Diabetes 54:1615-1625,2005.
 
6) Akude E,et al:Diminished superoxide generation is associated with respiratory chain dysfunction and changes in the mitochondrial proteome of sensory neurons from diabetic rats. Diabetes 60:288-297,2011.
PubMed
7) Bierhaus A,et al:Loss of pain perception in diabetes is dependent on a receptor of the immuno-globulin superfamily. J Clin Invest 114:1741-1751,2004.
 
8) Stracke H,et al:Benfotiamine in diabetic polyneuropathy(BENDIP):results of a randomised,dou-ble blind,placebo-controlled clinical study. Exp Clin Endocrinol Diabetes 116:600-605,2008.
 
9) Ziegler D,et al:Efficacy and safety of antioxidant treatment with α-lipoic acid over 4 years in dia-betic polyneuropathy:the NATHAN 1 trial. Diabetes Care 34:2054-2060,2011.
 
10) Del Carro U,et al:Evaluation of polyneuropathy markers in type 1 diabetic kidney transplant patients and effects of islet transplantation:neurophysiological and skin biopsy longitudinal analysis. Diabetes Care 30:3063-3069,2007.
PubMed
11) Toth C,et al:Receptor for advanced glycation end products(RAGEs) and experimental diabetic neuropathy. Diabetes 57:1002-1017,2008.
PubMed
12) Ybarra J,et al:Transforming growth factor beta 1 as a biomarker of diabetic peripheral neuropa-thy:cross-sectional study. J Diabetes Complications 24:306-312,2010.
 
13) Terashima T,et al:The fusion of bone-marrow-derived proinsulin-expressing cells with nerve cells underlies diabetic neuropathy. Proc Natl Acad Sci USA 102:12525-12530,2005.
PubMed
14) Yamakawa I,et al:Inactivation of TNF-αameliorates diabetic neuropathy in mice. Am J Physiol Endocrinol Metab 301:E844-852,2011.
 
15) Hur J,et al:The identification of gene expression profiles associated with progression of human dia-betic neuropathy. Brain 134:3222-3235,2011.
 
P.444 掲載の参考文献
1) Thomas PK:Classification,differential diagnosis and staging of diabetic peripheral neuropathy. Dia-betes 46(Suppl 2):S54-57,1997.
 
2) Thomas PK:Classification of the diabetic neuropathies. In:Textbook of Diabetic Neuropathy(ed by Gries G,et al),p175-177,Thieme,Stuttgart,2003.
 
3) Boulton AJM,et al:Diabetic somatic neuropathies. Diabetes Care 27:1458-1486,2004.
PubMed
4) Boulton AJM,et al;American Diabetes Association:Diabetic neuropathies:astatement by the American Diabetes Association. Diabetes Care 28:956-962,2005.
 
5) Dyck PJ,et al;on behalf of the Toronto Expert Panel on Diabetic Neuropathy:Diabetic polyneuro-pathies:update on research definition,diagnostic criteria and estimation of severity. Diabetes Metab Res Rev 27:260-268,2011.
 
6) Dyck PJ,et al:Clinical and neuropathological criteria for the diagnosis and staging of diabetic polyneuropathy. Brain 108:861-880,1985.
PubMed
7) Dyck PJ,et al:The Rochester Diabetic Neuropathy Study:reassessment of tests and criteria for diagnosis and staged severity. Neurology 42:1164-1170,1992.
PubMed
8) Feldman EL,et al:A practical two-step quantitative clinical and electrophysiological assessment for the diagnosis and staging of diabetic neuropathy. Diabetes Care 17:1281-1289,1994.
PubMed
9) Bril V, Perkins BA:Validation of the Toronto Clinical Scoring System for diabetic polyneuropathy.Diabetes Care 25:2048-2052,2002.
PubMed
10) Tesfaye S,et al;Toronto Diabetic Neuropathy Expert Group:Diabetic neuropathies:update on definitions,diagnostic criteria,estimation of severity,and treatments. Diabetes Care 33:2285-2293,2010.
 
11) 糖尿病性神経障害を考える会:簡易診断基準をもとにした糖尿病性多発神経障害の病期分類の公表にあたって.Peripheral Nerve 21:372-373,2010.
 
12) 八木橋操六(研究代表者):糖尿病性多発神経障害の臨床病期分類の確立と病期に基づいた治療ガイドラインの作成.厚生労働省科学研究循環器疾患・糖尿病等生活習慣病対策研究事業,平成20年度～22年度総合研究報告書,2010.
 
P.450 掲載の参考文献
1) Consensus statement:Report and recommendations of the San Antonio conference on diabetic neu-ropathy.American Diabetes Association American Academy of Neurology. Diabetes Care 11:592-597,1988.
 
2) Tesfaye S,et al;Tronto Diabetic Neuropathy Expert Group:Diabetic neuropathies:update on definitions,diagnostic criteria,estimation of severity,and treatments. Diabetes Care 33:2285-2293,2010.
 
3) Tesfaye S:Recent advances in the management of diabetic distal symmetrical polyneuropathy. J Dia-betes Invest 2:33-42,2011.
 
4) Vinik AI,et al:Diabetic autonomic neuropathy. Diabetes Care 26:1553-1579,2003.
PubMed
5) Yagihashi S,et al:Mechanism of diabetic neuropathy;Where are we now and where to go? J Dia-betes Invest 2:18-32,2011.
 
6) Ogawa K,et al:Peripheral nerve functions may deteriorate parallel to the progression of microangio-pathy in diabetic patients. Nutr Metab Cardiovasc Dis 16:313-321,2006.
 
7) Lauria G,et al:EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neurop-athy. Eur J Neurol 12:747-758,2005.
 
8) Tavakoli M,et al:Corneal confocal microscopy:a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care 33:1792-1797,2010.
PubMed
9) Martin CL,et al:Vibration perception threshold as a measure of distal symmetrical neuropathy in type 1 diabetes. Diabetes Care 33:2635-2641,2010.
PubMed
10) Nakayama M,et al:Aldose reductase inhibition ameliorates pupillary light reflex and F-wave latency in patients with mild diabetic neuropathy. Diabetes Care 24:1093-1098,2001.
 
11) Sasaki H,et al:Prevalence and risk factors for erectile dysfunction in Japanese diabetics. Diabetes Res Clin Pract 70:81-89,2005.
PubMed
12) 馬場正之:III.合併症対策の進歩 3.糖尿病性多発神経障害.日内会誌 98:67-74,2009.
 
13) 糖尿病性神経障害を考える会:糖尿病性多発神経障害の簡易診断基準の改定について.末梢神経 14:225-227,2003.
 
14) Nakatani M,et al:Numbness and paresthesia in bilateral toes and soles, and disproportional sweat-ing restricted to face and trunk are suitable symptoms useful for the diagnosis of diabetic symmetric polyneuropathy. J Diabetes Invest 2:464 -473,2011.
 
15) Yasuda H,et al:Rationale and usefulness of newly devised abbreviated diagnostic criteria and stag-ing for diabetic polyneuropathy. Diabetes Res Clin Pract 77(Suppl 1):S178-183,2007.
 
P.456 掲載の参考文献
1) 馬場正之:糖尿病性神経障害.日内会誌 98:779-786,2010.
 
2) Forsblom CM,et al:Risk factors for mortality in type-II(non-insulin-dependent) diabetes:evi-dence of a role of neuropathy and predictive effect of HLA-DR4. Diabetologia 4:1253-1262,1998.
 
3) 八木橋操六:臨床医のための糖尿病の病理,診断と治療社,2004.
 
4) Greene DA,et al:Effect of aldose reductase inhibition on nerve conduction and morphometry in dia-betic neuropathy.Zenarestat Study Group. Neurology 53:580-591,1999.
 
5) 馬場正之:糖尿病有痛性神経障害の鑑別と治療の実際Diabetes J 36:49-55,2008.
 
6) Diabetes Control and Complications Trial Research Group:The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329:977-986,1993.
 
7) Adler AI,et al:UKPDS 59:Hyperglycemia and other potentially modifiable risk factors for periph-eral vascular disease in type 2 diabetes. Diabetes Care 25:894-899,2002.
 
8) Martin CL,et al:Neuropathy among the diabetes control and complications trial cohort 8 years after trial completion. Diabetes Care 29:340-344,2006.
PubMed
9) 上條美樹子,馬場正之:標準治療と最新治療:糖・尿病性ニューロパチー.Clin Neurosci 21:1332-1333,2003.
 
10) 馬場正之:神経伝導検査:糖尿病性神経障害への応用.神経内科 65(Suppl 4):227,2006.
 
11) Chalk C,et al:Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. Cochrane Database Syst Rev(4):CD004572,2007.
PubMed
12) Baba M,et al:Three-year inhibition of aldose reductase on development of symptomatic neuropa-thy in diabetic patients. J Peripher Nerv Syst 11:176-178,2006.
 
13) Hotta N,et al:Long-term clinical effects of epalrestat,an aldose resuctase inhibitor,on diabetic peripheral neuropathy. Diabetes Care 29:1538-1544,2006.
 
14) Hotta N,et al:Stratified analysis for selecting appropriate target patients with diabetic peripheral neuropathy for long-term treatment with an aldose reductase inhibitor,epalrestat. Diabet Med 25:818-825,2008.
 
15) Tesfaye S:Recent advances in the management of diabetic distal symmetrical polyneuropathy. J Dia-betes Invest 2:33-42,2011.
 
16) Veves A,et al:Painful diabetic neuropathy:epidemiology,natural history,early diagnosis,and treatment options. Pain Med 9:660-674,2008.
PubMed
17) 佐藤譲ほか:糖尿病性神経障害の発症頻度と臨床診断におけるアキレス腱反射の意義.糖尿病 50:799-806,2007.
 
18) Diabetic peripheral neuropathic pain:Consensus guidelines for treatment. J Fam Pract Suppl:3-19,2006.
PubMed
19) 馬場正之:糖尿病性神経障害によるしびれ・いたみをどう診るか.medicina 45:272-274,2008.
 
20) 馬場正之:疾痛疾患:糖尿病神経障害.Clin Neurosci 27:521-523,2009.
 
21) Sindrup SH,Jensen TS:Pharmacologic treatment of pain in polyneuropathy. Neurology 55:915-920,2000.
PubMed
22) Mendell JR,Sahenk Z:Painful sensory neuropathy. N Engl J Med 348:1243-1255,2003.
PubMed
23) Attal N,et al:EFNS guidelines on pharmacological treatment of neuropathic pain. Eur J Neurol 13:1153-1169,2006.
PubMed
24) Dworkin RH,et al:Pharmacologic management of neuropathic pain:evidence-based recommenda-tions. Pain 132:237-251,2007.
 
25) Kajdasz DK,et al:Duloxetine for the management of diabetic peripheral neuropathic pain:evi-dence-based findings from post hoc analysis of three multicenter,randomized,double-blined,pla-cebo-controlled,parallel-group studies. Clin Ther 29(Suppl):2536-2546,2007.
 
26) Yasuda H,et al:Superiority of duloxetine to placebo in improving diabetic neuropathic pain:Results of a randomized controlled trial in Japan. J Diabetes Invest 2:132-139,2011.
 
27) Satoh J,et al:Efficacy and safety of pregabalin for treating neuropathic pain associated with diabetic peripheral neuropathy:a 14-week, randomized, double-blind, placebo-controlled trial. Diabet Med 28:109-116,2011.
PubMed
28) Bril V,et al:Evidence-based guideline:Treatment of painful diabetic neuropathy:report of the American Academy of Neurology,the American Association of Neuromuscular and Electrodiagnos-tic Medicine,and the American Academy of Physical Medicine and Rehabilitation. Neurology 76:1758-1765, 2011.
 
29) Satoh J,et al:Efficacy and safety evaluation of pregabalin treatment over 52 weeks in patients with diabetic neuropathic pain extended after a double-blind placebo-controlled trial. J Diabetes Invest 2:457-463,2011.
 
30) Nelson KA,et al:High-dose oral dextrometholphan versus placebo in painful diabetic neuropathy and postherpetic neuralgia. Neurology 48:1212-1218,1997.
PubMed
P.462 掲載の参考文献
1) International Working Group on the Diabetic Foot:International Consensus on the Diabetic Foot and Practical Guidelines on the Management and the Prevention of the Diabetic Foot:Amsterdam,on the CD-RPM[http://www.idf.org/bookshop],2007.
 
2) Abbott CA,et al:Multicenter study of the incidence of and predictive risk factors for diabetic neuro-pathic foot ulceration. Diabetes Care 21:1071-1075,1998.
 
3) Ramsey SD,et al:Incidence,outcomes,and cost of foot ulcers in patients with diabetes. Diabetes Care 22:382-387, 1999.
PubMed
4) Abbott CA,et al:The North-West Diabetes Foot Care Study:incidence of,and risk factors for,new diabetic foot ulceration in a community-based patient cohort. Diabet Med 19:377-384,2002.
 
5) Frykberg RG,et al:Diabetic foot disorders:Aclinical practice guideline(2006 revision). J Foot An-kle Surg 45(5 Suppl):S1-S66,2006.
 
6) Pinzur MS,et al:Guidelines for diabetic foot care:recommendations endorsed by the Diabetes Committee of the American Orthopaedic Foot and Ankle Society. Foot Ankle Int 26:113-119,2005.
PubMed
7) Prompers L,et al:High prevalence of ischaemia,infection,and serious comorbidity in patients with diabetic foot disease in Europe:Baseline result from the Eurodiale study. Diabetologia 50:18-25,2007.
PubMed
8) Apeiqvist J,et al:Long-term prognosis for diabetic patients with foot ulcers. J Intern Med 233:485-491,1993.
PubMed
9) Resnick HE,et al:Relation of lower-extremity amputation to all-cause and cardiovascular disease mortality in American Indians. Diabetes Care 27:1286-1293,2004.
PubMed
10) Moulik PK,et al:Amputation and mortality in new-onset diabetic foot ulcers stratified etiology. Dia-betes Care 26:491-494,2003.
 
11) Edmonds ME,et al:Improved survival of the diabetic foot:The role of a specialized foot clinic. QJM 60(2):763-771,1986.
 
12) LoGerfo FW,Coffman JD:Current concepts.Vascular and microvascular disease of the foot in diabetes.Implications for foot care. N Engl J Med 311:1615-1619,1984.
 
13) Eskelinen E,et al:Major amputation incidence decreases both in non-diabetic and in diabetic patients in Helsinki. Scand J Surg 95:185-189,2006.
PubMed
14) van Houton WH,et al:Reduction in diabetes-related lower extremity amputations in the Nether-lands:1991-2000. Diabetes Care 27:1042-1046,2004.
 
15) Vamos EP,et al:Changes in the incidence of lower extremity amputations in individuals with and without diabetes in England between 2004 and 2008. Diabetes Care 33:2592-2597,2010.
PubMed
P.465 掲載の参考文献
1) Boulton AJ,et al:Global burden of diabetic foot disease. Lancet 366(9498):1719-1724,2005.
PubMed
2) Johannesson A,et al:Incidence of lower-limb amputation in the diabetic and nondiabetic general population. A 10-year population-based cohort study of initial unilateral and contralateral amputa-tions and reamputations. Diabetes Care 32(2):275-280,2009.
 
3) Boulton AJM,et al:Dynamic foot pressure and other studiesas diagnostic and management aids in diabetic neuropathy. Diabetes Care 6:26-33,1985.
 
4) 金森晃ほか:糖尿病性足壊疽の予防と対策-糖尿病患者を対象とした足底圧測定と整形靴の作製-.日義装会誌 13:339-346,1997.
 
5) Edelman SV,et al:Neuro-osteoarthropathy(Charcot's joint) in diabetes mellitus following revascu-larization surgery. Three case reports and a review of the literature. Arch Intern Med 147:1504-1508,1987.
 
6) Parkhouse N, Le Quesne PM:Impaired neurogenic vascular response in patients with diabetes and neuropathic foot lesions. N Engl J Med 318:1306-1309,1988.
PubMed
7) Levin ME,et al:The Diabetic Foot,p17-60,Mosby Year Book,St.Louis,1995.
 
8) 西田壽代:糖尿病性足病変のアセスメント.月刊ナースデータ 25(2):30,2005.
 
9) 糖尿病足病変に関する国際ワーキンググループ(編),内村功,渥美義仁(監訳):インターナショナル・コンセンサス 糖尿病足病変,p57-62,医歯薬出版,2000.
 
10) Mowat A,Baum J:Chemotaxis of polymorphonuclear leukocytes patients with diabetes mellitus. N Engl J Med 284:621-627,1971.
PubMed
11) 塚口勝彦ほか:糖尿病合併肺結核患者のIFN-γ産生能の経時的変化の検討.結核 77:409-413,2002.
 
12) Leichter SB,et al:Clinical characteristics of diabetic patients with serious pedal infections. Metabo-lism 37(2 Suppl 1):22-24,1988.
 
13) Dellinger EP:Severe necrotizing soft-tissue infections.Multiple disease entities requiring a com-mon approach. JAMA 246:1717-1721,1981.
 
P.470 掲載の参考文献
1) Smith AG,et al:Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 29:1294-1299,2006.
PubMed
2) ロコモティブシンドローム診療ガイド2010(日本整形外科学会編),文光堂,2010.
 
3) O'Hare AM,et al:Peripheral vascular disease risk factors among patients undergoing hemo-dialysis. J Am Soc Nephrol 13:497-503,2002.
 
4) 新城孝道:多様な糖尿病足病変と多面的な治療.脈管学 50:693-696,2011.
 
5) Caputo GM,et al:Assesment and management of foot disease in patients with diabetes. N Engl J Med 331:854-860,1994.
 
6) Norgren L,et al:Inter-Society Consensus for the Management of Peripheral Arterial Disease(TASC II). J Vasc Surg 45(Suppl S):S5-S67,2007.
 
7) 新城孝道:糖尿病フットケアと運動器障害.新城孝道のビジュアルガイド糖尿病フットケア,p129-135,医歯薬出版,2011.
 
8) American Diabetes Association:Foot care in patients with diabetes mellitus. Diabetes Care 14(Suppl 2):18,1991.
 
9) Pinzur MS,et al:Guidelines for diabetic foot care:recommendations endorsed by the Diabetes Committee of the American Orthopaedic Foot and Ankle Society. Foot Ankle Int 26(1):113-119,2005.
PubMed
10) American Diabetes Association:Peripheral arterial disease in peaple With diabetes. Diabetes Care 26:3333-3341,2003.
 
11) Apelqvist J,et al:Practical guidelines on the management and prevention of the diabetic foot:based upon the Intemational Consensus on the Diabetic Foot(2007) Prepared by the Intemational Working Group on the Diabetic Foot. Diabetes Metab Res Rev 24(Suppl 1):S181-S187,2008.
 
12) 新城孝道:糖尿病フットケアガイド-診断,治療,ケアの指針,p72-83,医歯薬出版,2004.
 
13) Lipsky BA,et al:Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39(7):885-910,2004.
PubMed
14) 新城孝道:糖尿病患者の靴型装具.リハビリテーションMOOK7 義肢装具とリハビリテーション,p173-177,金原出版,2003.
 
15) American Diabetes Association:Consensus Development Conference on Diabetic Foot Wound Care. Diabetes Care 22:1354-1360,1999.
PubMed
P.475 掲載の参考文献
1) Armstrong DG,Lavery LA(eds):Clinical Care of the Diabetic Foot,2nd ed, American Diabetes Association,2010.
 
2) Edmonds ME,Foster AVM(著),内村功(監訳),糖尿病足病変研究会(訳):糖尿病フットケアハンドブック,シュプリンガージャパン,2006.
 
3) 河野茂男:糖尿病-フットマネージメント,診断と治療社,2002.
 
4) Butalia S,et al:Does this patient with diabetes have osteomyelitis of the lower extremity?JAMA 299(7):806-813,2008.
PubMed
5) Schaper NC:Diabetic foot ulcer classification system for research purposes:a progress report on cri-teria for including patients in research studies. Diabetes Mmetab Res Rev 20(Suppl 1):S90-95,2004.
 
6) Terashi H,et al:Total management of diabetic foot ulcerations-Kobe classification as a new classification of diabetic foot wounds. Keio J Med 60(1):17-21,2011.
PubMed
7) Edmonds ME,et al:Improved survival of the diabetic foot:the role of a specialized foot clinic. Q J Med 60(232):763-771,1986.
PubMed
8) Lipsky BA,et al:Antibiotic therapy for diabetic foot infections:comparison of two parenteral-to-oral regimens. Clin Infect Dis 24(4):643-648,1997.
PubMed
P.479 掲載の参考文献
1) Schultz GS,et al:Wound bed preparation:A systematic approach to wound management. Wound Repair Regen 11(Suppl 1):Sl-S28,2003.
 
2) 大浦紀彦:Wound bed preparationとは.形成外科 50:533-541,2007.
 
3) 大浦紀彦:足部切断術(小切断術).下肢救済のための創傷治療とケア(大浦紀彦編),p185,照林社,2011.
 
4) Femandez R,Griffiths R:Water for wound cleansing. Cochrane Database Syst Rev 23(1):CD003861,2008.
 
5) Argenta LC,Morykwas MJ:Vacuum-assisted closure:a new method for wound control and treat-ment:clinical experience. Ann Plast Surg 38:563-576,1997.
 
P.491 掲載の参考文献
1) Baer WS:The treatment of chronic osteomyelitis with the maggot. J Bone Joint Surg 13:438,1931.
 
2) Horn KL,et al:Maggot therapy for subacute mastoiditis. Arch Otolaryngol 102:377-379,1976.
PubMed
3) Bell NJ,Thomas S:Use of sterile maggots to treat panniculitis in an aged donkey. Vet Rec 149(25):768-770,2001.
 
4) Alderman C:New success for old treatment. Nurs Stand 10(37):26-27,1996.
PubMed
5) Young T:Maggot therapy in wound management. Community Nurse 3(8):43-45,1997.
PubMed
6) Prete PE:Growth effects of Phaenicia sericata larval extracts on fibroblasts:mechanism for wound healing by maggot therapy. Life Sci 60:505-510,1997.
PubMed
7) Sherman RA:Maggot versus conservative debridement therapy for the treatment of pressure ulcers. Wound Rep Reg 10:208-214,2002.
 
8) 藤本啓志ほか:医療用ウジを用いた多剤耐性緑膿菌(MDRP)合併糖尿病壊疽治療.糖尿病 49:517-521,2006.
 
9) 宮本正章ほか:重症難治性潰瘍に対する医療用ウジ治療と血管再生療法.Pharma Medica 23:41-47,2005.
Medical*Online
10) Miyamoto M,et al:Therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease using assessment of neovascularization by 99mTc-tetro-fosmin(TF) perfusion scintigraphy. Cell Transplant 13(4):429-437,2004.
 
11) Miyamoto M,et al:Application of new vascular regenerative therapy using autologous bone marrow cells for intractable cardiovascular diseases. Masui 52:S67-75,2003.
PubMed
12) Miyamoto M,et al:Present status of therapeutic angiogenesis by autologous bone marrow cell implantation for refractory chronic peripheral arterial disease and ischemic heart disease. J Nippon Med Sch 70(5):436-441,2003.
PubMed
13) 宮本正章ほか:マゴットセラピー.透析患者の末梢動脈疾患とフットケア-早期発見と治療戦略-(小林修三編),p115-125,医薬ジャーナル社,2008.
 
14) 宮本正章:難治性創傷に対するマゴットセラピー.日本医事新報(4360):89,2007.
Medical*Online
15) 宮本正章ほか:マゴットセラピー;そのメリット,ケアの実際 月刊ナーシング 27(9):78-85,2007.
 
16) 宮本正章ほか:重症糖尿病性足壊疽におけるマゴットセラピーの有効性.Diabetes Frontier 19(3):331-339,2008.
Medical*Online
P.498 掲載の参考文献
1) Makela J,et al:Bone marrow-derived mononuclear cell transplantation improves myocardial recov-ery by enhancing cellular recruitment and differentiation at the infarction site. J Thorac Cardiovasc Surg 134:565-573,2007.
 
2) Tatsumi T,et al:Intracoronary transplantation of non-expanded peripheral blood-derived mononu-clear cells promotes improvement of cardiac function in patients with acute myocardial infarction. Circ J 71:1199-1207, 2007.
 
3) Beeres SL,et al:Intramyocardial injection of autologous bone marrow mononuclear cells in patients with chronic myocardial infarction and severe left ventricular dysfunction. Am J Cardiol 100:1094-1098,2007.
PubMed
4) Tepper OM,et al:Human endothelial progenitor cells from type ii diabetics exhibit impaired proliferation,adhesion,and incorporation into vascular structures. Circulation 106:2781-2786,2002.
PubMed
5) Capla JM,et al:Diabetes impairs endothelial progenitor cell-mediated blood vessel formation in response to hypoxia. Plast Reconstr Surg 119:59-70,2007.
PubMed
6) Kalka C,et al:Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization. Proc Natl Acad Sci USA 97:3422-3427,2000.
PubMed
7) Asahara T,et al:Bone marrow origin of endothelial progenitor cells responsible for postnatal vascu-logenesis in physiological and pathological neovascularization. Circ Res 85:221-228,1999.
 
8) Tateishi-Yuyama E,et al:Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells:A pilot study and a randomised controlled trial. Lancet 360:427-435,2002.
 
9) Huang P,et al:Autologous transplantation of granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cells improves critical limb ischemia in diabetes. Diabetes Care 28:2155-2160,2005.
PubMed
10) Hoshino J,et al:Quality of life improvement and long-term effects of peripheral blood mononuclear cell transplantation for severe arteriosclerosis obliterans in diabetic patients on dialysis. Circ J 71:1193-1198,2007.
PubMed
11) Kawamoto A,et al:Intramuscular transplantation of g-csf-mobilized cd34(+) cells in patients with critical limb ischemia:A phase i/iia,multicenter,single-blinded,dose-escalation clinical trial. Stem Cells 27:2857-2864,2009.
PubMed
P.501 掲載の参考文献
1) Loe H:Periodontal disease.The sixth complication of diabetes mellitus. Diabetes Care 16:329-334,1993.
PubMed
2) Grossi SG,et al:Treatment of periodontal disease in diabetics reduces glycated hemoglobin. J Periodontol 68:713-719,1997.
PubMed
3) Uysal KT,et al:Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389:610-614,1997.
PubMed
4) Iwamoto Y,et al:The effect of antimicrobial periodontal treatment on circulating tumor necrosis fac-tor-alpha and glycated hemoglobin level in patients with type 2 diabetes. J Periodontol 72:774-778,2001.
 
5) Teeuw WJ,et al:Effect of periodontal treatment on glycemic control of diabetic patients:a system-atic review and meta-analysis. Diabetes Care 33:421-427,2010.
 
6) Nishimura F,et al:Porphyromonas gingivalis infection is associated with elevated C-reactive protein in nonobese Japanese type 2 diabetic subjects. Diabetes Care 25:1888,2002.
PubMed
7) D'Aiuto F,et al:Short-term effects of intensive periodontal therapy on serum inflammatory mark-ers and cholesterol. J Dent Res 84:269-273,2005.
 
8) Iwamoto Y,et al:Antimicrobial periodontal treatment decreases serum C-reactive protein, tumor necrosis factor-alpha,but not adiponectin levels in patients with chronic periodontitis. J periodontol 74:1231-1236,2003.
 
9) Festa A,et al:Inflammation in the prediabetic state is related to increased insulin resistance rather than decreased insulin secretion. Circulation 108:1822-1830,2003.
PubMed
10) Matsumoto K,et al:Inflammation and insulin resistance are independently related to all-cause of death and cardiovascular events in Japanese patients with type 2 diabetes mellitus. Atherosclerosis 169:317-321,2003.
PubMed
11) Ross R:Atherosclerosis-an inflammatory disease. N Engl J Med 340:115-126,1999.
PubMed
12) Devaraj S,et al:Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase c-{alpha} and-{beta}. Diabetes 54:85-91,2005.
PubMed
13) Iwata H,et al:High glucose up-regulates lipopolysaccharide-stimulated inflammatory cytoldne pro-duction via c-jun N-terminal kinase in monocytic cell line THP-1. J Endotoxin Res 13:227-234,2007.
 
14) Wellen KE, Hotamisligil GS:Obesity-induced infiammatory changes in adipose tissue. J Clin Invest 112:1785-1788,2003.
 
15) Xu H,et al:Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830,2003.
 
16) Shi H,et al:TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Invest 116:3015-3025,2006.
PubMed
17) Yamashita A,et al:Macrophage-adipocyte interaction:Marked IL-6 production by co-cultures stimulated with LPS. Obesity 15:2549-2552,2007.
PubMed
18) Rotter V,et al:Interleukin-6(IL-6) induces insulin resistance in 3T3-L1 adipocytes and is,like IL-8 and tumor necrosis factor-alpha,overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem 278:45777-45784,2003.
PubMed
19) Yamashita A,et al:DNA microarray analyses of genes expressed differentially in 3T3-L1 adipo-cytes co-cultured with murine macrophage cell line RAW 264.7 in the presence of the toll-like recep-tor 4 ligand bacterial endotoxin. Int J Obese 32:1725-1729,2008.
 
20) Nakarai H,et al:Adipocyte-macrophage interaction may mediate LPS-induced low-grade inflam-mation:Potential link with metabolic complications. Innate Immun 18:164-170,2012.
 
P.506 掲載の参考文献
1) Biessels GJ,et al:Risk of dementia in diabetes mellitus:asystematic review. Lancet Neurol 5:64-74,2006.
 
2) Cukierman T,et al:Cognitive decline and dementia in diabetes-systematic overview of prospective observational studies. Diabetologia 48:2460-2469,2005.
PubMed
3) Cox DJ,et al:Relationships between hyperglycemia and cognitive performance among adults with type 1 and type 2 diabetes. Diabetes Care 28:71-77,2005.
PubMed
4) Matsuzaki T,et al:Insulin resistance is associated with the pathology of Alzheimer disease:the Hisayama study. Neurology 75:764-770,2010.
PubMed
5) Craft S:Insulin resistance syndrome and Alzheimer's disease:age-and obesity-related effects on memory,amyloid,and inflammation. Neurobiol Aging 26(Suppl 1):65-69,2005.
 
6) Yaffe K,et al:Glycosylated hemoglobin level and development of mild cognitive impairment or dementia in older women. J Nutr Health Aging 10:293-295,2006.
PubMed
7) Whitmer R,et al:Hypoglycemic episodes and risk of dementia in older patients with type 2 diabetes mellitus. JAMA 301:1565-1572,2009.
PubMed
8) Rizzo MR,et al:Relationships between daily acute glucose fluctuations and cognitive performance among aged type 2 diabetic patients. Diabetes Care 33:2169-2174,2010.
PubMed
9) Kameyama M,et al:Diabetes mellitus and cerebral vascular disease. Diabetes Res Clin Pract 24(Suppl):S205-208,1994.
 
10) 脳卒中治療ガイドライン2009(篠原幸人ほか,脳卒中合同ガイドライン委員会編),共和企画[http://www.jsts.gr.jp/guideline/025_026.pdf].
 
11) van Harten B,et al:Brain imaging in patients with diabetes:a systematic review. Diabetes Care 29:2539-2548,2006.
PubMed
12) Akisaki T,et al:Cognitive dysfunction associates with white matter hyperintensities and subcortical atrophy on magnetic resonance imaging of the elderly diabetes mellitus Japanese elderly diabetes intervention trial(J-EDIT). Diabetes Metab Res Rev 22:376-384,2006.
 
13) Jack CR Jr,et al:Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cas-cade. Lancet Neurol 9:119-128,2010.
 
14) Sakurai T,et al:Age-associated increase in abdominal obesity and insulin resistance, and useful-ness of AHA/NHLBI definition of metabolic syndrome for predicting cardiovascular disease in Japa-nese elderly with type 2 diabetes mellitus. Gerontology 56:141-149,2010.
 
15) Shinohara Y,et al:Antiplatelet cilostazol is beneficial in diabetic and/or hypertensive ischemic stroke patients.Subgroup analysis of the cilostazol stroke prevention study. Cerebrovasc Dis 26:63-70, 2008.
PubMed
P.510 掲載の参考文献
1) Delamaire M,et al:Impaired leucocyte functions in diabetic patients. Diabet Med 14:29-34,1997.
PubMed
2) Falagas ME, Kompoti M:Obesity and infection. Lancet Infect Dis 6:438-446,2006.
PubMed
3) Joshi N,et al:Infections in patients with diabetes mellitus. N Engl J Med 341:1906-1912,1999.
PubMed
4) Rajagopalan S:Serious infections in elderly patients with diabetes mellitus. Clin Infect Dis 40:990-996,2005.
PubMed
5) Muller LM,et al:Increased risk of common infections in patients with type 1 and type 2 diabetes mellitus. Clin Infect Dis 41:281-288,2005.
PubMed
6) Koziel H, Koziel MJ:Pulmonary complications of diabetes mellitus. Pneumonia. Infect Dis Clin North Am 9:65-96,1995.
PubMed
7) 山岸文雄:免疫抑制宿主における結核の臨床像とその対策.結核 81:631-638,2006.
 
8) Senneville E,et al:Culture of percutaneous bone biopsy specimens for diagnosis of diabetic foot osteomyelitis:concordance with ulcer swab cultures. Clin Infect Dis 42:57-62,2006.
PubMed
9) Lipsky BA,et al:Infectious Disease Society of America:Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39:885-910,2004.
 
10) Lipsky BA:A report from the international consensus on diagnosing and treating the infected dia-betic foot. Diabetes Metab Res Rev 20(Suppl 1):S68-77,2004.
 
11) Joseph WS, Lipsky BA:Medical therapy of diabetic foot infections. J Vasc Surg 52(3 Suppl):67S-71S,2010.
 
12) McAlister FA,et al:The relation between hyperglycemia and outcomes in 2,471 patients admitted to the hospital with community-acquired pneumonia. Diabetes Care 28:810-815,2005.
 
13) Yende S,et al:The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia:analysis of two multicentre cohort studies. Thorax 65:870-877,2010.
PubMed
14) Brink S,et al:Sick day management in children and adolescents with diabetes. Pediatr Diabetes8:401-407,2007.
 
P.514 掲載の参考文献
1) Yamamoto M,et al:Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 24:702-709,2009.
 
2) Levy JR,et al:Demonstration of insulin receptors and modulation of alkaline phosphatase activity by insulin in rat osteoblastic cells. Endocrinology 119:1786-1792,1986.
PubMed
3) Akune T,et al:Insulin receptor substrate-2 maintains predominance of anabolic function over cata-bolic function of osteoblasts. J Cell Biol 159:147-156,2002.
 
4) Luo XH,et al:Adiponectin stimulates RANKL and inhibits OPG expression in human osteoblasts through the MAPK signaling pathway. J Bone Miner Res 21:1648-1656,2006.
PubMed
5) Takeda S,et al:Leptin regulates bone formation via the sympathetic nervous system. Cell 111:305-317,2002.
PubMed
6) Botolin S,et al:Chronic hyperglycemia modulates osteoblast gene expression through osmotic and non-osmotic pathways. J Cell Biochem 99:411-424,2006.
PubMed
7) Inaba M,et al:Importance of sustained high glucose condition in the development of diabetic osteopenia:possible involvement of the polyol pathway. Osteoporos Int 7:S209-212,1997.
PubMed
8) Takagi M,et al:Advanced glycation endproducts stimulate interleukin-6 production by human bone-derived cells. J Bone Miner Res 12:439-446,1997.
 
9) Alikhani M,et al:Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cytosolic apoptotic pathways. Bone 40:345-353,2007.
PubMed
10) Ikeda K,et al:The role of insulin in the stimulation of renal 1,25-dihydroxyvitamin D synthesis by parathyroid hormone in rats. Endocrinology 121:1721-1726,1987.
PubMed
11) Patel SR,et al:Effect of glucose on the function of the calcitriol receptor and vitamin D metabolism. Kidney Int 52:79-86,1997.
PubMed
12) Wan Y,et al:PPAR-gamma regulates osteoclastogenesis in mice. Nat Med 13:1496-1503,2007.
PubMed
13) Kanazawa I,et al:Metformin enhances the differentiation and mineralization of osteoblastic MC3T3-E1 cells via AMP kinase activation as well as eNOS and BMP-2 expression. Biochem Bio-phys Res Commun 375:414-419,2008.
 
14) Tsukiyama K,et al:Gastric inhibitory polypeptide as an endogenous factor promoting new bone for-mation after food ingestion. Mol Endocrinol 20:1644-1651,2006.
 
15) Keegan TH,et al:Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women:the fracture intervention trial. Diabetes Care 27:1547-1553,2004.
 
P.518 掲載の参考文献
1) Shaw JE,et al:Sleep-disordered breathing and type 2 diabetes:a report from the International Dia-betes Federation Taskforce on Epidemiology and Prevention. Diabetes Res Clin Pract 81:2-12,2008.
 
2) Kawakami N,et al:Sleep disturbance and onset of type 2 diabetes. Diabetes Care 27:282-283,2004.
PubMed
3) Cappuccio FP,et al:Quantity and quality of sleep and incidence of type 2 diabetes:asystematic review and meta-analysis. Diabetes Care 33:414-420,2010.
 
4) Young T,et al:The occurrence of sleep-disordered breathing among middle-aged adults. N Engl J Med 328:1230-1235,1993.
PubMed
5) Kayukawa Y,et al:Habitual snoring in an outpatient population in Japan. Psychiatry Clin Neurosci 54:385-391,2000.
 
6) Nakayama-Ashida Y,et al:Sleep-disordered breathing in the usual lifestyle setting as detected with home monitoring in a population of working men in Japan. Sleep 31:419-425,2008.
 
7) West SD,et al:Prevalence of obstructive sleep apnoea in men with type 2 diabetes. Thorax 61:945-950,2006.
PubMed
8) Resnick HE,et al:Diabetes and sleep disturbances:Findings from the Sleep Heart Health Study. Diabetes Care 26:702-709,2003.
PubMed
9) Elmasry A,et al:Sleep-disordered breathing and glucose metabolism in hypertensive men:a popu-lation-based study. J Intern Med 249:153-161,2001.
 
10) Katsumata K,et al:High incidence of sleep apnea syndrome in a male diabetic population. Diabetes Res Clin Pract 13:45-51,1991.
 
11) Punjabi NM,et al:Sleep-disordered breathing, glucose intolerance, and insulin resistance:the Sleep Heart Health Study. Am J Epidemiol 160:521-530,2004.
PubMed
12) Li KK,et al:Obstructive sleep apnea syndrome:A comparison betWeen Far-East Asian and white men. Laryngoscope 110:1689-1693,2000.
PubMed
13) Ficker JH,et al:Obstructive sleep apnoea and diabetes mellitus:the role of cardiovascular auto-nomic neuropathy. Eur Respir J 11:14-19,1998.
 
14) Schober AN,et al:Prevalence of sleep apnea in diabetic patients. Clin Respir J 5:165-172,2011.
PubMed
15) Nomura K,et al:Relation between sleep-disordered breathing and cardiac autonomic neuropathy in non-obese Japanese subjects with type 2 diabetes. Diabetologia 54(Suppl 1):S463,2011.
 
16) Reichmuth KI,et al:Association of sleep apnea and type II diabetes:a population-based study. Am J Respir Crit Care Med 172:1590-1595,2005.
 
17) Otake K,et al:Glucose intolerance in Japanese patients with obstructive sleep apnea. Intern Med 48:863-868,2009.
 
18) Peppard PE,et al:Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med 342:1378-1384,2000.
PubMed
19) Logan AG,et al:Refractory hypertension and sleep apnoea:effect of CPAP on blood pressure and baroreflex. Eur Respir J 21:241-247,2003.
PubMed
20) Marin JM,et al:Long-term cardiovascular outcemes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure:an observational study. Lancet 365:1046-1053,2005.
PubMed
21) Trenell MI,et al:Influence of constant positive airway pressure therapy on lipid storage, muscle metabolism and insulin action in obese patients with severe obstructive sleep apnoea syndrome. Dia-betes Obes Metab 9:679-687,2007.
 
P.523 掲載の参考文献
1) Impotence:NIH Consensus Development Panel on Impotence. JAMA 270:83-90,1993.
PubMed
2) Feldman HA,et al:Impotence and its medical and psychosocial correlates:results of the Massachu-setts Male Aging Study. J Urol 151:54-61,1994.
 
3) Gazzaruso C,et al:Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetic patients. Circulation 110:22-26,2004.
PubMed
4) Creager MA,et al:Diabetes and vascular disease:pathophysiology,clinical consequences,and medical therapy:Part I. Circulation 108:1527-1532,2003.
PubMed
5) Bivalacqua TJ,et al:Superoxide anion production in the rat penis impairs erectile function in diabe-tes:influence of in vivo extracellular superoxide dismutase gene therapy. J Sex Med 2:187-198,2005.
 
6) Sullivan M,et al:Differential alterations of prostacyclin,cyclic AMP and cyclic GMP formation in the corpus cavernosum of diabetic rabbit. Br J Urol 82:578-584,1998.
PubMed
7) Rees RW,et al:Human and rabbit cavemosal smooth muscle cells express Rho-kinase. Int J Impot Res 14:1-7,2002.
 
8) Corona G,et al:Association of hypogonadism and type II diabetes in men attending an outpatient erectile dysfunction clinic. Int J Impot Res 18:190-197,2006.
PubMed
9) Sato Y,et al:How long do patients with erectile dysfunction continue to use sildenafil citrate?Dropout rate from treatment course as outcome in real life. Int J Urol 14:339-342,2007.
 
10) Vickers MA, Satynarayana R:Phosphodiesterase type 5 inhibitors for the treatment of erectile dys-function inpatients with diabetes mellitus. Int J Impot Res 14:466-471,2002.
 
11) Fonceca V,et al:Impact of diabetes mellitus on the survey of erectile dysfunction and response to treatment:analysis of data from tadalafil clinical trials. Diabetologia 47:1914-1923,2004.
 
12) Jiann BP,et al:Rechallenge prior sildenafil nonresponders. Int J Impot Res 16:64-68,2004.
PubMed
13) Hatzimouratidis K,et al:Treatment strategy for non-responders to tadalafil and valdenafil:areal life study. Eur Uro150:126-133,2006.
 
14) 佐々木春明ほか:インターネットを介した偽造ED医薬品4社合同調査.日性機能会誌 25:19-28,2010.
Medical*Online
P.527 掲載の参考文献
1) Prince M,et al:Grobal mental health 1. No health without mental health. Lancet 370:859-877,2007.
 
2) Egede LE,et al:Depression and all-cause and coronary heart disease mortality among adults with and without diabetes. Diabetes Care 28:1339-1345,2005.
PubMed
3) Anderson RJ,et al:The prevalence of comorbid depression in adults with diabetes. Diabetes Care 24:1069-1078,2001.
PubMed
4) Mezuk B,et al:Depression and type 2 diabetes over the lifespan. Diabetes Care 31:2383-2390,2008.
PubMed
5) Nouwen A,et al:Prevalence of Depression in individuals with impaired glucose metabolism or undi-agnosed diabetes. Diabetes Care 34:752-762,2011.
 
6) De Groot M,et al:Association of depression and diabetes complication:a meta-analysis. Psycho-som Med 63:619-630,2001.
 
7) Kivimaki M,et al:Antidepressant medication use,weight gain,and risk of type 2 diabetes. Diabe-tes Care 33:2611-2616,2010.
 
8) Rubin RR,et al:Antidepressant medicine use and risk of developing diabetes during the diabetes prevention program and diabetes prevention program outcomes study. Diabetes Care 33:2549-2551, 2010.
 
9) Lin EHB,et al:Relationship of depression and diabetes self-care,medication adherence,and pre-ventive care. Diabetes Care 27(9):2154-2160,2004.
 
10) Trong K Le,et al:Resource use among patients with diabetes,diabetic neuropathy,or diabetes with depression. Cost Eff Resour Alloc 4:18,2006.
PubMed
11) Petrak F,et al:Treatment of depression in diabetes:an update. Curr Opin Psychiatry 22:211-217,2009.
PubMed
12) Egede LE,Ellis C:Diabetes and depression:Global perspectives. Diabetes Res Clin Pract 87:302-312,2010.
PubMed
P.532 掲載の参考文献
1) Hamaguchi M,et al:The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann Intern Med 143:722-728,2005.
PubMed
2) Miyake T,et al:Metabolic Markers and ALT Cutoff Level for Diagnosing Nonalcoholic Fatty Liver Disease:A Community-based Cross-sectional Study. J Gastoroenterol, DOI 10.1007/s00535-012-0534-y,2012.[Epub ahead of print]
 
3) Yatsuji S,et al:Clinical features and outcomes of cirrhosis due to non-alcoholic steatohepatitis com-pared with cirrhosis caused by chronic hepatitis C. J Gastroenterol Hepatol 24:248-254,2009.
 
4) Michitaka K,et al:Etiology of liver cirrhosis in Japan:a nationwide survey. J Gastroenterol 45:86-94,2010.
PubMed
5) Jimba S,et al:Prevalence of non-alcoholic fatty liver disease and its association with impaired glu-cose metabolism in Japanese adults. Diabet Med 22:1141-1145,2005.
 
6) Donnelly KL,et al:Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115:1343-1135,2005.
PubMed
7) Kohjima M,et al:SREBP-1c, regulated by the insulin and AMPK signaling pathways,plays a role in nonalcoholic fatty liver disease. Int J Mol Med 21:507-511,2008.
 
8) Yoneda M,et al:Platelet count for predicting fibrosis in nonalcoholic fatty liver disease. J Gastroen-terol 46:1300-1306,2011.
 
9) Sumida Y,et al:A simple clinical scoring system using ferritin,fasting insulin,and type IV collagen 7S for predicting steatohepatitis in non-alcoholic fatty liver disease. J Gastroenterol 46:257-268,2011.
 
10) Miyaaki H,et al:Clinicopathological study of nonalcoholic fatty liver disease in Japan:the risk fac-tors for fibrosis. Liver Int 28:519-524,2008.
 
11) Musso G,et al:Meta-analysis:natural history of non-alcoholic fatty liver disease(NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 43:617-649,2011.
PubMed
12) Hotta K,et al:Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease. BMC Med Genet 11:172,2010.
PubMed
13) Lazo M,et al:Non-alcoholic fatty liver disease and mortality among US adults:prospective cohort study. BMJ 343:d6891,2011.
PubMed
14) Yasui K,et al:Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellu-lar carcinoma. Clin Gastroenterol Hepatol 9:428-433,2011.
 
15) Toshimitsu K,et al:Dietary habits and nutrient intake in non-alcoholic steatohepatitis. Nutrition 23:46-52,2007.
PubMed
P.536 掲載の参考文献
1) Global Initiative for Chronic Obstructive Lung Disease(GOLD) 2006,National Heart,Lung and Blood Institute,National Institute of Health, Bethesda,2006.
 
2) Rana JS,et al:Chronic obstructive pulmonary disease, asthma, and risk of type 2 diabetes in women. Diabetes Care 27:2478-2484,2004.
PubMed
3) Gan WQ,et al:Association between chronic obstructive pulmonary disease and systemic inflamma-tion:a systematic review and a meta-analysis. Thorax 59:574-580,2004.
 
4) 日本呼吸器学会COPDガイドライン第3版作成委員会:COPD(慢性閉塞性肺疾患)診断と治療のためのガイドライン,第3版,メディカルレビュー社,2009.
 
5) Fabbri LM,et al:Complex chronic comorbidities of COPD. Eur Respir J 31:204-212,2008.
PubMed
6) Facchini FS,et al:Insulin resistance and cigarette smoking. Lancet 339(8802):1128-1130,1992.
PubMed
7) Walter RE,et al:Association between glycemic state and lung function:the Framingham Heart Study. Am J Respir Crit Care Med 167:911-916,2003.
PubMed
8) Iwamoto H,et al:Airflow limitation in smokers is associated with subclinical atherosclerosis. Am J Respir Crit Care Med 179:35-40,2009.
PubMed
9) Mannino DM,et al:Global Initiative on Obstructive Lung Disease(GOLD) classification of lung dis-ease and mortality:findings from the Atherosclerosis Risk in Communities(ARIC) study. Respir Med 100:115-122,2006.
 
10) Holguin F,et al:Comorbidity and mortality in COPD-related hospitalizations in the United States, 1979 to 2001. Chest 128:2005-2011,2005.
PubMed
11) Parappil A,et al:Effect of comorbid diabetes on length of stay and risk of death in patients admitted with acute exacerbations of COPD. Respirology 15:918-922,2010.
PubMed
12) Tashkin D,et al:A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 359(15):1543-1554,2008.
PubMed
13) Tamura G,et al:Adherence to treatment by patients with asthma or COPD:comparison between inhaled drugs and transdermal patch. Respir Med 101(9):1895-1902,2007.
 
P.540 掲載の参考文献
1) Mokdad AH,et al:The continuing epidemics of obesity and diabetes in the United States. JAMA 286:1195-1200,2001.
PubMed
2) Norgren L,et al;TASC II Working Group:Inter-Society Consensus for the Management of Periph-eral Arterial Disease(TASC II). J Vasc Surg 45(Suppl S):S5-67,2007.
 
3) Dormandy JA,Rutherford RB:Management of peripheral arterial disease(PAD). TASC Working Group. TransAtlantic Inter-Society Consensus(TASC). J Vasc Surg 31:S1-S296,2000.
 
4) Bernstein EE Fronek A:Current status of noninvasive tests in the diagnosis of peripheral arterial disease. Surg Clin North Am 62:473-487,1982.
 
5) Castronuovo JJ Jr,et al:Skin perfusion pressure measurement is valuable in the diagnosis of critical limb ischemia. J Vasc Surg 26:629-637,1997.
PubMed
6) Faglia E,et al:Long-term prognosis of diabetic patients with critical limb ischemia:a population-based cohort study. Diabetes Care 32:822-827,2009.
PubMed
7) Pomposelli FB,et al:A decade of experience with dorsalis pedis artery bypass:analysis of outcome in more than 1000 cases. J Vasc Surg 37:307-315,2003.
 
8) Abou-Zamzam AM Jr,et al:Functional outcome after infrainguinal bypass for limb salvage. J Vasc Surg 25:287-295 1997.
PubMed
9) Allie DE,et al:24-carat gold,14-carat gold,or platinum standards in the treatment of critical limb ischemia:bypass surgery or endovascular intervention?J Endovasc Ther 16(Suppl 1):1134-1146,2009.
PubMed
10) Adam DJ,et al:BASIL trial participants.Bypass versus angioplasty in severe ischaemia of the leg(BASIL):multicentre,randomised controlled trial. Lancet 366:1925-1934,2005.
PubMed
11) Bradbury AW,et al:Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease.The Bypass versus Angioplasty in Severe Ischaemia of the Leg(BASIL) trial. Health Technol Assess 14(14):1-210,iii-iv,2010.
 
12) 半田宣弘,川本篤彦:チーム医療のアプローチと重症虚血肢に対する血管再生療法.重症虚血肢診療の実践(南都伸介監修),p126-129,南江堂,2008.
 
P.545 掲載の参考文献
1) Giovannucci E,et al:Diabetes and cancer:aconsensus report. Diabetes Care 33:1674-1685,2010.
 
2) Hotta N,et al:Causes of Death in Japanese Diabetics Based on the Results of a Survey of 18,385 Dia-betics during 1991-2000-Report of Committee on Cause of Death in Diabetes Mellitus-. Journal of the Japan Diabetic Society 50:47-61,2007.
 
3) Renehan A,et al:Linking diabetes and cancer:aconsensus on complexity. Lancet 375:2201-2202,2010.
 
4) Barone BB,et al:Long-term all-cause mortality in cancer patients with preexisting diabetes melli-tus:a systematic review and meta-analysis. JAMA 300:2754-2764,2008.
 
5) Barone BB,et al:Postoperative mortality in cancer patients with preexisting diabetes:systematic review and meta-analysis. Diabetes Care 33:931-939,2010.
PubMed
6) Noto H,et al:Significantly increased risk of cancer in patients with diabetes mellitus:a systematic review and meta-analysis. Endocr Pract 17:616-628,2011.
PubMed
7) Noto H,et al:Significantly Increased Risk of Cancer in Diabetes Mellitus Patients:A meta-analysis of epidemiologic evidence in Asians and non-Asians. Journal of Diabetes Investigation.(in press)
 
8) Noto H,et al:Substantially increased risk of cancer in patients with diabetes mellitus:a systematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 24:345-353, 2010.
PubMed
9) Johnson JA,et al:Time-varying incidence of cancer after the onset of type 2 diabetes:evidence of potential detection bias. Diabetologia 54:2263-2271,2011.
PubMed
10) Bowker SL,et al:Risk of breast cancer after onset of type 2 diabetes:evidence of detection bias in postmenopausal women. Diabetes Care 34:2542-2544,2011.
PubMed
11) Noto H, Raskin P:Hepatitis C infection and diabetes. J Diabetes Complications 20:113-120,2006.
PubMed
12) Hosono K,et al:Metformin suppresses azoxymethane-induced colorectal aberrant crypt foci by acti-vating AMP-activated protein kinase. Mol Carcinog 49:662-671,2010.
 
13) 能登 洋:メトホルミンと癌.糖尿病(in press)
 
P.550 掲載の参考文献
1) Inoue M,et al:Diabetes mellitus and the risk of cancer:results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871-1877,2006.
PubMed
2) Inoue M,et al:Impact of metabolic factors on subsequent cancer risk:results from a large-scale population-based cohort study in Japan. Eur J Cancer Prev 18:240-247,2009.
PubMed
3) Huxley Ret al:Type-II diabetes and pancreatic cancer:a meta-analysis of 36 studies. Br J Cancer 92:2076-2083,2005.
 
4) El-Serag HB,et al:The association between diabetes and hepatocellular carcinoma:a systematic review of epidemiologic evidence. Clin Gastroenterol Hepatol 4:369-380,2006.
PubMed
5) Larsson SC,et al:Diabetes mellitus and risk of colorectal cancer:a meta-analysis. J Natl Cancer Inst 97:1679-1687,2005.
PubMed
6) Larsson SC,et al:Diabetes mellitus and risk of bladder cancer:a meta-analysis. Diabetologia 49:2819-2823,2006.
PubMed
7) Larsson SC,et al:Diabetes mellitus and risk of breast cancer:a meta-analysis. Int J Cancer 121:856-862,2007.
PubMed
8) Friberg E,et al:Diabetes mellitus and risk of endometrial cancer:ameta-analysis. Diabetologia 50:1365-1374,2007.
 
9) Kasper JS,Giovannucci E:A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15:2056-2062,2006.
 
10) Inoue M,et al:Evaluation based on systematic review of epidemiological evidence among Japanese populations:tobacco smoking and total cancer risk. Jpn J Clin Oncol 35:404 -411,2005.
PubMed
11) Wakai K,et al:Tobacco smoking and lung cancer risk:an evaluation based on a systematic review of epidemiological evidence among the Japanese population. Jpn J Clin Oncol 36:309-324,2006.
PubMed
12) Nishino Y,et al:Tobacco smoking and gastric cancer risk:an evaluation based on a systematic review of epidemiologic evidence among the Japanese population. JPn J Clin Oncol 36:800-807,2006.
PubMed
P.555 掲載の参考文献
1) Gallagher EJ,LeRoith D:IGF,Insulin,and Cancer. Endocrinology 152:2546-2551,2011.
PubMed
2) Wu Y,et al:Reduced circulating insulin-like growth factor I levels delay the onset of chemically and genetically induced mammary tumors. Cancer Res 63:4384-4388,2003.
PubMed
3) Loeper S,Ezzat S:Acromegaly:re-thinking the cancer risk. Rev Endocr Metab Disord 9:41-58,2008.
PubMed
4) Vella V,et al:A novel autocrine loop involVing IGF-II and the insulin receptor isoform-A stimulates growth of thyroid cancer. J Clin Endocrinol Metab 87:245-254,2002,
 
5) Malaguarnera R,et al:Insulin receptor isoforms and insulin-like growth factor receptor in human follicular cell precursors from papillary thyroid cancer and normal thyroid. J Clin Endocrinol Metab 96:766-774,2010.
PubMed
6) Ewing GP, Goff LW:The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer 9:219-223,2010.
PubMed
7) Gunter MJ,et al:Insulin,insulin-like growth factor-I,and risk of breast cancer in postmeno-pausal women. J Natl Cancer Inst 101:48-60,2009.
 
8) Perseghin G,et al:Insulin resistance/hyperinsulinemia and cancer mortality:the Cremona study at the 15th year of follow-up. Acta Diabetol,2012.[Epub ahead of print]
 
9) Hemkens LG,et al:Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues:a cohort study. Diabetologia 52:1732-1744,2009.
 
10) Novosyadlyy R,et al:Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 70:741-751,2010.
 
11) Frystyk J,et al:Circulating levels of free insulin-like growth factors in obese subjects:the impact of type 2 diabetes. Diabetes Metab Res Rev 15:314-322,1999.
PubMed
P.559 掲載の参考文献
1) Tiaka EK,et al:The implication of adiponectin and resistin in gastrointestinal diseases. Cytokine Growth Factor Rev 22:109-119,2011.
PubMed
2) Ishikawa M,et al:Plasma adiponectin and gastric cancer. Clin Cancer Res 11:466-472,2005.
PubMed
3) Xu XT,et al:Meta-analysis:circulating adiponectin levels and risk of colorectal cancer and ade-noma. J Dig Dis 12:234-244,2011.
 
4) Grote VA,et al:The association of circulating adiponectin levels with pancreatic cancer risk:A study within the prospective EPIC cohort. Int J Cancer 130:2428-2437,2012.
 
5) Barb D,et al:Adiponectin in relation to malignancies:areview of existing basic research and clini-cal evidence. Am J Clin Nutr 86:s858-866,2007.
 
6) Barresi V,et al:The expression of adiponectin receptors Adipo-R1 and Adipo-R2 is associated with an intestinal histotype and longer survival in gastric carcinoma. J Clin Pathol 62:705-709,2009.
PubMed
7) Otani K,et al:Adiponectin receptors are downregulated in human gastric cancer. J Gastroenterol 45(9):918-927,2010.
PubMed
8) Williams CJ,et al:Adiponectin receptor expression is elevated in colorectal carcinomas but not in gastrointestinal stromal tumors. Endocr Relat Cancer 15:289-299,2008.
 
9) Byeon JS,et al:Adiponectin and adiponectin receptor in relation to colorectal cancer progression. Int J Cancer 127(12):2758-2767,2010.
PubMed
10) Chou SH,et al:Adiponectin receptor expression in human malignant tissues. Horm Cancer 1:136-145,2010.
PubMed
11) Ishikawa M,et al:Adiponectin inhibits the growth and peritoneal metastasis of gastric cancer through its specific membrane receptors AdipoR1 and AdipoR2. Cancer Sci 98:1120-1127,2007.
PubMed
12) Otani K,et al:Adiponectin suppresses tumorigenesis in Apc(Min)(/+)mice. Cancer Lett 288:177-182,2010.
PubMed
13) Habeeb BS,et al:Adiponectin supports cell survival in glucose deprivation through enhancement of autophagic response in colorectal cancer cells. Cancer Sci 102:999-1006,2011.
PubMed
14) Kelesidis I,et al:Adiponectin and cancer:a systematic review. Br J Cancer 94(9):1221-1225,2006.
 
15) Sugiyama M,et al:Adiponectin inhibits colorectal cancer cell growth through the AMPK/mTOR pathway. Int J Oncol 34:339-344,2009.
PubMed
16) Nakayama S,et al:Growth-inhibitory effect of adiponectin via adiponectin receptor 1 on human breast cancer cells through inhibition of S-phase entry without inducing apoptosis. Breast Cancer Res Treat 112:405-410,2008.
PubMed
P.564 掲載の参考文献
1) 山田大輔,田中雅夫:糖尿病と膵癌.内科 107:496-499,2011.
 
2) 日本膵臓学会膵癌登録委員会:膵癌登録報告2007.膵臓 22:e54-e54,2007.
 
3) DiMagno EP,et al:AGA technical review on the epidemiology, diagnosis, and treatment of pancre-atic ductal adenocarcinoma. Gastroenterology 117:1464-1484,1999.
 
4) Huxley R,et al:Type-II diabetes and pancreatic cancer:a meta-analysis of 36 studies. Br J Cancer 92:2076-2083,2005.
PubMed
5) Inoue M,et al:Diabetes mellitus and the risk of cancer:results from a large-scale population-based cohort study in Japan. Arch Intern Med 166:1871-1877,2006.
PubMed
6) Li D,et al:Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 137:482-488,2009.
PubMed
7) Ogawa Y,et al:A prospective pancreatographic study of the prevalence of pancreatic carcinoma in patients with diabetes mellitus. Cancer 94:2344-2349,2002.
PubMed
8) 山田大輔,田中雅夫:膵癌高危険群はどこまで明らかになったか 最近発症した糖尿病.肝胆膵 62:513-517,2011.
 
9) McCarty MF:Insulin secretion as a determinant of pancreatic cancer risk. Med Hypotheses 57:146-150,2001.
PubMed
10) Dalamaga M,et al:Pancreatic cancer expresses adiponectin receptors and is associated with hypoleptinemia and hyperadiponectinemia:a case-control study. Cancer Causes Control 20:625-633, 2001.
 
11) Mori Y,et al:Different incretin responses after pancreatoduodenectomy and distal pancreatectomy. Pancreas 41:455-460,2012.
PubMed
12) Ingkakul T,et al:Predictors of the presence of concomitant invasive ductal carcinoma in intraductal papillary mucinous neoplasm of the pancreas. Ann Surg 251:70-75,2010.
PubMed
13) 家永 淳ほか:膵癌のリスクファクターとしての糖尿病.胆と膵 31:137-141,2010.
Medical*Online
14) Kolb A,et al:Glucagon/insulin ratio as a potential biomarker for pancreatic cancer in patients with new-onset diabetes mellitus. Cancer Biol Ther 8:1527-1533,2009.
PubMed
15) Saruc M,et al:Morphometric studies in human pancreatic cancer argues against the etiological role of type 2 diabetes in pancreatic cancer. Histol Histopathol 25:423-432,2010.
PubMed
P.572 掲載の参考文献
1) Taura N,et al:Long-term trends of the incidence of hepatocellular carcinoma in the Nagasaki prefecture,Japan. Oncol Rep 21:223-227,2009.
PubMed
2) Taura N,et al:The incidence of hepatocellular carcinoma associated with hepatitis C infection decreased in Kyushu area. Med Sci Monit 17:PH7-11,2011.
PubMed
3) El-Serag HB,et al:Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 126:460-468,2004.
PubMed
4) Moriya K,et al:Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol 78(Pt 7):1527-1531,1997.
 
5) Ohata K,et al:Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Cancer 97:3036-3043,2003.
PubMed
6) Kita Y,et al:Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Metabolism 56:1682-1688,2007.
PubMed
7) Calle EE,Kaaks R:Overweight,obesity and cancer:epidemiological evidence and proposed mech-anisms. Nat Rev Cancer 4:579-591,2004.
 
8) Kaji K,et al:Impact of insulin resistance on the progression of chronic liver diseases. Int J Mol Med 22:801-808,2008.
PubMed
9) Kawaguchi T,et al:Association of exogenous insulin or sulphonylurea treatment with an increased incidence of hepatoma in patients with hepatitis C virus infection. Liver Int 30:479-486,2010.
 
10) Saito K,et al:Augmentation effect of postprandial hyperinsulinaemia on groWth of human hepatocel-lular carcinoma. Gut 51:100-104,2002.
 
11) Ohki T,et al:Visceral fat accumulation is an independent risk factor for hepatocellular carcinoma recurrence after curative treatment in patients with suspected NASH. Gut 58:839-844,2009.
PubMed
12) Komura T,et al:Impact of diabetes on recurrence of hepatocellular carcinoma after surgical treat-ment in patients with viral hepatitis. Am J Gastroenterol 102:1939-1946,2007.
 
13) Miuma S,et al:The level of fasting serum insulin,but not adiponectin,is associated with the prog-nosis of early stage hepatocellular carcinoma. Oncol Rep 22:1415-1424,2009.
PubMed
P.576 掲載の参考文献
1) World Cancer Research Fund/American Institute for Cancer Research:Food,Nutrition,Physical Activity,and the Prevention of Cancer:a Global Perspective,p280,AICR,Washington DC,2007.
 
2) Cho E,et al:Alcohol intake and colorectal cancer:a pooled analysis of 8 cohort studies. Ann Intern Med 140(8):603-613,2004.
PubMed
3) Mizoue T,et al:Alcohol drinking and colorectal cancer in Japanese:a pooled analysis of results from five cohort studies. Am J Epidemiol 167(12):1397-1406,2008.
PubMed
4) Secretan B,et al;WHO International Agency for Research on Cancer Monograph Working Group:Areview of human carcinogens-Part E:tobacco,areca nut,alcohol,coal smoke,and salted fish. Lancet Oncol 10(11):1033-1034,2009.
 
5) Botteri E,et al:Smoking and colorectal cancer:a meta-analysis. JAMA 300(23):2765-2778,2008.
PubMed
6) Campbell PT,et al:Prospective study reveals associations between colorectal cancer and type 2 dia-betes mellitus or insulin use in men. Gastroenterology 139(4):1138-1146,2010.
PubMed
7) Larsson SC,et al:Diabetes mellitus and risk of colorectal cancer:a meta-analysis. J Natl Cancer Inst 97(22):1679-1687,2005.
PubMed
8) Yuhara H,et al:Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol 106(11):1911-1921,2011.
PubMed
9) 小島孝雄ほか:胃癌・大腸癌と生活習慣,Metabolic syndromeとの関連に関する検討.日消がん検診誌 46:558-566,2008.
 
10) Campbell PT,et al:Impact of Body Mass Index on Survival After Colorectal Cancer Diagnosis:The Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 30(1):42-52,2012.
PubMed
11) Dehal AN,et al:Impact of Diabetes Mellitus and Insulin Use on Survival After Colorectal Cancer Diag-nosis:The Cancer Prevention Study-II Nutrition Cohort. J Clin Oncol 30(1):53-59,2012.
 
12) Meyerhardt JA,et al:Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol 21(3):433-440,2003.
PubMed
13) Meyerhardt JA,et al:Association of dietary patterns with cancer recurrence and survival in patients with stage III colon cancer. JAMA 298(7):754-764,2007.
PubMed
14) Zhang ZJ,et al:Reduced risk of colorectal cancer with metformin therapy in patients with type 2 dia-betes:a meta-analysis. Diabetes Care 34(10):2323-2328,2011.
 
P.580 掲載の参考文献
1) International Agency for Research on Cancer:Infection with Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum 61:177-240,1994.
 
2) Nakajima S,et al:Changes in the prevalence of Helicobacter pylori infection and gastrointestinal dis-eases in the past 17 years. J Gastroenterol Hepatol 25(Suppl 1):S99-S110,2010.
 
3) Ikeda F,et al:Hyperglycemia increases risk of gastric cancer posed by Helicobacter pylori infection:a population-based cohort study. Gastroenterology 136:1234-1241,2009.
PubMed
4) Gunji T,et al:Helicobacter pylori infection significantly increases insulin resistance in the asympto-matic Japanese population. Helicobacter 14:496-502,2009.
 
5) Kubo A,Corley DA:Body mass index and adenocarcionomas of the esophagus or gastric cardia:a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev 15:872-878,2006.
PubMed
6) Huang JQ,et al:Meta-analysis of the relationship between Helicobacter pylori seropositivity and gas-tric cancer. Gastroenterology 114:1169-1179,1998.
 
7) Lin SW,et al:Prospective study of self-reported diabetes and risk of upper gastrointestinal can-cers. Cancer Epidemiol Biomarkers Prev 20:954-961,2011.
 
8) Kuriyama S,et al:Obesity and risk of cancer in Japan. Int J Cancer 113:148-157,2005.
PubMed
9) Kawamura A,et al:Helicobacter pylori-independent effect of hyperglycemia on gastric mucosal atrophy. Am J Gastroenterol 97:2479-2480,2002.
PubMed
10) Yi HK,et al:Expression of the insulin-like growth factors(IGFs)and the IGF-binding proteins(IGFBPs) in human gastric cancer cells. Eur J Cancer 37:2257-2263,2001.
PubMed
11) Pham TM,et al:Anested case-control study of stomach cancer and serum insulin-like growth fac-tor(IGF)-1,IGF-2 and IGF-binding protein(IGFBP)-3. Eur J Cancer 43:1611-1616,2007.
 
12) Ishikawa M,et al:Plasma adiponectin and gastric cancer. Clin Cancer Res 11:466-472,2005.
PubMed
13) Seker M,et al:The association of serum adiponectin levels with histopathological variables in gas-tric cancer patients. Med Oncol 27:1319-1323,2010.
 
14) Fukase K,et al:Effect of eradication Helicobacter pylori on incidence of metachronous gastric carci-noma after endoscopic resection of early gastric cancer:an open-label,randomised controlled trial. Lancet 372:392-397,2008.
 
15) Polyzos SA,et al:The association between Helicobacter pylori infection and insulin resistance:a systematic review. Helicobacter 16:79-88,2011.
PubMed
P.585 掲載の参考文献
1) Dunn JE:Cancer epidemiology in populations of the United States-with emphasis on Hawaii and California-and Japan. Cancer Res 35:3240-3245,1975.
PubMed
2) Bonovas S,et al:Diabetes mellitus and risk of prostate cancer:a meta-analysis. Diabetologia 47:1071-1078,2004.
PubMed
3) Kasper JS, Giovannucci E:A meta-analysis of diabetes mellitus and the risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 15:2056-2062,2006.
 
4) Mitin T,et al:Diabetes mellitus,race and the odds of high grade prostate cancer in men treated with radiation therapy. J Urol 186:2233-2237,2011.
PubMed
5) Moses KA,et al:The association of diabetes and positive prostate biopsy in a US veteran popula-tion. Prostate Cancer Prostatic Dis 15:70-74,2012.
 
6) Abdollah F,et al:Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy? Prostate Cancer Prostatic Dis 14:74-78,2011.
PubMed
7) Andriole GL,et al:Effect of dutasteride on the risk of prostate cancer. N Engl J Med 362:1192-1202,2010.
PubMed
8) Wu C,et al:Diabetes and prostate cancer risk in the REDUCE trial. Prostate Cancer Prostatic Dis 14:326-331,2011.
PubMed
9) Tseng CH:Diabetes and risk of prostate cancer:a study using the National Health Insurance. Diabe-tes Care 34:616-621,2011.
 
10) Hong SK,et al:Impact of diabetes mellitus on the detection of prostate cancer via contemporary multi(≧12)-core prostate biopsy. Prostate 72:51-57,2012.
 
11) Li Q,et al:History of diabetes mellitus and the risk of prostate cancer:the Ohsaki Cohort Study. Cancer Causes Control 21:1025-1032,2010.
PubMed
12) Peehl DM, Stamey TA:Serum-free growth of adult human prostatic epithelial cells. In Vitro Cell Dev Biol 22:82-90,1986.
PubMed
13) Polychronakos C,et al:Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells:characterization of the receptors involved. Prostate 19:313-321,1991.
 
14) Hsing AW,et al:Prostate cancer risk and serum levels of insulin and leptin:a population-based study. J Natl Cancer Inst 93:783-789,2001.
PubMed
15) Lehrer S,et al:Increased serum insulin associated with increased risk of prostate cancer recur-rence. Prostate 50:1-3,2002.
 
16) Clauson PG,et al:Insulin-like growth factor-I and insulin-like growth factor binding protein-1 in a representative population of type 2 diabetic patients in Sweden. Scand J Clin Lab Invest 58:353-360,1998.
 
17) LeRoith D,et al:Insulin-like growth factors and cancer. Ann Intern Med 122:54-59,1995.
PubMed
18) Iwamura M,et al:Insulin-like growth factor I:action and receptor characterization in human pros-tate cancer cell lines. Prostate 22:243-252,1993.
 
19) DiGiovanni J,et al:Deregulated expression of insulin-like growth factor 1 in prostate epithelium leads to neoplasia in transgenic mice. Proc Natl Acad Sci USA 97:3455-3460,2000.
PubMed
20) Konno-Takahashi N,et al:Engineered IGF-I expression induces glandular enlargement in the murine prostate. J Endocrinol 177:389-398,2003.
PubMed
21) Snyder CF,et al:Does pre-existing diabetes affect prostate cancer prognosis? A systematic review. Prostate Cancer Prostatic Dis 13:58-64,2010.
PubMed
P.589 掲載の参考文献
1) Cong L,et al:Human adiponectin inhibits cell growth and induces apoptosis in human endometrial carcinoma cells, HEC-1-A and RL952. Endocr Relat Cancer 14:713-720,2007.
PubMed
2) Grossmann ME,et al:Effects of adiponectin on breast cancer cell growth and signaling. Br J Cancer 98:370-379,2008.
PubMed
3) Li G,et al:Mechanisms underlying the anti-proliferative actions of adiponectin in human breast can-cer cells, MCF7-dependency on the cAMP/protein kinase-A pathway. Nutr Cancer 63:80-88,2011.
 
4) Gao J,et al:Leptin induces functional activation of cyclooxygenase-2 through JAK2/STAT3,MAPK/ERK, and PI3K/AKT pathways in human endometrial cancer cells. Cancer Sci 100:389-395,2009.
PubMed
5) Sharma D,et al:Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer 13:629-640,2006.
PubMed
6) Mantzoros C,et al:Adiponectin and breast cancer risk. J Clin Endocrinol Metab 89:1102-1107,2004.
 
7) Cust AE,et al:Plasma adiponectin levels and endometrial cancer risk in pre-and postmenopausal women. J Clin Endocrinol Metab 92:255-263,2007.
PubMed
8) Tessitore L,et al:Adipocyte expression and circulating levels of leptin increase in both gynaecologi-cal and breast cancer patients. Int J Oncol 24:1529-1535,2004.
 
9) Cymbaluk A,et al:Leptin levels in serum depending on Body Mass Index in patients with endome-trial hyperplasia and cancer. Eur J Obstet Gynecol Reprod Biol 136:74-77,2008.
 
10) Gaudet MM,et al:Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women?Cancer Epidemiol 34:580-586,2010.
PubMed
11) Soliman PT,et al:Circulating adiponectin levels and risk of endometrial cancer:the prospective Nurses' Health Study. Am J Obstet Gynecol 204:167,e1-5,2011.
 
12) Papa V,et al:Insulin-like growth factor-I receptors are overexpressed and predict a low risk in human breast cancer. Cancer Res 53:3736-3740,1993.
PubMed
13) Hankinson SE,et al:Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 351:1393-1396, 1998.
PubMed
14) Toniolo P,et al:Serum insulin-like growth factor-I and breast cancer. Int J Cancer 88:828-832,2000.
PubMed
15) Allen NE,et al:Aprospective study of serum insulin-like growth factor-1(IGF-1), IGF-II, IGFbinding protein-3 and breast cancer risk. Br J Cancer 92:1283-1287,2005.
 
16) Ayabe T,et al:Increased circulating levels of insulin-like growth factor-I and decreased circulating levels of insulin-like growth factor binding protein-1 in postmenopausal women with endometrial cancer. Endocr J 44:419-424,1997.
PubMed
17) Petridou E,et al:Endometrial cancer and the IGF system:a case-control study in Greece. Oncol-ogy 64:341-345,2003.
 
18) Gunter MJ,et al:Aprospective evaluation of insulin and insulin-like growth factor-I as risk factors for endometrial cancer. Cancer Epidemiol Biomarkers Prev 17:921-929,2008.
 
19) Paveli6 J,et al:Insulin-like growth factor 2 and its receptors(IGF IR and IGF 2R/mannose 6-phosphate) in endometrial adenocarcinoma. Gynecol Oncol l05:727-735,2007.
 
20) Friberg E,et al:Diabetes mellitus and risk of endometrial cancer:ameta-analysis. Diabetologia 50:1365-1374, 2007.
 
21) Lindemann K,et al:Body mass, diabetes and smoking, and endometrial cancer risk:afollow-up study. Br J Cancer 98:1582-1585,2008.
 
22) Chodick G,et al:Diabetes and risk of incident cancer:alarge population-based cohort study in Israel. Cancer Causes Control 21:879-887,2010.
 
23) Inoue M,et al:Diabetes mellitus and the risk of cancer:results from a large-scale populationbased cohort study in Japan. Arch Intern Med 166:1871-1877,2006.
PubMed
24) Noto H,et al:Substantially increased risk of cancer in patients with diabetes mellitus:asystematic review and meta-analysis of epidemiologic evidence in Japan. J Diabetes Complications 24:345-353,2010.
 
25) Rosato V,et al:Metabolic syndrome and endometrial cancer risk. Ann Oncol 22:884-889,2011.
PubMed
26) Larsson SC,et al:Diabetes mellitus and risk of breast cancer:ameta-analysis. Int J Cancer 121:856-862,2007.
 
27) Friedenreich CM:Review of anthropometric factors and breast cancer risk. Eur J Cancer Prev 10:15-32,2001.
PubMed

X 糖尿病診療における医療連携

P.598 掲載の参考文献
1) 根本昌実,田嶼尚子:クリティカル・パスによる糖尿病診療とは.Diabetes Frontier 13:463-467,2002.
Medical*Online
2) 厚生労働省:社会保障全般,II安心・信頼の医療の確保と予防の重視[http://www.mhlw.go.jp/bunya/shakaihosho/iryouseido01/taikou03.html].
 
3) 中塔辰明ほか:糖尿病病診連携体制-クリニカルパスの運用-.日本臨牀 66(増刊号9):586-595,2008.
Medical*Online
4) 池田正毅:糖尿病専門病院におけるクリニカルパス.ホルモンと臨床 53(秋季増刊号):95-102,2005.
 
5) 高橋義彦:改正医療法と糖尿病地域連携パス.プラクティス 27:384-390,2010.
Medical*Online
6) 全国保健所長会:地域連携クリティカルパスの普及・推進方策骨子[http://www.phcd.jp/katsudou/chihoken/H20/H20_chiikihoken_path_kotsushi_kaitei.pdf].
 
7) 宇治原誠:地域連携クリティカルパスと糖尿病の地域医療Diabetes Frontier 22:136-139,2011.
 
8) 藤本新平,稲垣暢也:日本糖尿病協会の糖尿病連携手帳利用のすすめ.Diabetes Frontier 22:164-168,2011.
Medical*Online
P.603 掲載の参考文献
1) 中島直樹:ディジーズマネジメント視点での糖尿病地域連携への可能性と具体的効果.新医療 2:44-47,2009.
 
2) 伊藤眞一:糖尿病治療のシステムと実践-クリティカルパスから病診連携まで-Panel 4.西東京における糖尿病を中心とした医療連携の実際.別冊プラクティス,p84-97,医歯薬出版2004.
 
3) 鈴木厚ほか:地域中核病院を中心とした糖尿病病診連携の取り組みと長期経過-大垣病診連携研究-.糖尿病 50:303-311,2007.
 
4) 中塔辰明ほか:糖尿病病診連携クリニカルパスの作成から運用開始までの取り組み.岡山済生会病誌 38:22-28,2006.
 
5) 山本眞由美ほか:糖尿病の遠隔病診連携を支援する岐阜県医師会病診連携システム構築の報告.日遠隔医療会誌 4:325-327,2006.
 
6) 江本直也:糖尿病病診連携システム導入時の問題点.日医師会誌 133:481-484,2005.
 
7) Arai K,et al:The status of glycemic control by general practitioners and specialists for diabetes in Japan:a cross-sectional survey of 15652 patients with diabetes mellitus. Diabetes Res Clin Pract 83:397-401,2009.
 
8) 江本直也ほか:当院糖尿病地域連携における基幹病院から診療所への紹介システムの有用性に関する検討.糖尿病 54:675-680,2011.
 
9) 平井愛山:医師不足と糖尿病連携.治療(増刊号) 90:1036-1047,2008.
 
10) 酒井武則ほか:八幡浜西宇和郡地区の糖尿病診療における病診連携の試み.糖尿病 47(Suppl):343,2004.
 
11) 古川慎哉ほか:愛媛県における糖尿病地域連携(愛媛DM連携Circle)の現状と将来展望.日病態栄会誌 11(Suppl):83,2009.
 
12) 宇治原誠:患者携帯型・医療者用/患者用パス一体型糖尿病地域連携クリティカルパス.治療 90:1081-1085,2008.
Medical*Online
13) 飯田さよみほか:糖尿病と地域連携パス-連携パス導入における現況と運用上の課題-.医薬ジャーナル 44:1943-1949,2008.
 
14) 井上貴美子ほか:糖尿病の病診連携における管理栄養士の役割.日病態栄会誌 12:217-221,2009.
Medical*Online
15) 井上貴美子ほか:糖尿病地域連携における管理栄養士の役割.プラクティス 27:421-425,2010.
Medical*Online
P.612 掲載の参考文献
1) 平井愛山:東金病院の改革の歩みと今後の展望-新たな医療連携システムを目指して-.千葉医学 76:323-335,1999.
 
2) 平井愛山,秋山美紀:地域医療を守れ-「わかしおネットワーク」からの提案,岩波書店,2008.
 
3) 平井愛山:地域医療の崩壊から再生へ-人材育成と医療連携-.計画行政 30(3):51-61,2007.
 
4) 平井愛山:わかしお医療ネットワーク.ヘルスサポートの方法と実践(田中 滋ほか編),p152-162,東京大学出版会,2006.
 
5) 平井愛山ほか:慢性疾患ケアモデル,中央法規,2007.
 
6) 江本直也ほか:当院糖尿病地域連携における基幹病院から診療所への紹介システムの有用性に関する検討.糖尿病 54(8):675-680,2011.
 
7) 平井愛山:電子カルテを中核とした新たな病・診・薬連携ネットワークの構築と展開.INNERVISION 17(7):82-89,2002.
Medical*Online
8) 平井愛山ほか:電子カルテを中核とした新たな病・診・薬連携ネットワークの構築と展開-わかしお医療ネットワークの現状と展望-(第41回全国自治体病院学会・静岡 管理分科推薦演題).全国自治体病協誌 42(6):866-872,2003.
 
9) 平井愛山:電子カルテを中核とした地域医療情報ネットワークによる糖尿病診療のレベルアップ-わかしお医療ネットワークの構築と展開-.肥満と糖尿病 2:43-53,2003.
 
10) 秋山美紀ほか:保険調剤薬局薬剤師と病院医師とのネットワークを用いた情報共有が服薬指導に与える効果.医療マネジメント会誌 9(4):504,2009.
Medical*Online
11) 平井愛山,開原成允:電子カルテを利用した病院と診療所の連携 IT革命時代の医学と医療(25). 日医師会誌 130(9):1250-1258,2003.
 
12) 平井愛山:千葉「わかしおネット」に学ぶ失敗しない地域医療連携,医学芸術社,2004.
 
13) 平井愛山:厚生労働科学研究費補助金(医療安全・医療技術評価総合研究事業)(総合)研究報告書 日本版EHR(生涯健康医療電子記録)の実現に向けた研究(19252701)分担研究報告書'日本版Regional EHRを創る',2010.
 
14) Cebul RD,et al:Electronic health records and quality of diabetes care. N Engl J Med 365:825-833,2011.
PubMed

XI 糖尿病患者の教育・看護

P.623 掲載の参考文献
1) Funnell MM,et al:National standards for diabetes self-management education. Diabetes Care 30(6):1630-1637,2007.
PubMed
2) AADE:AADE7 Self-Care Behaviors. Diabetes Educ 34(3):445-449,2008.
PubMed
3) [http://www.cdc.gov/diabetes/pubs/factsheet11.htm].
 
4) マルカム・ノールズ:成人教育の現代的実践(堀薫夫ほか訳),鳳書房,2008.
 
5) National Diabetes Advisory Board:National standards for diabetes patient education programs. Dia-betes Educ 9(4):11-14,1984.
 
6) Funnell MM, Haas LB:National Standards for Diabetes Self-Management Education Programs. Diabetes Care 18(1):100-116,1995.
PubMed
7) Mensing C,et al:National standards for diabetes self-management education. Task Force to Review and Revise the National Standards for Diabetes Self-Management Education Programs. Dia-betes Care 23(5):682-689,2000.
 
8) 「日本における糖尿病自己管理アウトカム指標の開発研究班」(森川浩子ほか)訳:糖尿病セルフマネジメント教育コアアウトカム測定尺度.看護研究 37(6):3-28,2004.
 
9) Funnell MMほか(門脇孝監訳,大橋健訳):糖尿病セルフマネジメント教育101のコツ,医歯薬出版,2006.
 
10) Tang TS,et al:Group education strategies for diabetes self-management. Diabetes Spectrum 19(2):99-105,2006.
 
11) [http://www.diabeteseducator.org/export/sites/aade].
 
12) Weinger K,et al:Educating Your Patient with Diabetes, p3-14,Humana Press,New York,2009.
 
13) Flader J,et al:Type 2 Diabetes BASICS,3rd ed, International Diabetes Center, Minneapolis,2010.
 
P.627 掲載の参考文献
1) American Diabetes Association:Insulin administration. Diabetes Care 27(Supple 1):S106-109,2004.
 
2) Polonsky KS,et al:Twenty-four-hour profiles and pulsatile patterns of insulin secretion in normal and obese subjects. J Clin Invest 81:442-448, 1988.
PubMed
3) Dashora U,et al:An exploratory study of the effect of using high-mix biphasic insulin aspart in peo-ple with type 2 diabetes. Diabetes Obes Metab 11:680-687,2009.
 
4) 後藤広昌ほか:2型糖尿病のスルホニル尿素薬効果不十分例におけるインスリングラルギンの上乗せ効果 18カ月間の長期治療効果の検討.糖尿病50:591-597,2007.
 
5) 清野弘明,朝倉俊成:インスリン注入器専用注射針の選択・指導.インスリン療法マスターガイドブック-導入からトラブル対処法まで-,p43-63,南江堂,2007.
 
6) Hirose T,et al:Glucose monitoring after fruit peeling:pseudohyperglycemia when neglecting hand washing before fingertip blood sampling:wash your hands with tap water before you check blood glucose level. Diabetes Care 34:596-597,2011.
PubMed
7) 尾畑千代美ほか:SMBGにおける自己申告値の信頼性・虚偽申告の分析とその要因.日先進糖尿病治療研会誌 5:12-15,2009.
 
8) 日本糖尿病学会(編):糖尿病治療ガイド,p69,文光堂,2010.
 
9) Evans ML,et al:Delay in onset of awareness of acute hypoglycemia and of restoration of cognitive performance during recovery. Diabetes Care 23:893-897,2000.
PubMed
10) Horton ES:Role and management of exercise in diabetes mellitus. Diabetes Care 11:201-211,1988.
PubMed
P.631 掲載の参考文献
1) 松岡健平:糖尿病の教育入院 その活用と効果.診断と治療 77:113-118,1989.
 
2) 細川和弘:糖尿病教室,教育(体験)入院.糖尿病診療マニュアル.日医師会誌特別号 130:S222-S225,2003.
 
3) 宇佐美勝,池田正毅:クリニカルパスによる糖尿病診療.Diabetes Frontier 16:230-235,2005.
Medical*Online
4) 森久也ほか:2週間の糖尿病教育入院の効果について-3・4週間からの短縮効果-.糖尿病 47:837-844,2004.
 
5) 松尾靖人ほか:1週間および2週間糖尿病教育入院クリティカルパスの比較-2型糖尿病患者における退院後3年間のHbA1cおよび合併症の推移-.糖尿病 51:101-107,2008.
 
6) 松本一成:教育入院パスの血糖改善効果は? 肥満と糖尿病 9:25-27,2010.
Medical*Online
7) 永田裕章ほか:クリティカルパス導入後の教育入院に対する評価.糖尿病 48:777-781,2005.
 
8) 本田佳子ほか:2型糖尿病患者における教育入院後の外来通院状況.糖尿病 47:355-361,2004.
 
9) 石井均:糖尿病エンパワーメント,医歯薬出版,2003.
 
10) 秋本倫子ほか:教育入院における糖尿病患者の心理的変化-グループ療法の内容分析から-.糖尿病 43:63-66,2000.
 
11) 小松 桂ほか:糖尿病教育入院前後での糖尿病に関する負担感情の変化-PAIDの質問表と患者背景因子の関連要因の検討-.糖尿病 48:57-62,2005.
 
12) 宮城裕子ほか:糖尿病患者の変化ステージと知識・自己管理・自信に関する研究.沖縄看大紀要 7:1-9,2006.
 
13) 松本一成:糖尿病療養指導へのコーチングの適用-患者さんが自分で考えて行動を変えていくコミュニケーション-.糖尿病診療マスター 7:447-451,2009.
 
P.638 掲載の参考文献
1) Prochaska JO,et al:In search of how people change. Applications to addictive behaviors. Am Psy-chol 47:1102-1114,1992.
 
2) 石井均:「多理論統合モデル(変化ステージモデル)」の本質と方法論.糖尿病医療学入門,p92-158,医学書院,2011.
 
3) 石井 均:希望を失わない-糖尿病治療とこころのケア.糖尿病診療マスター 6:659-669,2007.
 
4) 石井 均:<行動の心理的要因>感情に焦点を当てる.糖尿病医療学入門,p62-69,医学書院,2011.
 
5) 石井 均,瀧本奈奈:外来で糖尿病患者の心理的な負担を軽減する方法.糖尿病診療マスター 1:25-34,2008.
 

XII 特論

P.646 掲載の参考文献
1) Shigeta H,et al:Lifestyle,obesity and insulin resistance. Diabetes Care 24:608,2001.
PubMed
2) Amagai Y,et al:Sleep duration and mortality in Japan:the Jichi Medical School Cohort Study. J Epi-demiol 20:106-110,2010.
 
3) Morikawa Y,et al:Shift work and risk of diabetes among Japaese male factory workers. Scand J Work Environ Health 31:179-183,2005.
 
4) Duez H, Steals B:Nuclear receptors linking circadian rhythms and cardiometabolic control. Arterio-scler Thromb Vasc Biol 30:1529-1534,2010.
 
5) Zhang EE,et al:Cryptochrome mediates circadian regulation of cAMP signaling and hepatic gluco-neogenesis. Nature Med 16:1152-1156,2010.
 
6) Lamia KA,et al:Cryptochromes mediate rhythmic repression of the glucocorticoid receptor. Nature 482:552-556,2011.
 
7) Mistlberger RE:Neurobiology of food anticipatory circadian rhythms. Physiol Behav 104:535-545,2011.
PubMed
8) Mohawk JA,et al:Inhibiting cortisol response accelerates recovery from a photic phase shift. Am J Physiol Regul Integr Comp Physiol 288:R221-R228,2005.
PubMed
9) Lee B,et al:CREB influences timing and entrainment of the SCN circadian clock. J Biological Rhythms 25:410-420,2010.
PubMed
10) Doi M,et al:Circadian regulation of intracellular G-protein signaling mediates intercellular synchrony and rhythmicity in the suprachiasmatic nucleus. Nat Commun 2:327,2011.
PubMed
11) Hayasaka N,et al:Attenuated food anticipatory activity and abnormal circadian locomotor rhythms in Rgs16 knockdown mice. PLoS One 6:e17655,2011.
PubMed
12) Oishi K,et al:Ketogenic diet disrupts the circadian clock and increases hypofibrinolytic risk by inducing expression of plasminogen activator inhibitor-1. Arterioscler Thromb Vasc Biol 29:1571-1577,2009.
PubMed
13) Oishi K,et al:Circadian expression of FGF21 is induces by PPARα activation in the mouse liver. FEBS Lett 582:3639-3642,2008.
 
14) Tong X,et al:Transcriptional repressor E4-binding protein 4(E4BP4) regulates metabolic hor-mone fibroblast growth factor 21(FGF21) during circadian cycles and feeding. J Biol Chem 285:36401-36409,2010.
 
15) Holt RI,et al:Bromocriptine:old drug,new formulation and new indication. Diabetes Obes Metab 12:1048-1057,2010.
PubMed
16) Gaziano JM,et al:Randomized clinical trial of quick-release bromocriptin among patients with type 2 diabetes on overall safety and cardiovascular outcomes. Diabetes Care 33:1503-1508,2010.
PubMed
P.650 掲載の参考文献
1) Franceschi C,et al:The immunology of exceptional individuals:the lesson of centenarians. Immu-nol Today 16:12-16,1995.
 
2) Takayama M,et al:Morbidity of Tokyo-area centenarians and its relationship to functional status. J Gerontol A Biol Sci Med Sci 62:774-782,2007.
PubMed
3) Terry DR,et al:Cardiovascular disease delay in centenarian offspring. J Gerontol A Biol Sci Med Sci 59(4):385-389,2004.
 
4) Paolisso G,et al:Glucose tolerance and insulin action in healthy centenarians. Am J physiol Endo-crinol Metab 270:E890-E894,1996.
 
5) Li S,et al:Adiponectin levels and risk of type 2 diabetes:a systematic review and meta-analysis. JAMA 302(2):179-188,2009.
PubMed
6) Arai Y,et al:High adiponectin concentration and its role for longevity in female centenarians. Geri-atr Gerontol Int 6:32-39,2006.
 
7) Bik W,et al:The relationship between adiponectin levels and metabolic status in centenarian, early elderly,young and obese women. Neuro Endocrinol Lett 27(4):493-500,2006.
 
8) Hara K,et al:Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51(2):536-540,2002.
PubMed
9) Atzmon G,et al:Adiponectin levels and genotype:apotential regulator of life span in humans. J Gerontol A Biol Sci Med Sci 63:447-453,2008.
 
10) Wellcome Trust Case Control Consortium. Genome-wide association study of 14,000 cases of seven common disease and 3,000 shared controls. Nature 447:661-678,2007.
 
11) Sebastiani P,et al:RNA editing genes associated with extreme old age in humans and with lifespan in C.elegans. PLoS One 4(12):e8210,2009.
 
12) Oguro R,et al:A single nucleotide polymorphism of the adenosine deaminase,RNA-specific gene is associated with the serum triglyceride level,abdominal circumference,and serum adiponectin concentration. Exp Gerontol 47(2):183-187,2012.
PubMed
13) Arai Y,et al:Adipose endocrine function, insulin-like growth factor-1 axis,and exceptional sur-vival beyond 100 years of age. J Gerontol A Biol Sci Med Sci 63:1209-1218,2008.
 
14) Hozawa A,et al:Relationship Between Serum Adiponectin Levels and Disability-Free Survival Among Community-Dwelling Elderly Individuals:The Tsurugaya Project. J Gerontol A Biol Sci Med Sci,2011.[Epub ahead of print]
 
P.658 掲載の参考文献
1) Ogawa H,et al(ed):Sportology,International Academy of Sportology,2011.
 
2) Vranic M,et al:The essentiality of insulin and the role of glucagon in regulating glucose utilization and production during strenuous exercise in dogs. J Clin Invest 57:245-255,1976.
 
3) Kawamori R,Vranic M:Mechanism of exercise-induced hypoglycemia in depancreatized dogs maintained on long-acting insulin. J Clin Invest 59:331-337,1977.
PubMed
4) Vranic M,Kawamori R:Essential roles of insulin and glucagon in regulating glucose fluxes during exercise in dogs. Diabetes 28:45-52,1979.
PubMed
5) Tamura Y,et al:Effects of diet and exercise on muscle and liver intracellular lipid contents and insu-lin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 90:3191-3196,2005.
 
6) Sato F,et al:Effects of diet-induced moderate weight reduction on intrahepatic and intramyocellu-lar triglycerides and glucose metabolism in obese subjects. J Clin Endcrinol Metab 92:3326-3329,2007.
 
7) Browning JD,et al:Short-term weight loss and hepatic triglyceride reduction:evidence of a meta-bolic advantage with dietary carbohydrate restriction. Am J Clin Nutr 93:1048-1052,2011.
 
8) Taskinen MR,et al:Dual metabolic defects are required to produce hypertriglyceridemia in obese subjects. Arterioscler Thromb Vasc Biol 31:2144-2150,2011.
PubMed
P.662 掲載の参考文献
1) (社)日本糖尿病学会専門医制度規則 「糖尿病」巻末[http://www.jds.or.jp/].
 
2) (社)日本専門医制評価・認定機構[http://www.japan-senmon-i.jp/].
 
3) 松谷朗:糖尿病専門医取得の意義と準備.糖尿病学の進歩(日本糖尿病学会編),p116-119,診断と治療社,2010.
 
4) 日本糖尿病学会(編):糖尿病専門医研修ガイドブック,改訂第4版,診断と治療社,2009.
 
P.666 掲載の参考文献
1) International Diabetes Federation:Diabetes atlas.[http://www.idf.org/media-events/press-releases/2011/diabetes-atlas-5th-edition]
 
2) International Diabetes Federation:Diabetes atlas.[http://www.idf.org/sites/default/files/attachments/WP-Press-Release-WDD.pdf#search]=[http://www.idf.org/sites/default/files/attachments/WPPressReleaseWDD.pdf]
 
3) International Diabetes Federation:Diabetes atlas.[http://www.idf.org/atlasmap/atlasmap]
 
4) 厚生労働省:平成21年度国民医療費の概況.[http://www.mhlw.go.jp/toukei/saikin/hw/k-iryohi/09/index.html]
 
5) 厚生労働省:平成19年国民健康・栄養調査結果の概要について.[http://www.mhlw.go.jp/houdou/2008/12/h1225-5a.html]
 
6) 厚生労働省:政府管掌健康保険における医療費等に関する調査研究報告書.[http://www.mhlw.gojp/shingi/2005/10/s1027-5c5.html]
 
7) 稲田扇ほか:2型糖尿病における外来医療費の研究-医療改革が糖尿病科に与える影響-.糖尿病 48(9):677-684,2005.
 
8) 杉崎弘章ほか:第13回透析医療費実態調査報告.日透析医会誌 25(1):56-86,2010.
 
9) 荒木栄一,岸川秀樹:Kumamoto Study.日本臨牀 68(増刊号9):114-120,2010.
Medical*Online
10) 厚生労働省:平成22年国民健康・栄養調査結果の概要.[http://www.mhlw.go.jp/stf/houdou/2r98520000020qbb.html]
 
P.670 掲載の参考文献
1) Ward Platt M,Deshpande S:Metabolic adaptation at birth. Semin Fetal Neonatal Med 10:341-350,2005.
PubMed
2) 河井昌彦ほか:新生児の低血糖症.NICU 厳選150症例の診断と治療,p216-220,金芳堂,2004.
 
3) McQuarrie I:Idiopathic spontaneous occuring hypoglycemia in infants:clinical significance of prob-lem and treatment. AMA Am J Dis Child 87:399-428,1954.
 
4) Sharma N,et al:Familial hyperinsulinism and pancreatic β-cell ATP-sensitive potassium channels. Kidney Int 57:803-808,2000.
 
5) Shyng SL,et al:Functional analyses of novel mutations in the sulfonylurea receptor 1 associated with persistent hyperinsulinemic hypoglycemia of infancy. Diabetes 47(7):1145-1151,1998.
PubMed
6) Otonkoski T,et al:A point mutation inactivating the sulfonylurea receptor causes the severe form of persistent hyperinsulinemic hypoglycemia of infancy in Finland. Diabetes 48(2):408-415,1999.
PubMed
7) Shimomura K,et al:Adjacent mutations in the gating loop of Kir6.2 produce neonatal diabetes and hyperinsulinism. EMBO Mol Med 1:166-177,2009.
PubMed
8) 長谷川奉延ほか:日本小児内分泌学会薬事委員会:高インスリン血性低血糖症の診断と治療ガイドライン.日小児会誌 110(10):1472-1474,2006.
 
P.674 掲載の参考文献
1) Frier BM,et al:Hypoglycemia and cardiovascular risks. Diabetes Care 34(Suppl 2):S132-137,2011.
 
2) Whitmer RA,et al:Hypoglycemic episodes and risk of dementia in older patients with type 2 diabe-tes mellitus. JAMA 301:1565-1572,2009.
 
3) McCrimmon Rl,et al:Key role for AMP-activated protein kinase in the ventromedial hypothalamus in regulating counterregulatory hormone responses to acute hypoglycemia. Diabetes 57:444-450,2008.
 
4) Roderick E,et al:Hypoglycaemia and cognitive function. Diabetes Obes Metab 7:493-503,2005.
 
5) Evans ML,et al:Delay in onset of awareness of acute hypoglycemia and of restoration of cognitive performance during recovery. Diabetes Care 23:893-897,2000.
PubMed
6) Strachan MW,et al:Recovery of cognitive function and mood after severe hypoglycemia in adults with insulin-treated diabetes. Diabetes Care 23:305-312,2000.
PubMed
7) Araki A,Ito H:A symptomatic cerebral infarction on brain MR images and cognitive function in eld-erly diabetic patients. Geriatr Gerontol Int 2:206-214,2002.
 
8) Fujioka M,et al:Specific changes in human brain after hypoglycemic injury. Stroke 28:584-587,1997.
PubMed
9) Ma JH,et al:MR imaging of hypoglycemic encephalopathy:lesion distribution and prognosis predic-tion by diffusion-weighted imaging. Neuroradiology 51:641-649,2009.
 
10) Wessels AM,et al:Microvascular disease in type 1 diabetes alters brain activation:a functional mag-netic resonance imaging study. Diabetes 55:334-340,2006.
 
11) Akyol A,et al:Repeated hypoglycemia and cognitive decline. A case report. Neuro Endocrinol Lett 24:54-56,2003.
PubMed
12) Bree AJ,et al:Diabetes increases brain damage caused by severe hypoglycemia. Am J physiol Endocrinol Metab 297:E194-201,2009.
PubMed
13) Joseph A,et al:Increased glutamate receptor gene expression in the cerebral cortex of hlsulin induced hypoglycemic and streptozotocin-induced diabetic rats. Neuroscience 156:298-304,2008.
PubMed
14) Silverstein JM,et al:Pharmacologic amelioration of severe hypoglycemia-induced neuronal dam-age. Neurosci Lett 492:23-28,2011.
 
15) Dave KR,et al:Recurrent hypoglycemia exacerbates cerebral ischemic damage in streptozotocin-induced diabetic rats. Stroke 42:1404-1411,2011.
PubMed
16) Bruce DG,et al:Severe hypoglycaemia and cognitive impairment in older patients with diabetes:the Fremantle Diabetes Study. Diabetologia 52:1808-1815,2009.
PubMed
17) Feil DG,et al:Risk of hypoglycemia in older veterans with dementia and cognitive impairment:implications for practice and policy, J Am Geriatr Soc 59:2263-2272,2011.
 

書評

最近チェックした商品履歴

Loading...